Page last updated: 2024-12-05

ketoprofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce fever. It is a propionic acid derivative and is available in various forms, including tablets, capsules, and topical gels. Ketoprofen is thought to work by inhibiting the production of prostaglandins, which are chemicals in the body that cause pain, swelling, and inflammation. The synthesis of ketoprofen involves a multi-step process starting with the reaction of 2-methylpropionic acid with 4-fluoroanisole followed by a series of reactions, including Friedel-Crafts acylation, reduction, and cyclization. Ketoprofen is widely used for the treatment of a variety of conditions, including pain from arthritis, dental procedures, and menstrual cramps. Research continues to investigate its effectiveness for other conditions such as cancer pain and migraines. Ketoprofen is an important drug due to its analgesic and anti-inflammatory properties. It is studied to understand its efficacy, safety, and potential new applications. It has been shown to have analgesic and anti-inflammatory effects in both experimental and clinical settings.'

Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID180540
CHEMBL ID372052
SCHEMBL ID195303
MeSH IDM0011996
PubMed CID3825
CHEMBL ID571
CHEBI ID6128
SCHEMBL ID2896
MeSH IDM0011996

Synonyms (317)

Synonym
lopac-k-1751
NCGC00015578-01
cas-22071-15-4
NCGC00016757-01
(r)-2-(3-benzoylphenyl)propanoic acid
bdbm50169048
(r)-2-(3-benzoylphenyl)propionic acid
(r)-2-(3-benzoyl-phenyl)-propionic acid
(2r)-2-(3-benzoylphenyl)propanoic acid
CHEMBL372052 ,
r-ketoprofen
(2r)-2-(3-benzoylphenyl)propionic acid
(-)-2-(3-benzoylphenyl)propionic acid
(r)-(-)-ketoprofen
(-)-ketoprofen
ketoprofen, (r)-
(r)-ketoprophen
(r)-ketoprofen
unii-s03709d0th
(-)-3-benzoyl-alpha-methylbenzeneacetic acid
s03709d0th ,
NCGC00015578-06
56105-81-8
enzeneacetic acid, 3-benzoyl-alpha-methyl-, (r)-
(.alpha.r)-3-benzoyl-.alpha.-methylbenzeneacetic acid
benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, (.alpha.r)-
ketoprofen,l-
ketoprofen, r-
benzeneacetic acid, 3-benzoyl-alpha-methyl-, (r)-
AKOS022182275
SCHEMBL195303
2-(3-benzoylphenyl)-propionic acid
(r)-(-)-2-(3-benzoylphenyl)propionic acid
DKYWVDODHFEZIM-LLVKDONJSA-N
DTXSID50204652
Q27288378
JGE ,
(r)-2-(3-benzoylphenyl)propanoicacid
CS-0363152
EN300-25002870
BIDD:GT0443
AB00052249-20
AB00052249-19
BRD-A97739905-001-05-9
benzeneacetic acid, 3-benzoyl-.alpha.-methyl-
MLS000079024 ,
DIVK1C_000598
KBIO1_000598
3-benzoylhydratropic acid
2-(3-benzoylphenyl)propanoic acid
2-(3-benzoylphenyl)propionic acid
m-benzoylhydratropic acid
MLS000028446
l'acide (benzoyl-3-phenyl)-2-propionique
CHEBI:6128 ,
3-benzoyl-alpha-methylbenzeneacetic acid
2-[3-(phenylcarbonyl)phenyl]propanoic acid
actron
orudis kt
acide (benzoyl-3-phenyl)-2-propionique [french]
rp-19583
(+-)-m-benzoylhydratropic acid
einecs 244-759-8
aneol
ketoprofeno [inn-spanish]
propionic acid, 2-(3-benzoylphenyl)-
ketoprophene
benzeneacetic acid, 3-benzoyl-alpha-methyl-
alrheumat
(+-)-3-benzoyl-alpha-methylbenzeneacetic acid
benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+-)-
oruvail
2-(m-benzoylphenyl)propionic acid
ketoprofen (+-)
racemic-ketoprofen
epatec
ccris 4508
hydratropic acid, m-benzoyl-, (+-)-
benzoylhydratropic acid
capisten
19583 rp
ru 4733
profenid
ketoprofenum [inn-latin]
alrheumun
ketoprofene
ketoprofene [inn-french]
rp 19583
orudis
EU-0100686
orudis (tn)
D00132
ketoprofen (jp17/usp/inn)
SPECTRUM_001309
LOPAC0_000686
PRESTWICK_617
PRESTWICK2_000219
BSPBIO_000237
BPBIO1_000261
PRESTWICK3_000219
BSPBIO_003037
IDI1_000598
OPREA1_117113
AB00052249
BIM-0050664.0001
ketoprofen
22071-15-4
C01716
ketoprofen, meets usp testing specifications
DB01009
SPECTRUM5_001254
NCGC00094043-02
NCGC00094043-03
smr000040181
KBIO2_006925
KBIOSS_001789
KBIO2_001789
KBIO2_004357
KBIOGR_000435
KBIO3_002537
SPECTRUM4_000028
NINDS_000598
SPBIO_000952
PRESTWICK0_000219
SPBIO_002158
PRESTWICK1_000219
SPECTRUM2_000956
SPECTRUM3_001479
SPECTRUM1501215
NCGC00094043-04
MLS001201752
NCGC00094043-01
MLS001306444
ketoprofen, >=98% (tlc)
NCGC00015578-02
AC-1486
HMS2092L19
HMS2089B16
K 1751 ,
NCGC00015578-07
UNM-0000306100
(rs)-ketoprofen
r.p. 19583
nsc-758144
hydratropic acid, m-benzoyl-
CHEMBL571 ,
actron ketoprofen
r.p. 19,583
19583rp
ru-4733
sector
idea-033
iso-k
ketorin
HMS501N20
rac ketoprofen-13c,d3
inchi=1/c16h14o3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11h,1h3,(h,18,19)
dkywvdodhfezim-uhfffaoysa-
2-[3-(benzoyl)phenyl]propanoic acid
K0038
HMS1921B12
HMS1568L19
l''acide (benzoyl-3-phenyl)-2-propionique
bdbm50022271
HMS2095L19
HMS3262I13
HMS3259I05
AKOS007930512
NCGC00258401-01
tox21_200847
A815896
nsc758144
MLS002548889
pharmakon1600-01501215
tox21_110594
dtxcid40771
dtxsid6020771 ,
HMS2234H16
CCG-39685
NCGC00015578-04
NCGC00015578-03
NCGC00015578-05
NCGC00015578-08
ketoprofenum
acide (benzoyl-3-phenyl)-2-propionique
ketoprofen [usan:usp:inn:ban:jan]
90y4qc304k ,
unii-90y4qc304k
nsc 758144
ketoprofeno
BCP9000810
toprek
lertus
orugesic
toprec
meprofen
dexal
kefenid
ketopron
oscorel
fastum
menamin
FT-0670646
FT-0670647
ketoprofen (actron)
BCP0726000302
FT-0602834
NCGC00015578-10
AM20060549
LP00686
EPITOPE ID:131783
S1645
HMS3373G09
HMS3372M08
gtpl4795
ketoprofen [green book]
(+/-)-m-benzoylhydratropic acid
ketoprofen [usan]
172964-50-0
ketoprofen [mart.]
ketoprofen [ep monograph]
ketoprofen [jan]
ketoprofen [who-dd]
(+/-)-3-benzoyl-.alpha.-methylbenzeneacetic acid
ketoprofen [usp monograph]
(+/-)-ketoprofen
ketoprofen [inn]
ketoprofen [vandf]
ketoprofen [mi]
ketoprofen [usp impurity]
nexcede
ketoprofen [ep impurity]
ketoprofen [orange book]
HY-B0227
AB00052249-17
NC00459
SCHEMBL2896
tox21_110594_1
NCGC00015578-12
KS-5031
alpha-(3-benzoylphenyl)propionic acid
alpha-(m-benzoylphenyl) propionic acid
2-(3-benzoylphenyl) propionoic acid
2-(3'-benzoylphenyl)propionic acid
alpha(3-benzoylphenyl)propionic acid
m-benzoyl-hydratropic acid
alpha-(m-benzoylphenyl)propionic acid
2-(3-benzoylphenyl) propionic acid
(+) ketoprofen
(+/-)-2-(3-benzoylphenyl)propionic acid
racemic ketoprofen
NCGC00261371-01
tox21_500686
22161-86-0
2-(3-benzoylphenyl)propanoic acid #
(.+/-.)-m-benzoylhydratropic acid
3-benzoyl-.alpha.-methylbenzeneacetic acid
(.+/-.)-3-benzoyl-.alpha.-methylbenzeneacetic acid
F2173-0960
MLS006011967
Q-201268
ketoprofen, british pharmacopoeia (bp) reference standard
HMS3649N10
AB00052249_21
OPERA_ID_509
AB00052249_22
mfcd00055790
STL450995
1189508-77-7
SR-01000075949-9
sr-01000075949
ketoprofen, united states pharmacopeia (usp) reference standard
ketoprofen, vetranal(tm), analytical standard
ketoprofen, european pharmacopoeia (ep) reference standard
HMS3655C15
D78110
ketoprofen, pharmaceutical secondary standard; certified reference material
SR-01000075949-1
SR-01000075949-6
SBI-0050664.P003
HMS3712L19
SW196784-3
ketoprofen ,(s)
154907-35-4
ketoprofen 100 microg/ml in acetonitrile
SR-01000075949-18
BCP23428
Q409192
(+/-)-ketoprofen-d4
BRD-A97739905-001-15-8
EN300-120644
SDCCGSBI-0050664.P004
HMS3884K04
NCGC00015578-23
(s)-ketoprofen;dexketoprofen
n-fmoc-3-amino-4-(4-tert-butoxy-phenyl)-butyricacid
rac ketoprofen
2-(3-benzoylphenyl)propanoicacid
BK166172
Z1530532758
ketoprofen 1000 microg/ml in acetonitrile
ketoprofen (mart.)
ketophene
m01ae03
(+/-)-3-benzoyl-alpha-methylbenzeneacetic acid
ketoprofen (usp monograph)
m02aa10
ketoprofen (usp impurity)
ketoprofen (ep impurity)
ketofen
ketomed
ketoprofen (usan:usp:inn:ban:jan)
ketoprofene (inn-french)
ketoprofenum (inn-latin)
ketoprofen (ep monograph)
(2rs)-2-(3-benzoylphenyl)propanoic acid
ketoprofeno (inn-spanish)

Research Excerpts

Overview

Ketoprofen (KTP) is an Active Pharmaceutical Ingredient (API) that has low solubility in aqueous solvents. Dexketofen (DEX) is a nonselective nonsteroidal anti-inflammatory drug that is used as an analgesic.

ExcerptReferenceRelevance
"Ketoprofen (KTP) is an Active Pharmaceutical Ingredient (API) that has low solubility in aqueous solvents. "( A New Crystalline Ketoprofen Sodium Salt: Solid-State Characterization, Solubility, and Stability.
Barbosa, TWL; Batista, A; Bonfilio, R; Borges, BA; Braga, MTL; de Araújo, MB; de Oliveira Junior, H, 2022
)
2.5
"Dexketoprofen is an enantiomer of ketoprofen (S+) that belongs to nonsteroidal anti-inflammatory drugs and has analgesic, anti-inflammatory, and antipyretic properties. "( The comparison of dexketoprofen and other painkilling medications (review from 2018 to 2021).
Kuczyńska, J; Nieradko-Iwanicka, B; Pawlak, A, 2022
)
1.66
"Ketoprofen is a Non-steroidal anti-inflammatory drug (NSAID) with anti-tumor properties."( Ketoprofen suppresses triple negative breast cancer cell growth by inducing apoptosis and inhibiting autophagy.
Ahmad, I; Awadh, SA; Hamad, DA; Hameed, NM; Hussam, F; Kadhim, MM; Mustafa, YF; Naser, RH; Parra, RMR; Patra, I, 2023
)
3.07
"Ketoprofen is a nonsteroidal anti-inflammatory drug composed of a benzoylphenyl propionic acid that is commonly used both topically and systemically for the treatment of musculoskeletal diseases because of its analgesic and anti-inflammatory effects and low toxicity, but it is one of the most frequent photoallergens (1,5,6)."( Ketoprofen-induced Photoallergic Reaction.
Ljubojević Hadžavdić, S; Rosan, T, 2022
)
2.89
"Ketoprofen (KET) is a nonsteroidal anti-inflammatory and analgesic drug commonly used in human and veterinary medicine. "( Ketoprofen affects swimming behavior and impairs physiological endpoints of Daphnia magna.
Bownik, A; Jasieczek, M; Kosztowny, E, 2020
)
3.44
"Ketoprofen is a widely used NSAID which incurs gastric mucosal damage. "( Mechanistic perspective of morin protection against ketoprofen-induced gastric mucosal injury: Targeting HMGB1/RAGE/NF-κB, DJ-1/Nrf2/HO-1 and PI3K/mTOR pathways.
Al-Shorbagy, MY; Arab, HH; El-Sahar, AE; Saad, MA, 2020
)
2.25
"Dexketoprofen (DEX) is a nonselective nonsteroidal anti-inflammatory drug that is used as an analgesic."( The effect of dexketoprofen trometamol on WAG/Rij rats with absence epilepsy (dexketoprofen in absence epilepsy).
Aygun, H; Çolak, S; Demirsoy, MS; Duman, E; Erdil, A; Sümbül, O, 2021
)
1.47
"Ketoprofen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. "( The effect of ketoprofen lysine salt on mucosa of rat stomach after ethyl alcohol intoxication.
Kuczyńska, J; Nieradko-Iwanicka, B, 2021
)
2.42
"Ketoprofen is a non-selective nonsteroidal anti-inflammatory drug (NSAID) used to treat acute and chronic painful conditions."( Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults.
Derry, S; Gaskell, H; Moore, RA; Wiffen, PJ, 2017
)
1.52
"Ketoprofen (KET) is a mostly used nonsteroidal anti-inflammatory drug that has been frequently detected in wastewater effluents and surface waters. "( Degradation of ketoprofen by sulfate radical-based advanced oxidation processes: Kinetics, mechanisms, and effects of natural water matrices.
Feng, Y; Liu, G; Lv, W; Song, Q, 2017
)
2.25
"Dexketoprofen trometamol is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations. "( A review of dexketoprofen trometamol in acute pain.
Hanna, M; Moon, JY, 2019
)
1.49
"Ketoprofen is a well-known nonsteroidal anti-inflammatory drug involved in the early stage inflammation cascade."( Antifibrotic Effect of Ketoprofen-Grafted Alginate Microcapsules in the Transplantation of Insulin Producing Cells.
Bühler, LH; Gerber-Lemaire, S; Gonelle-Gispert, C; Montanari, E; Noverraz, F; Ortiz, D; Pimenta, J; Szabó, L, 2018
)
1.51
"Ketoprofen is a well known nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic effects. "( Molecular dynamics in liquid and glassy states of non-steroidal anti-inflammatory drug: ketoprofen.
Govindaraj, G; Krishna Kumar, NS; Sailaja, U; Shahin Thayyil, M, 2013
)
2.05
"Ketoprofen is an anti-inflammatory agent commonly used as a component of mouth rinse for oral lesions."( Ketoprofen inhibits expression of inflammatory mediators in human dental pulp cells.
Choi, EK; Hwang, YC; Jeong, JY; Kang, IC; Kim, SH; Koh, JT; Lee, BN; Min, KS; Nör, JE; Oh, WM, 2013
)
2.55
"Ketoprofen (KP) is a widely used nonsteroidal anti-inflammatory drug for the treatment of osteoarthritis and various rheumatic diseases. "( Singlet oxygen mediated DNA damage induced phototoxicity by ketoprofen resulting in mitochondrial depolarization and lysosomal destabilization.
Amar, SK; Chopra, D; Dwivedi, A; Goel, S; Kushwaha, HN; Mujtaba, SF; Ray, RS; Verma, A; Yadav, N, 2013
)
2.07
"Ketoprofen was found to be a competitive inhibitor of LDH in human platelets. "( Effect of ketoprofen on lactic dehydrogenase from human platelets.
Choudry, MZ; Javed, I; Khan, MT; Mukhtar, N; Razi, MT,
)
1.98
"Dexketoprofen is a nonsteroidal anti-inflammatory drug with a relatively short half-life and rapid onset of action, blocking the action of cyclo-oxygenase, which is involved in prostaglandins' production, thus reducing inflammation and pain."( The efficacy and tolerability of frovatriptan and dexketoprofen for the treatment of acute migraine attacks.
Allais, G; Benedetto, C; De Lorenzo, C; Rolando, S, 2014
)
1.17
"Ketoprofen is a nonsteroidal antiinflammatory drug, recently approved as an over-the-counter (OTC) analgesic at a 12.5 mg dosage strength. "( Ketoprofen Dental Pain Study.
Betts, NJ; Cooper, SA; Hermann, DG; Hersh, EV; Lamp, C; Levin, LM; Secreto, SA; Wedell, D, 1997
)
3.18
"Ketoprofen is an analgesic, anti-inflammatory agent commonly used in the management of chronic musculoskeletal pain. "( Characterization of the Percutaneous Absorption of Ketoprofen Using the Franz Skin Finite Dose Model.
Banov, D; Bassani, AS; Phan, H, 2016
)
2.13
"Ketoprofen (KP) is a widely used nonsteroidal anti-inflammatory drug that inhibits prostaglandin biosynthesis. "( Skin application of ketoprofen systemically suppresses contact hypersensitivity by inducing CD4(+) CD25(+) regulatory T cells.
Atarashi, K; Kabashima, K; Kuma, H; Mori, T; Tokura, Y; Yoshiki, R, 2009
)
2.12
"Ketoprofen is a potent non-steroidal anti-inflammatory drug (NSAID) that has been widely used in the treatment of rheumatoid arthritis and other related conditions. "( Gastroresistant microcapsules: new approaches for site-specific delivery of ketoprofen.
Bigucci, F; Cerchiara, T; Luppi, B; Zecchi, V, 2009
)
2.03
"Ketoprofen is a non-selective non-steroidal anti-inflammatory drug (NSAID) used to treat acute and chronic painful conditions. "( Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults.
Barden, J; Derry, S; McQuay, HJ; Moore, RA, 2009
)
2.14
"Ketoprofen is a nonsteroidal anti-inflammatory drug that has been detected in the environment in the range of ng L(-1)-microg L(-1) due to its low degradability in some wastewater treatment plants. "( White-rot fungus-mediated degradation of the analgesic ketoprofen and identification of intermediates by HPLC-DAD-MS and NMR.
Caminal, G; Cruz-Morató, C; Marco-Urrea, E; Pérez-Trujillo, M; Vicent, T, 2010
)
2.05
"Ketoprofen is a highly effective NSAID with antipyretic and analgesic properties for the symptomatic management of pain and fever in both adults and children."( Dose-finding studies of ketoprofen in the management of fever in children: report on two randomized, single-blind, comparator-controlled, single-dose, multicentre, phase II studies.
Kokki, H; Kokki, M, 2010
)
2.11
"Ketoprofen is an important photosensitive drug molecule that has received much attention for the study of its photochemistry in different solvents. "( Water concentration dependent photochemistry of ketoprofen in aqueous solutions.
Chuang, YP; Du, Y; Li, MD; Phillips, DL; Xue, J, 2010
)
2.06
"Ketoprofen (KP) is a widely used transdermal non-steroidal anti-inflammatory drug. "( Titanium dioxide inclusion in backing reduce the photoallergenicity of ketoprofen transdermal patch.
Ah, YC; Bae, IH; Bae, JH; Choi, YG; Ki, HM; Lee, JH; Lee, KC; Lim, KM; Park, YH, 2011
)
2.05
"Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug ketoprofen. "( [The effects of intravenous dexketoprofen on postoperative analgesia and morphine consumption in patients undergoing abdominal hysterectomy].
Erol, A; Keçecioğlu, M; Reisli, R; Tuncer, S, 2010
)
1.27
"Ketoprofen is a drug belonging to the family of non-steroidal anti-inflammatory drugs (NSAIDs). "( Pain and ketoprofen: what is its role in clinical practice?
Atzeni, F; Bagnasco, M; Colombo, M; D'Imporzano, M; Fischer, F; Lanata, L; Sarzi-Puttini, P,
)
1.99
"Ketoprofen is a potent non-steroidal anti-inflammatory drug has been used in the treatment of various kinds of pains, inflammation and arthritis. "( Anti-inflammatory and analgesic effects of ketoprofen in palm oil esters nanoemulsion.
Azmin, MN; Elrashid, SM; Munavvar, AS; Sakeena, MH; Yam, MF, 2010
)
2.07
"Ketoprofen (KP) is a nonsteroidal anti-inflammatory drug, which during UV irradiation rapidly transforms into benzophenone derivatives. "( Application of complementary mass spectrometric techniques to the identification of ketoprofen phototransformation products.
Heath, E; Kosjek, T; Kralj, B; Perko, S; Žigon, D, 2011
)
2.04
"Ketoprofen is a non-steroid anti-inflammatory drug (NSAID) used in the treatment of rheumatic diseases and in mild to moderate pain. "( Design and characterization of sustained release ketoprofen entrapped carnauba wax microparticles.
Lima, EM; Nascimento, TL; Oliveira, RB, 2012
)
2.08
"Ketoprofen is a common human medicine from a class of non-steroidal anti-inflammatory drugs (NSAIDs), which is provably detected in surface waters in concentrations ordinarily in μg.L-1. "( Comparison of acute toxicity of ketoprofen to juvenile and embryonic stages of Danio rerio.
Bedanova, I; Macova, S; Marsalek, P; Pistekova, V; Plhalova, L; Praskova, E; Siroka, Z; Svobodova, Z; Voslarova, E, 2011
)
2.1
"Ketoprofen is a non-steroidal anti-inflammatory drug which has been widely used for domestic animals. "( Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs.
Heinonen, M; Mustonen, K; Niemi, A; Palviainen, M; Peltoniemi, M; Peltoniemi, OA; Raekallio, M; Siven, M; Vainio, O, 2012
)
2.17
"Ketoprofen is a NSAIDs of the 2-aryl propionic acid class commonly used in the treatment of inflammatory rheumatic disease, acute pain and fever. "( Adding ketoprofen to intravenous patient-controlled analgesia with tramadol after major gynecological cancer surgery: a double-blinded, randomized, placebo-controlled clinical trial.
Balat, O; Capar, M; Pirbudak, L; Tuncer, S, 2003
)
2.22
"Ketoprofen is a satisfactory alternative analgesic to pethidine for vitreoretinal surgery and results in a lower incidence of postoperative nausea and vomiting."( A comparison of intravenous ketoprofen versus pethidine on peri-operative analgesia and post-operative nausea and vomiting in paediatric vitreoretinal surgery.
Ghai, B; Khetarpal, M; Subramaniam, R; Subramanyam, MS,
)
1.87
"Dexketoprofen trometamol is an effective and rapidly acting analgesic for the treatment of acute musculoskeletal injuries."( Randomised controlled trial of the onset of analgesic efficacy of dexketoprofen and diclofenac in lower limb injury.
Herington, J; Kapadia, Y; Leman, P, 2003
)
1.17
"Ketoprofen is a photolabile drug. "( Bioequivalence determination of topical ketoprofen using a dermatopharmacokinetic approach and excised skin penetration.
Akerström, U; Berne, B; Lindahl, K; Lodén, M, 2004
)
2.03
"Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) orally effective in treating fever, pain, and inflammation but gastrointestinal side effects were observed. "( Antipyretic, analgesic and anti-inflammatory activities of ketoprofen beta-cyclodextrin inclusion complexes in animals.
Li, RY; Lu, WL; Shen, WB; Tu, XD; Wang, H; Zhang, LF; Zhang, Q; Zheng, L, 2004
)
2.01
"Ketoprofen is a non-steroidal anti-inflammatory drug which is not freely soluble in water and creates gastrointestinal problems. "( Polyamidoamine dendrimers used as solubility enhancers of ketoprofen.
Rongqiang, F; Tongwen, X; Yiyun, C, 2005
)
2.02
"Ketoprofen is an important anti-inflammatory drug, but its dermal application is limited because of the photosensitizing properties causing phototoxic reactions of the skin when exposed to UV light. "( The detection of UV-induced membrane damages by a combination of two biosensor techniques.
Bendas, G; Christ, K; Höpfner, M; Rothe, U; Rüttinger, HH,
)
1.57
"Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of nonsteroidal anti-inflamatory drug ketoprofen. "( [Postoperatif ağrida deksketoprofen kullanimi].
Köstekçi, H; Otelcioğlu, S; Reisli, R; Tavlan, A; Tuncer, S, 2006
)
1.26
"Ketoprofen (KP) is a widely used non-steroidal anti-inflammatory drug (NSAID). "( Ketoprofen: experimental overview of dermal toxicity.
Choi, YG; Jung, KM; Kim, BH; Kim, JJ; Lee, BS; Son, WC, 2007
)
3.23
"Dexketoprofen is an NSAID belonging to the arylpropionic acid group that has demonstrated good analgesic efficacy and a good safety profile in different acute and chronic painful conditions."( A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.
Wagenitz, A; Zippel, H, 2007
)
1.07
"Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid family with demonstrated efficacy in the treatment of rheumatoid arthritis and osteoarthritis; a distinguished safety profile; and good tolerability. "( Ketoprofen extended-release capsules: a new formulation for the treatment of osteoarthritis and rheumatoid arthritis.
Schumacher, HR,
)
3.02
"Ketoprofen (Orudis) is a nonsteroidal anti-inflammatory drug that is currently approved in the United States for the management of mild to moderate pain. "( Ketoprofen, acetaminophen plus oxycodone, and acetaminophen in the relief of postoperative pain.
De Castro, A; Olson, NZ; Sunshine, A; Zighelboim, I, 1993
)
3.17
"Ketoprofen (KP) is a potent non-steroidal anti-inflammatory drug which is used for the treatment of rheumatoid arthritis. "( Percutaneous absorption of ketoprofen. I. In vitro release and percutaneous absorption of ketoprofen from different ointment bases.
Demirdamar, R; Gürol, Z; Hekimoğlu, S; Sumnu, M, 1996
)
2.03
"Ketoprofen is a safe and effective drug for the treatment of locomotor symptoms of milk fever, but has no effect on the duration of clinical respiratory abnormalities."( Evaluation of the effect of ketoprofen on experimentally induced ephemeral fever in dairy heifers.
Daniel, RC; Fenwick, DC, 1996
)
2.03
"Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen. "( Preclinical and clinical development of dexketoprofen.
Artigas, R; Carganico, G; García, ML; Mauleón, D, 1996
)
1.18
"Ketoprofen is an effective post-operative analgesic in combination with an opioid, but has no preemptive effect according to the results of this study."( [The preemptive action of ketoprofen. Randomized, double-blind study with gynecologic operations].
Bernatzky, G; Breschan, C; Burtscher, M; Krumpholz, R; Likar, R; Mathiaschitz, K; Ozegovic, G; Pipam, W; Sittl, R, 1997
)
2.04
"Dexketoprofen was found to be a potent inhibitor of this PGF2 alpha production in rat brain (IC50 = 6.2 nM), and it completely suppressed PGF2 alpha production at 1 microM concentration."( Stereoselective inhibition of rat brain cyclooxygenase by dexketoprofen.
Cabré, F; Carabaza, A; García, AM; García, ML; Mauleón, D; Rotllan, E, 1997
)
1.05
"Ketoprofen is a non-steroidal antiinflammatory drug (NSAID) which provides effective analgesia in situations of pain provoked by tissue inflammation. "( Central and peripheral actions of the NSAID ketoprofen on spinal cord nociceptive reflexes.
Cervero, F; Herrero, JF; Parrado, A, 1997
)
2
"Ketoprofen injection is an alternative for post operative pain relief."( Comparison of ketoprofen and morphine for post-operative analgesia in orthopaedic patients.
Pakpianpairoj, C; Prasartritha, T; Vathana, P, 1998
)
1.38
"Ketoprofen is a chiral non-steroidal anti-inflammatory drug (NSAID) available as a racemic (rac) mixture of S-(+)- and R-(-)-isomers. "( Passage of S-(+)- and R-(-)-ketoprofen across the human isolated perfused placenta.
Bannwarth, B; Lagrange, F; Leng, JJ; Pehourcq, F; Saux, MC, 1998
)
2.04
"Ketoprofen is a potent nonsteroidal antiinflammatory agent (NSAID) recently approved for OTC use as an analgesic/antipyretic at doses of 75 mg versus the usual dose of < or = 300 mg daily."( An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen.
Codispoti, JR; Lanza, FL; Nelson, EB, 1998
)
1.25
"S(+)-ketoprofen is a potent antiinflammatory, analgesic, and antipyretic agent in vivo, consistent with its potent anti-COX activity."( Analgesic, antiinflammatory, and antipyretic effects of S(+)-ketoprofen in vivo.
Cabré, F; Calvo, L; Fernández, MF; Ferrer, X; García, ML; Mauleón, D, 1998
)
1
"Ketoprofen (KTP) is a chiral non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class, approved by the FDA for the allevation of pain associated with musculoskeletal disorders in horses. "( Bioavailability of racemic ketoprofen in healthy horses following rectal administration.
Aboul-Enein, HY; Baeyens, W; Corveleyn, S; Deprez, P; Haustraete, J; Henrist, D; Remon, JP; Sustronck, B; Van Der Weken, G, 1999
)
2.04
"Ketoprofen is a non-steroidal anti-inflammatory drug which is not soluble in water and creates gastrointestinal problems. "( Inclusion of ketoprofen with skimmed milk by freeze-drying.
Gönüllü, U; Topaloğlu, Y; Yener, G, 1999
)
2.12
"Ketoprofen is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. "( Pharmacokinetics of ketoprofen syrup in small children.
Heikkinen, M; Jekunen, A; Kokki, H; Le Liboux, A; Montay, G, 2000
)
2.07
"Ketoprofen (KP) is a potent nonsteroidal anti-inflammatory drug (NSAID) widely used in clinical practice for the control of acute and chronic pain of soft tissues and skeletal muscle system. "( In vitro release and antiinflammatory activity of topical formulations of ketoprofen.
Gavini, E; Moretti, MD; Peana, AT,
)
1.8
"Ketoprofen is a NSAID that exists as a pair of R(-) and S (+) enantiomers; like other 2-arylpropionic acids, its anti-inflammatory effects resides almost exclusively in the S (+) isomer."( Intestinal toxicity of ketoprofen-trometamol vs its enantiomers in rat. Role of oxidative stress.
Cabré, F; de la Lastra, CA; Herrerías, JM; Martín, MJ; Mauleón, D; Motilva, V; Nieto, A, 2000
)
1.34
"Ketoprofen (KP) is a potent nonsteroidal anti-inflammatory drug. "( UV-induces formation of hydrogen peroxide based on the photochemistry of ketoprofen.
Huschka, C; Nuhn, P; Radschuweit, A; Rüttinger, HH; Wohlrab, W, 2001
)
1.98
"Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen. "( Clinical pharmacokinetics of dexketoprofen.
Antonijoan, RM; Barbanoj, MJ; Gich, I, 2001
)
1.22
"Ketoprofen thus seems to be an effective and acceptable drug for the treatment of patients with rheumatoid arthritis."( A double-blind cross-over study of ketoprofen and phenylbutazone in rheumatoid arthritis.
Peltola, P, 1976
)
1.25
"Ketoprofen is a nonsteroidal anti-inflammatory drug with both anti-inflammatory and analgesic properties. "( The efficacy and safety of ketoprofen in postsurgical dental pain.
Hersh, EV, 1991
)
2.02
"Ketoprofen is a new peripherally acting analgesic and the most recently introduced nonsteroidal anti-inflammatory drug in the United States with indication for management of nonarthritic pain. "( Ketoprofen in oral surgery pain: a review.
Cooper, SA, 1988
)
3.16

Effects

Ketoprofen has a short biological half-life and the commercially available conventional release formulations require dosages to be administered at least 2-3 times a day. It has an antiepileptic feature and this effect increases as the dosage increases, but it is unknown through which mechanism this drug shows its anticonvulsant effect.

Ketoprofen has been investigated in children for the treatment of pain and fever, peri- and postoperative pain, and inflammatory pain conditions. It can be used as a new treatment option for skin cancers as a part of photochemotherapy.

ExcerptReferenceRelevance
"Dexketoprofen has a stronger effect than ketoprofen, which makes it a readily used preparation."( The comparison of dexketoprofen and other painkilling medications (review from 2018 to 2021).
Kuczyńska, J; Nieradko-Iwanicka, B; Pawlak, A, 2022
)
1.55
"Dexketoprofen has an antiepileptic feature and this effect increases as the dosage increases, however it is currently unknown through which mechanism this drug shows its anticonvulsant effect. "( Inhibitor effect of dexketoprofen in rat model of pentylenetetrazol-induced seizures.
Aksoy, D; Erbaş, O; Solmaz, V, 2015
)
1.35
"Ketoprofen has a short biological half-life and the commercially available conventional release formulations require dosages to be administered at least 2-3 times a day."( Design and characterization of sustained release ketoprofen entrapped carnauba wax microparticles.
Lima, EM; Nascimento, TL; Oliveira, RB, 2012
)
1.35
"Ketoprofen has a long terminal half-life and complete absorption in this species. "( Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE, 2003
)
2
"Ketoprofen has a short half-life, a simple metabolism, and a broad therapeutic window, and does not accumulate with multiple doses."( Ketoprofen: a review of its pharmacologic and clinical properties.
Kantor, TG,
)
2.3
"Dexketoprofen has a stronger effect than ketoprofen, which makes it a readily used preparation."( The comparison of dexketoprofen and other painkilling medications (review from 2018 to 2021).
Kuczyńska, J; Nieradko-Iwanicka, B; Pawlak, A, 2022
)
1.55
"Ketoprofen-RGD has been revealed to act as an anti-cancer agent against some tumors."( Anti-Breast Cancer Activities of Ketoprofen-RGD Conjugate by Targeting Breast Cancer Stem-Like Cells and Parental Cells.
Noori, S; Rajabi, S; Shokri, B; Tavirani, MR; Zarghi, A, 2021
)
1.62
"Ketoprofen has phototoxic properties and it can be used as a new treatment option for skin cancers as a part of photochemotherapy."( The role of UVA radiation in ketoprofen-mediated BRAF-mutant amelanotic melanoma cells death - A study at the cellular and molecular level.
Banach, K; Beberok, A; Kowalska, J; Rok, J; Rzepka, Z; Wrześniok, D, 2021
)
1.63
"Dexketoprofen has an antiepileptic feature and this effect increases as the dosage increases, however it is currently unknown through which mechanism this drug shows its anticonvulsant effect. "( Inhibitor effect of dexketoprofen in rat model of pentylenetetrazol-induced seizures.
Aksoy, D; Erbaş, O; Solmaz, V, 2015
)
1.35
"Ketoprofen has high analgesic efficacy against inflammatory and nociceptive pain. "( Intravenous dexketoprofen induces less injection pain than racemic ketoprofen.
Halinen, L; Kokki, H; Kokki, M; Nokela, A; Sjövall, S; Turunen, M, 2015
)
2.21
"Dexketoprofen has been shown to provide efficient analgesia and an opioid-sparing effect after orthopedic surgery. "( A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone.
Eskelinen, M; Häkkinen, MR; Hautajärvi, H; Immonen, S; Kokki, H; Kokki, M; Piirainen, A, 2015
)
1.34
"Ketoprofen has been investigated in children for the treatment of pain and fever, peri- and postoperative pain, and inflammatory pain conditions."( Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients.
Kokki, H, 2010
)
2.52
"Ketoprofen has shown to be an excellent choice of drug for the treatment of chronic pain in patients with osteoarthritis, rheumatoid arthritis or gout, demonstrating a high level of efficacy with good tolerability also in elderly patients."( Pain and ketoprofen: what is its role in clinical practice?
Atzeni, F; Bagnasco, M; Colombo, M; D'Imporzano, M; Fischer, F; Lanata, L; Sarzi-Puttini, P,
)
1.27
"Ketoprofen has a short biological half-life and the commercially available conventional release formulations require dosages to be administered at least 2-3 times a day."( Design and characterization of sustained release ketoprofen entrapped carnauba wax microparticles.
Lima, EM; Nascimento, TL; Oliveira, RB, 2012
)
1.35
"Ketoprofen monotherapy has been shown to be generally equivalent to other NSAIDs when used in the treatment of OA."( Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.
Gigante, A; Tagarro, I, 2012
)
1.32
"Ketoprofen has a long terminal half-life and complete absorption in this species. "( Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE, 2003
)
2
"Ketoprofen has been reported to have such side effects as photosensitive dermatitis in humans (The Ministry of Health, Labour and Welfare, 2001). "( Phototoxicity study of a ketoprofen poultice in guinea pigs.
Kato, H; Kokubu, M; Okumura, Y; Takayama, S; Yamauchi, H, 2005
)
2.07
"Ketoprofen has been revealed to have characteristics of adequate analgesia before an operation and prevents the development of pain syndrome in patients after they are operated."( [Using ketoprofen in gynaecological practice].
Oliĭnyk, IuV,
)
1.31
"Ketoprofen may have been the cause of pancreatitis in this case; we have suggested two possible mechanisms related to prostaglandin inhibition."( Acute pancreatitis associated with ketoprofen.
Cobb, TK; Pierce, JR, 1992
)
1.28
"Ketoprofen has emerged as a potent nonsteroidal anti-inflammatory drug. "( 20 years' experience with ketoprofen.
Veys, EM, 1991
)
2.02
"Ketoprofen has been associated with a very low incidence of serious renal, hepatic, or cutaneous reactions."( Ketoprofen: the European experience.
Avouac, B; Teule, M, 1988
)
2.44
"Ketoprofen has a short half-life, a simple metabolism, and a broad therapeutic window, and does not accumulate with multiple doses."( Ketoprofen: a review of its pharmacologic and clinical properties.
Kantor, TG,
)
2.3

Actions

Ketoprofen irradiation promotes the photolysis of erythrocyte suspensions. The Ketoproen group had lower numerical rating scale (P < 0.05) Patients received less morphine during the first 24 h after surgery.

ExcerptReferenceRelevance
"S-Ketoprofen presented a lower plasma exposure compared to R-enantiomer."( Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.
Fagiolino, P; Guevara, N; Ibarra, M; Lorier, M; Magallanes, L; Vázquez, M, 2016
)
1.27
"Ketoprofen alone did not produce any respiratory effects."( The effects of a nonsteroidal antiinflammatory drug (ketoprofen) on morphine respiratory depression: a double-blind, randomized study in volunteers.
Blanloeil, Y; Francois, T; Moren, J; Pinaud, M, 1997
)
1.27
"Ketoprofen did not suppress totally the PAF-induced changes in mechanics of breathing, which suggests that PAF or a secondary release of mediators could have a direct action on airway smooth muscle."( Ketoprofen and phenylbutazone attenuation of PAF-induced lung inflammation in calves.
Coghe, J; Deby-Dupont, G; Lekeux, P; Uystepruyst, C; Van de Weerdt, ML, 1999
)
2.47
"Ketoprofen irradiation promotes the photolysis of erythrocyte suspensions."( Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data.
Bagheri, H; Chouini-Lalanne, N; Lhiaubet, V; Montastruc, JL, 2000
)
1.35
"The Ketoprofen group had lower numerical rating scale (P < 0.05), received less morphine during the first 24 h after surgery (7.4 +/- 5 vs 11.7 +/- 6 mg, P < 0.05), had fewer nausea and vomiting episodes (21 vs 38, P < 0.05), and were less likely to require oxygen breathing after 1 h in the recovery room (33 vs 59 patients, P < 0.05)."( Intravenous ketoprofen in thyroid and parathyroid surgery.
Basto, ER; Eurin, BG; Jacob, LP; Landru, JP; Mourey, FD; Waintrop, C, 2001
)
1.17

Treatment

Ketoprofen 2% topical pretreatment might be an interesting strategy to reduce tDCS-induced erythema and might be useful for blinding improvement in further sham-controlled tDCS trials. Dexketofen pretreatment can protect the liver from IR injury by decreasing inflammation and lipid peroxidation.

ExcerptReferenceRelevance
"Ketoprofen-treated rats showed a smaller fall in arterial pressure in response to ganglion blockade during ANG-II infusion than did nontreated controls."( Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat.
Asirvatham-Jeyaraj, N; Fink, GD; King, AJ; Madan, S; Northcott, CA, 2013
)
1.11
"Ketoprofen 2% topical pretreatment might be an interesting strategy to reduce tDCS-induced erythema and might be useful for blinding improvement in further sham-controlled tDCS trials."( Reducing transcranial direct current stimulation-induced erythema with skin pretreatment: considerations for sham-controlled clinical trials.
Benseñor, IM; Bikson, M; Boggio, PS; Brunoni, AR; Caumo, W; Cordeiro, Q; Guarienti, F; Lotufo, PA; Shiozawa, P, 2015
)
1.86
"Dexketoprofen pretreatment can protect the liver from IR injury by decreasing inflammation and lipid peroxidation."( The effects of dexketoprofen on endogenous leptin and lipid peroxidation during liver ischemia reperfusion injury.
Aksoy, A; Gulbahar, Y; Kabak, Y; Kaya, C; Koksal, E; Sener, EB; Ustun, YB; Yarim, G,
)
0.98
"Ketoprofen treatment significantly reduced the rectal temperature and total clinical scores, and lowered blood thromboxane B(2) concentrations when compared with the control group."( Dose-response investigation of oral ketoprofen in pigs challenged with Escherichia coli endotoxin.
Banting, A; Heinonen, M; Mustonen, K; Peltoniemi, OA; Raekallio, M; Vainio, O, 2012
)
1.38
"Ketoprofen treatment improved survival of septic Balb/c mice subjected to secondary infection, while also enhancing macrophage phagocytosis and neutrophil recruitment to the lungs."( Ketoprofen impairs immunosuppression induced by severe sepsis and reveals an important role for prostaglandin E2.
Antunes, CA; Benjamim, CF; Bozza, MT; Brogliato, AR; Canetti, C; Carvalho, RS; Kunkel, SL; Monteiro, AP; Peters-Golden, M; Tinoco, RF; Vianna-Jorge, R, 2012
)
2.54
"S-ketoprofen treatment did not prevent this change at all dose levels, but reduced marrow cavity area to increase cortical bone area at the 0.1, 0.5 and 2.5 mg/kg per dose levels compared to tenotomy controls."( S-ketoprofen inhibits tenotomy-induced bone loss and dynamics in weanling rats.
Jee, WS; Ke, HZ; Wechter, WJ; Zeng, QQ, 1993
)
1.57
"Both ketoprofen treatments and patients treated with paracetamol 1000 mg reported significantly greater pain relief (P < 0.01) and a later time to taking escape analgesics (P < 0.01) than patients medicated with placebo."( The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery.
Hawkesford, JE; Kelly, PJ; Seymour, RA, 1996
)
1.1
"Ketoprofen pretreatment lowered PAF-induced thrombocytopenia and decrease in the number of dense bodies."( Morphological alterations of blood platelets induced by platelet activating factor (PAF) and partial inhibition by ketoprofen in calves.
Bastos da Silva, M; David, JL; Dessy, C; Lekeux, P,
)
1.06
"In S-ketoprofen-pretreated rats, the relaxant effect of MEN 11420 was significant at 2 but not at 1 ml of distension, and that of isoprenaline was reduced by 50% at both 1 and 2 ml."( Bladder distension and activation of the efferent function of sensory fibres: similarities with the effect of capsaicin.
Criscuoli, M; Dion, S; Giuliani, S; Lecci, A; Maggi, CA; Santicioli, P; Tramontana, M, 1998
)
0.76
"Ketoprofen treatment after muscle damaging exercise reduces muscle soreness and improves force recovery."( Effect of ketoprofen on muscle function and sEMG activity after eccentric exercise.
Clarkson, PM; Kamen, G; Knight, CA; Sayers, SP; Van Wegen, EH, 2001
)
2.16
"Ketoprofen treatment compared to placebo significantly reduced the size of the cysts and both ureteral and uterine pain behaviors post-stone implantation."( Influence of endometriosis on pain behaviors and muscle hyperalgesia induced by a ureteral calculosis in female rats.
Affaitati, G; Berkley, KJ; Centurione, L; Giamberardino, MA; Lapenna, D; Lerza, R; Vecchiet, L, 2002
)
1.04
"Ketoprofen treatment was not associated with any unusual or serious side effects in any of the three studies.(ABSTRACT TRUNCATED AT 250 WORDS)"( Ketoprofen in oral surgery pain: a review.
Cooper, SA, 1988
)
2.44
"Co-treatment with ketoprofen and UVA irradiation has cytotoxic and anti-proliferative and pro-apoptotic effect on C32."( The role of UVA radiation in ketoprofen-mediated BRAF-mutant amelanotic melanoma cells death - A study at the cellular and molecular level.
Banach, K; Beberok, A; Kowalska, J; Rok, J; Rzepka, Z; Wrześniok, D, 2021
)
1.24
"Cows treated with ketoprofen spent less time in lateral recumbency (p < 0.05) (overall and with the head rested); this was independent of assistance status, and lateral recumbency was not affected by the interaction between assistance and treatment status."( Administration of ketoprofen affects post-partum lying behaviours of Holstein dairy cows regardless of whether parturition is assisted.
Ellis, K; Gladden, N; Martin, J; McKeegan, D, 2021
)
1.28
"Treatment of ketoprofen-induced photoallergic dermatitis includes discontinuation of ketoprofen, topical or systemic corticosteroids and avoidance of sun exposure and agents known to exacerbate dermatitis."( Ketoprofen-induced photoallergic dermatitis.
Cohen, PR; Loh, TY, 2016
)
2.23
"Pretreatment with ketoprofen or meloxicam prevented hyperalgesia and elevation of spinal PGE2, increasing the escape behavior time during forced swimming 95% respect to saline-treated rats."( Reduction of spinal PGE2 concentrations prevents swim stress-induced thermal hyperalgesia.
Cardenas, R; Fernandez, AC; Guevara, C; Suarez-Roca, H, 2015
)
0.74
"Post-treatment with ketoprofen produced inhibition of c-Fos but parecoxib did not have any significant effect."( Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib.
Avila, R; Cardenas, R; Quintero, L; Siso, A; Suarez-Roca, H; Urdaneta, A; Urdaneta, B, 2009
)
0.67
"Treatment with ketoprofen was more likely to achieve temperature below 37.8°C compared to acetaminophen with odds ratio 6.25."( Comparison of acetaminophen and ketoprofen in febrile children: a single dose randomized clinical trial.
Erkek, N; Karacan, CD; Senel, S, 2012
)
1
"Treatment with ketoprofen lysine salt demonstrated a significantly more marked (p < 0.001) anti-inflammatory effect than placebo as regards all variables considered: burning, sensation pain, oedema and erythema, and by the 3rd day of treatment led to significant remission of the symptomatology. "( [The efficacy of and tolerance for ketoprofen lysine salt in solution for oropharyngeal use in inflammatory lesions of the oral cavity].
de' Lorenzi, C; Natale, F, 1997
)
0.93
"Treatment with ketoprofen provided rapid and marked pain relief similar to that afforded by mefenamic acid."( Double-blind comparison of ketoprofen and mefenamic acid in the treatment of primary dysmenorrhea.
Bourgouin, J; Hébert, JG; Le Morvan, P, 1986
)
0.91

Toxicity

Ketoprofen for topical use has been associated with a large number of cutaneous adverse effect reports. Meloxicam is a safe and effective method of controlling postoperative pain for 20 hours in dogs undergoing abdominal surgery.

ExcerptReferenceRelevance
"7%) had withdrawn from treatment for various reasons, including adverse reactions, inefficacy and improvement, or had been lost to follow-up."( Long-term safety of ketoprofen in an elderly population of arthritic patients.
Schattenkirchner, M, 1991
)
0.6
" The results obtained were as follows: LD50 of KP was estimated to be 434 mg/kg in male weanlings and 496 mg/kg in female weanlings."( [Acute toxicity of intrarectally administered (ketoprofen (T10) in rat weanlings].
Asai, I; Hiyoshi, K; Kaga, M; Matsuura, K; Shimpo, K; Takeuchi, M; Tsuchiya, J; Yamaguchi, M, 1983
)
0.52
" LD50 values of terms of KP were 84 mg/kg in male rats and 122 mg/kg in female rats when KP-CMC was administered intrarectally, and 117 mg/kg in male and 92 mg/kg in female when KP-T10 was administered intrarectally."( [Acute toxicity of ketoprofen intrarectally administered in rats, with special reference to histopathological changes (author's transl)].
Asai, I; Hiyoshi, K; Iwata, M; Matsuura, K; Shimpo, K; Takahashi, M; Takeuchi, M; Tanabe, T; Tsuchiya, J, 1981
)
0.59
" From the above results, it can be seen that the suppository of KP capsulated by the soft T10 does not show any irritating effect on anorectal mucosa and has no toxic effect on all organs systemically."( [Toxicological study on the anorectal irritation and systemic organ toxicity evoked by long-term intrarectal administration of ketoprofen in rabbits (author's transl)].
Asai, I; Hiyoshi, K; Iwata, M; Matsuura, K; Shimpo, K; Takahashi, M; Takeuchi, M; Tanabe, T; Tsuchiya, J, 1981
)
0.47
" There were no significant differences between treatments in the number of adverse events."( Comparison of the efficacy, safety, and pharmacokinetic profiles of extended-release ketoprofen and piroxicam in patients with rheumatoid arthritis.
Caldwell, JR,
)
0.36
"Eleven neonates from seven pregnancies were admitted because they suffered from adverse effects of ketoprofen given to their mothers before delivery."( [Adverse effects of ketoprofen after intrauterine exposure. Value of plasma determination].
Apere, H; Cavert, MH; Demarquez, JL; Llanas, B, 1996
)
0.83
" There were no serious adverse events observed in this study, with the overall incidence of side effects being somewhat less in the (R)- ketoprofen groups than in the acetaminophen 1,000 mg group."( Analgesic efficacy and safety of (R)- ketoprofen in postoperative dental pain.
Cooper, SA; Hersh, EV; Reynolds, B; Reynolds, DC, 1998
)
0.77
" The reported toxic serum level for bupivacaine was 4 micrograms/ml and for ketoprofen is 1128 micrograms/ml."( The safety of topical anaesthetic and analgesic agents in a gel when used to provide pain relief at split skin donor sites.
Alvi, R; Bunting, P; Burrows, D; Collins, W; Jones, RP; Jones, S; McKiernan, EP, 1998
)
0.53
"These results suggest that reactive oxygen metabolites can contribute significantly to the development of intestinal lesions, and that R(-)-ketoprofen present in racemic preparations can enhance the toxic intestinal effects of S (+)-enantiomer via modification of neutrophil migration and oxidative stress."( Intestinal toxicity of ketoprofen-trometamol vs its enantiomers in rat. Role of oxidative stress.
Cabré, F; de la Lastra, CA; Herrerías, JM; Martín, MJ; Mauleón, D; Motilva, V; Nieto, A, 2000
)
0.82
"Results suggest that preoperative administration of meloxicam is a safe and effective method of controlling postoperative pain for 20 hours in dogs undergoing abdominal surgery; the analgesic effects of meloxicam were comparable to those of ketoprofen and superior to those of butorphanol."( Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery.
Foster, R; Mathews, KA; McDonell, W; Pettifer, G, 2001
)
0.72
" Adverse drug-related effects reported included numbness of the tissues in the oral cavity, sensation of tingling in the tissues in the oral cavity, dry mouth, thirst, and nausea."( Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study.
Bellussi, L; Damiani, V; Passàli, D; Passàli, GC; Volonté, M, 2001
)
0.62
"Since assessment of the acute gastrotoxicity of nonsteroidal antiinflammatory drugs (NSAIDs) in rats requires high doses of the drugs, we sought to establish an experimental model with which this adverse NSAID effect can be estimated at therapy-relevant doses."( Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses.
Cabré, F; Holzer, P; Jocic, M; Mauléon, D, 2001
)
0.58
" There was no significant difference in the gastrotoxicity of FBP when the drug was administered subcutaneously or IG, whereas subcutaneously injected R/S-KP was slightly more toxic than IG R/S-KP."( Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses.
Cabré, F; Holzer, P; Jocic, M; Mauléon, D, 2001
)
0.58
"Ketorolac is approved for the relief of postoperative pain but concerns have been raised over a possible risk of serious adverse effects and death."( Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery.
Abdalla, M; Bianchi, PG; Bonnet, F; Camu, F; Ebrahim, S; Escolar, G; Forrest, JB; Greer, IA; Heitlinger, E; Jage, J; Kehlet, H; Langman, MJ; Pocock, S; Samama, MM; Velo, G, 2002
)
0.61
"38%) had a serious adverse outcome, with 19 deaths (0."( Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery.
Abdalla, M; Bianchi, PG; Bonnet, F; Camu, F; Ebrahim, S; Escolar, G; Forrest, JB; Greer, IA; Heitlinger, E; Jage, J; Kehlet, H; Langman, MJ; Pocock, S; Samama, MM; Velo, G, 2002
)
0.61
"We conclude that ketorolac is as safe as ketoprofen and diclofenac for the treatment of pain after major surgery."( Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery.
Abdalla, M; Bianchi, PG; Bonnet, F; Camu, F; Ebrahim, S; Escolar, G; Forrest, JB; Greer, IA; Heitlinger, E; Jage, J; Kehlet, H; Langman, MJ; Pocock, S; Samama, MM; Velo, G, 2002
)
0.88
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"RDKET induced mild to moderate gastric mucosal injuries especially in the pyloric antrum in healthy Beagles, whereas no adverse effects were observed in renal function or hemostasis."( Safety of reduced-dosage ketoprofen for long-term oral administration in healthy dogs.
Hara, S; Komori, S; Narita, T; Sato, R; Tani, K; Tomizawa, N, 2006
)
0.64
" Treatment- related adverse events were experienced by 16% of patients in the dexketoprofen trometamol group compared with 21."( Comparison of the efficacy and safety of intravenously administered dexketoprofen trometamol and ketoprofen in the management of pain after orthopaedic surgery: A multicentre, double-blind, randomised, parallel-group clinical trial.
Wagenitz, A; Zippel, H, 2006
)
0.79
"To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.77
"Carprofen induced the lowest frequency of gastrointestinal adverse effects, followed by meloxicam."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.55
" Gastrointestinal adverse events for IDEA-033 were similar to placebo."( Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial.
Kneer, W; Lavins, BJ; Lehnhardt, K; Mazgareanu, S; Rother, M; Seidel, EJ, 2007
)
0.61
" Most of these adverse effects have been attributed to the photoallergic potential of KP and photosensitivity."( Ketoprofen: experimental overview of dermal toxicity.
Choi, YG; Jung, KM; Kim, BH; Kim, JJ; Lee, BS; Son, WC, 2007
)
1.78
" These results suggest that the adverse effects seen after administration of ketoprofen were due to differences between barriers."( Adverse effects of incorporating ketoprofen into established rodent studies.
Browder, EJ; Ihrig, M; Lamon, TK; Sohrabji, F, 2008
)
0.86
"The risk of oral NSAID including Cox-2 inhibitors to cause gastrointestinal, renal or cardiovascular adverse events related to systemic drug exposure could be reduced by local application."( A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation.
Kneer, W; Rother, I; Rother, M; Seidel, E, 2009
)
0.56
" Adverse events (AEs) were recorded."( Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care.
Carne, X; Rios, J; Torres, F, 2009
)
0.59
" Surveys of livestock carcasses in India indicate that toxic levels of residual ketoprofen are already present in vulture food supplies."( Toxicity of non-steroidal anti-inflammatory drugs to Gyps vultures: a new threat from ketoprofen.
Cromarty, D; Cuthbert, R; Diekmann, M; Duncan, N; Meharg, AA; Naidoo, V; Taggart, MA; Venter, L; Wolter, K, 2010
)
0.81
" The frequency of adverse events was similar in both groups."( Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.
Kawai, S; Kondo, M; Nagaya, I; Nawata, Y; Obata, J; Ohno, S; Oribe, M; Sugimoto, K; Uchida, E, 2010
)
0.67
"Since its introduction in France, ketoprofen for topical use has been associated with a large number of cutaneous adverse effect reports."( Cutaneous adverse effects of ketoprofen for topical use: clinical patterns and costs.
Aulois-Griot, M; Bénard-Laribière, A; Haramburu, F; Miremont-Salamé, G; Moore, N; Noize, P, 2010
)
0.93
" Safety was evaluated according to the number of adverse events and their severity."( Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain.
Cruto, M; Debernardi, F; Massucco, P; Moselli, NM; Savojardo, M, 2010
)
0.62
"1% of patients after 3 months of treatment and the combination of NSAIDs and corticosteroids seems not to influence the risk of gastrointestinal adverse effects."( Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain.
Cruto, M; Debernardi, F; Massucco, P; Moselli, NM; Savojardo, M, 2010
)
0.62
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"To evaluate the adverse effects of flunixin, ketoprofen and phenylbutazone when administered I/V to clinically normal miniature donkeys."( A comparative study on the adverse effects of flunixin, ketoprofen and phenylbutazone in miniature donkeys: haematological, biochemical and pathological findings.
Alinejad, A; Derakhshanfar, A; Morovati, M; Mozaffari, AA, 2010
)
0.87
"The gastrointestinal, hepatic and renal lesions observed in the donkeys treated with NSAID demonstrated the toxic potential of NSAID, which was greatest for animals treated with phenylbutazone, less for flunixin, and least for ketoprofen."( A comparative study on the adverse effects of flunixin, ketoprofen and phenylbutazone in miniature donkeys: haematological, biochemical and pathological findings.
Alinejad, A; Derakhshanfar, A; Morovati, M; Mozaffari, AA, 2010
)
0.79
" However, this group of drugs is associated with serious adverse drug reactions."( Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs.
Unlü, B; van Leeuwen, JS; Vermeulen, NP; Vos, JC, 2012
)
0.38
"The acute toxicity of ketoprofen for juvenile stages of zebrafish is low, but the substance seems to be toxic for embryonic stages."( Comparison of acute toxicity of ketoprofen to juvenile and embryonic stages of Danio rerio.
Bedanova, I; Macova, S; Marsalek, P; Pistekova, V; Plhalova, L; Praskova, E; Siroka, Z; Svobodova, Z; Voslarova, E, 2011
)
0.97
"Although non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) and opioids are effective treatments for acute renal colic, they are associated with adverse events (AEs)."( Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial.
Afif-Abdo, J; Araya, G; Cairoli, CE; Damiao, R; Glina, S; Novoa, R; Santa Maria, CF; Wajsbrot, D,
)
0.13
" This work provides an insight into non-covalent interactions between emerging contaminants and biomolecule, and is helpful for clarifying the toxic mechanism of such emerging contaminants."( Interactions of acidic pharmaceuticals with human serum albumin: insights into the molecular toxicity of emerging pollutants.
Chen, J; Gao, H; Qian, Y; Zhang, Y; Zhou, X, 2012
)
0.38
"This study elucidated differences in predisposition to the gastrointestinal adverse effects of ketoprofen between young and adult cats."( Comparison of gastrointestinal adverse effects of ketoprofen between adult and young cats.
Hikasa, Y; Satoh, H; Takata, K, 2012
)
0.85
" The most frequent types of treatment-related adverse events reported were gastrointestinal for oral (15."( A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis.
Bolten, W; Cevc, G; Conaghan, PG; Dickson, J; Rother, M, 2013
)
0.6
" TDT 064 was well tolerated in all studies, and adverse events were typically mild-to-moderate effects on the skin."( Drug-free gel containing ultra-deformable phospholipid vesicles (TDT 064) as topical therapy for the treatment of pain associated with osteoarthritis: a review of clinical efficacy and safety.
Bijlsma, JW; Conaghan, PG; Kneer, W; Kvien, TK; Rother, M; Wise, E, 2014
)
0.4
" Results suggest that the photolysis by-products of diclofenac were more toxic than those from the other compounds tested, showing an increase in GST and CAT levels, which are also supported by higher MDA levels."( Ecotoxicity of ketoprofen, diclofenac, atenolol and their photolysis byproducts in zebrafish (Danio rerio).
Carvalho, G; Diniz, MS; Noronha, JP; Oehmen, A; Pereira, VJ; Reis, MA; Salgado, R, 2015
)
0.77
" Topical NSAIDs are known to have a lower side-effect profile when compared with systemic administration."( Safety and efficacy of topical ketoprofen in transfersome gel in knee osteoarthritis: A systematic review.
Burzynski, J; Sardana, V; Zalzal, P, 2017
)
0.74
" The majority of the adverse events were non-serious and related to skin and subcutaneous tissue disorders, with erythema being the most common."( Safety and efficacy of topical ketoprofen in transfersome gel in knee osteoarthritis: A systematic review.
Burzynski, J; Sardana, V; Zalzal, P, 2017
)
0.74
" The most commonly reported adverse events associated with the use of topical ketoprofen in Transfersome gel were non-severe skin and subcutaneous tissue disorders."( Safety and efficacy of topical ketoprofen in transfersome gel in knee osteoarthritis: A systematic review.
Burzynski, J; Sardana, V; Zalzal, P, 2017
)
0.97
" Both meloxicam and diclofenac exerted toxic effects on the hepatic cells."( The use of liver slices from the Cape vulture (Gyps coprotheres) to better understand the role of liver toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) in vultures.
Adawaren, EO; Bekker, L; Duncan, N; Mukandiwa, L; Naidoo, V; Njoya, EM, 2018
)
0.48
" Standard-dosage ketoprofen administration resulted in clinically relevant adverse effects."( Safety and efficacy of reduced dosage ketoprofen with or without tramadol for long-term treatment of osteoarthritis in dogs: a randomized clinical trial.
Bianchi, E; Genevois, JP; Lambert, C; Monteiro, BP; Soldani, G; Troncy, E, 2019
)
1.12
" Additionally, an in vitro approach to the toxicity assessment of daphnids was contrasted with ecotoxicity data based on the Ecological Structure Activity Relationships (ECOSAR) software comprising the in silico tool to determine the adverse effects of the whole mixture of photolabile parent compounds and TPs."( Exploring the phototransformation and assessing the in vitro and in silico toxicity of a mixture of pharmaceuticals susceptible to photolysis.
Evgenidou, E; Lambropoulou, D; Nannou, C; Ofrydopoulou, A; Vasquez, MI, 2021
)
0.62
" Many researchers have modified this drug to discover an improved and safe NSAID."( Future prospects of ketoprofen in improving the safety of the gastric mucosa.
Kuczyńska, J; Nieradko-Iwanicka, B, 2021
)
0.94
" The overall adverse event profile of the groups was similar, and no difference was found in skin reaction rates between the 2 groups."( Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial.
Cha, JE; Ershova, O; Hyun, BJ; Kastanayan, A; Krechikova, D; Nikulenkova, N; Polyakova, S; Shvarts, Y; Vinogradova, I; Yakushin, S, 2021
)
0.89
" Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic."( Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022
)
0.72

Pharmacokinetics

Zalcitabine was administered to rats via an iv injection in the presence or absence of ketoprofen or naproxen (20 mg/kg) The pharmacokinetic parameters were determined by using non-compartmental analysis.

ExcerptReferenceRelevance
" Pharmacokinetic studies in the rat, dog and monkey have shown that gastro-intestinal absorption of the drug is rapid and almost complete; the compound and its metabolites are excreted from the body fairly rapidly."( Ketoprofen (19.583 R.P.) (2-(3-benzoylphenyl)-propionic acid). Main pharmacological properties--outline of toxicological and pharmacokinetic data.
Ducrot, R; Fournel, J; Guyonnet, JC; Julou, L; Pasquet, J, 1976
)
1.7
" The pharmacokinetic parameters obtained following a single oral dose, were comparable with those obtained in previous studies with human subjects from Britain, America and France."( The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50 mg q.i.d.) with Orudis.
Lewellen, OR; Templeton, R, 1976
)
0.56
" Two pharmacokinetic studies were performed for each quinolone, on days four and eight of the treatment."( Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.
Borsa-Lebas, F; Etienne, I; Fillastre, JP; Gy, C; Humbert, G; Leroy, A, 1992
)
0.67
" Thus, changes in the pharmacokinetic parameters based on total drug concentrations were offset by the increase in the unbound fraction of ketoprofen."( Pharmacokinetics of ketoprofen in rats: effect of age and dose.
Boudinot, FD; Satterwhite, JH, 1992
)
0.81
" When the pharmacokinetic parameters of KP were compared between patient groups under spinal and local anesthesia, significant differences were found in the values of the peak level (C max), peak time (T max), and terminal phase half-life (t 1/2)."( The clinical pharmacokinetics of two different preparations of intrarectal ketoprofen following spinal or local anesthesia for anal surgery.
Arai, H; Fujimaki, M; Hirokawa, S; Kasagi, T; Katsuki, S; Katsuyama, S; Takemori, S; Tazawa, K; Yamamoto, K, 1991
)
0.51
" We conclude that the acetylation capacity for SDM is a factor determining the pharmacokinetic interaction between SDM and ketoprofen in rabbits."( Differential effects of ketoprofen on the pharmacokinetics of sulphadimethoxine in fast and slow acetylator rabbits.
Imamura, Y; Mori, H; Otagiri, M, 1990
)
0.79
" Sustained release dosage forms are available, which may be beneficial due to the short terminal phase half-life of ketoprofen (1 to 3h)."( Clinical pharmacokinetics of ketoprofen and its enantiomers.
Brocks, DR; Jamali, F, 1990
)
0.78
" Short- and long-term pharmacokinetic parameters were determined."( Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans.
Besner, JG; Caillé, G; du Souich, P; Gervais, P; Vézina, M, 1989
)
0.51
" At the end of the study, the apparent half-life of unchanged ketoprofen was 17."( Pharmacokinetics of ketoprofen in man after repeated percutaneous administration.
Delhotal-Landes, B; Flouvat, B; Roux, A, 1989
)
0.84
" There were no significant differences between the pharmacokinetic indices calculated after single and multiple administration of KT."( Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses.
Alballa, SR; Foster, RT; Jamali, F; Russell, AS, 1988
)
0.6
" There were no significant differences between pharmacokinetic indices calculated after single and multiple doses, or between the two groups."( Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses.
Alballa, SR; Foster, RT; Jamali, F; Russell, AS, 1988
)
0.6
" No difference was found in each corresponding pharmacokinetic parameter of the two dosage forms."( Pharmacokinetics of two rectal dosage forms of ketoprofen in patients after anal surgery.
Fujimaki, M; Horikoshi, I; Kanamoto, I; Koizumi, T; Nakagawa, T; Tazawa, K, 1988
)
0.53
" Although the time necessary to attain Cmax (tmax) for the three drugs tended to increase, only for indomethacin was this increase significant."( Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate.
Besner, JG; Caillé, G; Du Souich, P; Gervais, P,
)
0.41
"Several investigations which have taken treatment time into account have shown that the pharmacokinetic parameters, the therapeutic efficacy and even the toxicity of a large number of products may vary according to the administration schedule."( Circadian changes in the pharmacokinetics of oral ketoprofen.
Cherrah, Y; Decousus, H; Levi, F; Mechkouri, M; Ollagnier, M; Queneau, P; Reinberg, A, 1987
)
0.53
" As expected, results clearly show that the half-life of ketoprofen is prolonged in patients with renal failure."( [Pharmacokinetics of ketoprofen in patients with renal failure].
Hansen, H; Larsen, HW; Serensen, K; Stafanger, G, 1983
)
0.83
"2 micrograms/ml) and apparent elimination half-life (8."( A pharmacokinetic study of repeated doses of a new controlled release form of ketoprofen.
Calvert, RM; Cresswell, DG; Dennis, MJ; Houghton, GW; Templeton, R, 1984
)
0.5
" Population pharmacokinetic parameters have traditionally been estimated either by fitting all individuals' data together as though there were no individual kinetic differences [the naive pooled data (NPD) approach], or by fitting each individual's data separately and then combining the individual parameter estimates [the two-stage (TS) approach]."( The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.
Sheiner, LB, 1984
)
0.27
" Following oral administration of a 150 mg dose of ketoprofen, no difference in tmax was observed between the two groups."( Pharmacokinetics of ketoprofen in the elderly.
Advenier, C; Flouvat, B; Gobert, C; Massias, P; Roux, A; Varoquaux, O, 1983
)
0.84
" As expected, a reduction of the [51Cr]EDTA clearance was correlated with an increase in the elimination half-life of ketoprofen."( Pharmacokinetics of ketoprofen in patients with chronic renal failure.
Hansen, H; Larsen, HW; Stafanger, G, 1981
)
0.8
"Individual pharmacokinetic parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean-kinetics, interindividual variability, and residual variability, including intraindividual variability and measurement error."( Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.
Beal, SL; Sheiner, LB, 1981
)
0.26
"The pharmacokinetic profile of ketoprofen suppositories following single and chronic (32 doses) administration to 12 healthy adult male volunteers was established."( Pharmacokinetic characteristics of ketoprofen suppositories.
Besner, JG; Caillé, G; Lacasse, Y; Vézina, M,
)
0.69
" Plasma ketoprofen concentrations declined triexponentially after each dose with no significant differences in plasma concentrations or pharmacokinetic parameter values between the first and last doses."( Pharmacokinetics of ketoprofen after multiple intravenous doses to mares.
Ashcraft, SM; Gerken, DF; Sams, R, 1995
)
1.05
"The pharmacokinetic properties of a single intravenous dose of ketoprofen (2."( Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis.
Barker, SA; Kamerling, SG; Owens, JG, 1995
)
0.85
" Remarkable differences in the shape of concentration-time courses between the two formulations were found with higher Cmax (by about 70%) and earlier tmax (by 15 min) values for the ketoprofen solution."( Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets.
Birkel, M; Jost, V; Lange, R; Lücker, PW; Stiegler, S; Wetzelsberger, N, 1995
)
0.7
" No statistically significant differences in the pharmacokinetic parameters were noted between the first and last dose of extended-release ketoprofen; that is, there was no accumulation of ketoprofen."( Comparison of the efficacy, safety, and pharmacokinetic profiles of extended-release ketoprofen and piroxicam in patients with rheumatoid arthritis.
Caldwell, JR,
)
0.56
" No significant differences in CL/F, area under the curve (AUC), half-life (t1/2), time to reach peak concentration (tmax), or maximum peak plasma concentration (Cmax) were found between groups or between doses, and values were similar to those previously reported in young adults."( Ketoprofen pharmacokinetics in the elderly: influence of rheumatic disease, renal function, and dose.
Jamali, F; Russell, AS; Skeith, KJ, 1993
)
1.73
" With the exception of AUC values no dose dependent differences in pharmacokinetic parameters were observed."( Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate.
Brune, K; Geisslinger, G; Menzel, S; Wissel, K, 1995
)
0.61
" Pharmacodynamic properties were evaluated using a model of acute inflammation, comprising subcutaneously implanted tissue cages stimulated by intracaveal injection of carrageenan."( Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves.
Landoni, MF; Lees, P, 1995
)
0.56
" In addition, the half-life of each enantiomer was negatively correlated with CLCR."( The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis.
Ahern, MJ; Bochner, F; Hayball, PJ; Nation, RL; Sansom, LN; Smith, MD, 1993
)
0.5
" Time to Cmax (tmax) and mean residence time (MRT) tended to be or was shortened by buffering."( Effect of buffering on pharmacokinetics of ketoprofen enantiomers in man.
Fuder, H; Lange, R; Lücker, PW; Stiegler, S; Wetzelsberger, N; Wieckhorst, G, 1997
)
0.56
" Concentration versus time profiles were analyzed according to standard pharmacokinetic techniques."( Pharmacokinetics of ketoprofen in healthy foals less than twenty-four hours old.
Crisman, MV; Sams, RA; Scarratt, WK; Wilcke, JR, 1998
)
0.62
" Nonlinear least squares methods were used to calculate pharmacokinetic parameters."( Stereospecific pharmacokinetics of free and protein-bound ketoprofen in serum and synovial fluid of horses after intravenous and intramuscular administration.
Brink, P; Campbell, JD; DeGraves, F; Duran, SH; Johansen, D; Ravis, WR, 1998
)
0.54
" The kinetic parameters measured were area under the concentration (AUC), maximum peak plasma concentration (Cmax), time to reach peak concentration (tmax), elimination half-life (t1/2), mean residence time (MRT) and urinary excretion for R and S enantiomers."( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen.
Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998
)
0.53
"Dimethicone reduced the peak concentration of both R and S ketoprofen by about 10% (P<0."( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen.
Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998
)
0.77
" Dexketoprofen trometamol showed the most rapid absorption rate, with highest Cmax and shortest t(max) values, whereas dexketoprofen free acid had the slowest absorption rate, and ketoprofen had an intermediate absorption rate."( Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.
Antonijoan, RM; Artigas, R; Barbanoj, MJ; García, ML; Gich, I; Mauleón, D; Moros, C; Tost, D, 1998
)
1.17
") dose, and computer modelling to determine the pharmacokinetic parameters of the enantiomers in these two body fluids."( Pharmacokinetics of carprofen enantiomers in equine plasma and synovial fluid - a comparison with ketoprofen.
Armstrong, S; Frean, S; Lake, A; Lees, P; Tricklebank, P, 1999
)
0.52
"Pharmacokinetic and pharmacodynamic parameters were established for the enantiomers of the 2-arylpropionic acid (APA) nonsteroidal anti-inflammatory drug (NSAID), ketoprofen (KTP)."( Enantiospecific pharmacokinetics and pharmacodynamics of ketoprofen in sheep.
Anglarilli, G; Bidal, D; Comas, W; Landoni, MF; Lees, P; Mucci, N, 1999
)
0.74
"5 mgkg(-1)) pharmacokinetic parameters compared with administering AZT alone."( Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats.
Radwan, MA, 2000
)
0.6
" This randomized, partially double-blind, controlled trial was conducted to evaluate the pharmacodynamic effects of the NSAID, ketoprofen (KTP), on gingival crevicular fluid (GCF) prostanoids."( Pharmacodynamic effects of ketoprofen on crevicular fluid prostanoids in adult periodontitis.
Annett, M; Binder, TA; Friedman, M; Lawrence, HP; McCombs, GB; Offenbacher, S; Paquette, DW; Smith, PC; Troullos, E; Wilder, R, 2000
)
0.81
" All pharmacokinetic parameters for R- and S-KP in female camels were significantly different from their corresponding values in male camels."( Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender.
Al Katheeri, NA; Khan, IA; Lambert, M; Saeed, A; Wasfi, IA, 2000
)
0.63
"To establish pharmacokinetic and pharmacodynamic properties of a racemic mixture and individual R(-) and S(+) enantiomeric forms of ketoprofen (KTP) in sheep and determine pharmacodynamic variables of KTP by pharmacokinetic-pharmacodynamic modeling."( Pharmacodynamics and pharmacokinetics of ketoprofen enantiomers in sheep.
Arifah, AK; Frean, SP; Landoni, MF; Lees, P, 2001
)
0.78
"Both KTP enantiomers had elimination half-life and mean residence time measurements that were short and volume of the central compartment and steady state volume of distribution that were low."( Pharmacodynamics and pharmacokinetics of ketoprofen enantiomers in sheep.
Arifah, AK; Frean, SP; Landoni, MF; Lees, P, 2001
)
0.58
"According to the pharmacokinetic properties determined in this study, there is no justification for using intramuscular administration in awake children."( Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children.
Karvinen, M; Kokki, H; Tuomilehto, H, 2001
)
0.63
"No pharmacokinetic data are available with respect to the plasma concentration of ketoprofen during intravenous infusion in children."( Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children.
Jekunen, A; Karvinen, M; Kokki, H, 2002
)
0.8
" The validated method has been successfully applied for pharmacokinetic studies of KTP enantiomers from tablets with rac-KTP in man."( Determination of ketoprofen enantiomers in human serum by capillary zone electrophoresis: man pharmacokinetic studies after administration of rac-ketoprofen tablets.
Główka, FK, 2002
)
0.65
"To assess oral bioavailability (F) and pharmacokinetic characteristics of the R- and S-enantiomers of ketoprofen administered IV and orally to captive Asian elephants (Elephas maximus)."( Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE, 2003
)
0.78
" Pharmacokinetic parameters were determined by use of noncompartmental analysis."( Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE, 2003
)
0.56
"Ketoprofen has a long terminal half-life and complete absorption in this species."( Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE, 2003
)
2
"The non-steroidal anti-inflammatory drug ketoprofen (KTP) was administered as the racemate to cats intravenously (IV) and orally at clinically recommended dose rates of 2 and 1 mg/kg, respectively, to establish its chiral pharmacokinetic and pharmacodynamic properties."( Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics.
Arifah, AK; Landoni, FM; Lees, P; Taylor, PM; Waters, C, 2003
)
2.03
"The pharmacokinetic parameters of ketoprofen have previously been studied in cattle, but no studies have been performed on differing ages and metabolic situations in these animals."( Some pharmacokinetic parameters of R-(-)- and S-(+)-ketoprofen: the influence of age and differing physiological status in dairy cattle.
Auza, N; Igarza, L; Soraci, A; Zeballos, H, 2004
)
0.85
" The validated method was successfully applied to pharmacokinetic and bioavailability studies on KTP enantiomers in humans after administration of standard and sustained release tablets of rac-KTP."( High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets.
Główka, FK; Karaźniewicz, M, 2004
)
0.52
"Interspecies scaling of pharmacokinetic (PK) parameters is commonplace in drug development."( Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis.
Jusko, WJ; Lepist, EI, 2004
)
0.59
" Using the rationale of the BCS, it can be argued that biowaivers can, however, also be granted on the basis of standard pharmacokinetic data."( Biowaivers for oral immediate-release products: implications of linear pharmacokinetics.
Faassen, F; Vromans, H, 2004
)
0.32
" Pharmacokinetic parameters were determined following an intravenous administration of aciclovir (5 mg kg(-1)) to rats in the presence and absence of ketoprofen or naproxen (25 mg kg(-1))."( Effects of non-steroidal anti-inflammatory drugs on the pharmacokinetics and elimination of aciclovir in rats.
Gwak, HS; Han, HK; Oh, JH, 2005
)
0.53
"To investigate the pharmacokinetic interactions between zalcitabine and nonsteroidal anti-inflammatory drugs (NSAIDs) in rats."( Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats.
Han, HK; Oh, YH, 2006
)
0.33
"Zalcitabine was administered to rats via an iv injection (20 mg/kg) in the presence or absence of ketoprofen or naproxen (20 mg/kg), and the pharmacokinetic parameters were determined by using non-compartmental analysis."( Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats.
Han, HK; Oh, YH, 2006
)
0.55
"Compared with the control (zalcitabine alone), pretreatment with ketoprofen or naproxen 30 min prior to intravenous administration of zalcitabine significantly altered the pharmacokinetic profiles of zalcitabine in rats."( Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats.
Han, HK; Oh, YH, 2006
)
0.57
" The pharmacokinetic parameters for ketoprofen after intravenous administration of KPI-loaded LM and ketoprofen solution exhibited no statistically significant differences."( Pharmacokinetic study of ketoprofen isopropyl ester-loaded lipid microspheres in rat blood using microdialysis.
Cui, F; He, H; Tang, X, 2006
)
0.91
" The main pharmacokinetic parameters were determined by a noncompartmental approach."( Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects.
Artigas, R; Capriati, A; Crea, A; Muller, F; Paredes, I; Valles, J; Zapata, A, 2006
)
0.6
" Model-independent pharmacokinetic parameters were obtained."( Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function.
Artigas, R; Bertolotti, M; Capriati, A; Crea, A; Muller, F; Paredes, I; Valles, J, 2006
)
0.59
"To investigate the in vitro recovery and influencing factors of ketoprofen in microdialysis probe, and study the pharmacokinetic of unbound ketoprofen in rat after iv administration."( [Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique].
Cui, FD; He, HB; Tang, X, 2006
)
0.87
"Microdialysis sampling can be used for the pharmacokinetic study of unbound ketoprofen in rat."( [Pharmacokinetic study of ketoprofen in rat by blood microdialysis technique].
Cui, FD; He, HB; Tang, X, 2006
)
0.86
" Pharmacokinetic analyses were performed and indicated that ketoprofen in iguanas administered by the intravenous route has a classical two-compartmental distribution pattern, a slow clearance (67 ml/ kg/hr) and a long terminal half-life (31 hr) compared to ketoprofen studies reported in mammals."( Pharmacokinetics of ketoprofen in the green iguana (Iguana iguana) following single intravenous and intramuscular injections.
Christian, S; Gunkel, C; Harms, CA; Lewbart, GA; Papich, M; Tuttle, AD, 2006
)
0.9
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The most promising compounds of this study show enhanced IC 50 values in the low nanomolar range, a high selectivity toward 17beta-HSD2, a low binding affinity to ERalpha, a good metabolic stability in rat liver microsomes, and a reasonable pharmacokinetic profile after peroral application."( Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Al-Soud, YA; Bey, E; Birk, B; Frotscher, M; Hartmann, RW; Kruchten, P; Marchais-Oberwinkler, S; Negri, M; Oster, A; Werth, R, 2008
)
0.35
" This study examined the usefulness of Mexican hairless pigs for in vivo pharmacokinetic study, especially the drug concentration in the tissues."( In vivo pharmacokinetics of ketoprofen after patch application in the Mexican hairless pig.
Horie, M; Kobayashi, E; Maekawa, K; Muneta, T; Nakamura, T; Nakanishi, M; Sekiya, I; Tanaka, H, 2009
)
0.65
" The plasma concentration (C(p)) was obtained as a function of time (t), and the pharmacokinetic parameters were calculated using the BE program."( Effect of microneedle on the pharmacokinetics of ketoprofen from its transdermal formulations.
Cho, CW; Kim, DC; Lee, SS; Park, HH; Shin, SC; So, JW, 2009
)
0.61
"A novel, rapid and selective ultra performance liquid chromatography mass spectrometric method had been developed for the pharmacokinetic study of diclofenac sodium (DS) after single intravenous injection of DS aqueous injection and DS lipid microsphere (LM) injection in rats."( A new rapid ultra-performance liquid chromatography method for the pharmacokinetic and bioavailability study of diclofenac sodium aqueous injection and lipid microsphere injection in rats.
Cui, Y; Guan, TT; Lin, X; Tang, X; Zhang, Y, 2010
)
0.36
" Pharmacokinetic studies show that drug exposure after a single intravenous dose is similar in children and adults (after dose normalization), and thus similar mg/kg bodyweight dosing may be used in children and adults."( Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients.
Kokki, H, 2010
)
1.8
"The pharmacodynamic properties of tepoxalin, Na-salicylate and ketoprofen were determined in an intravenous lipopolysaccharide (LPS) inflammation model in broiler chickens."( Pharmacodynamics of tepoxalin, sodium-salicylate and ketoprofen in an intravenous lipopolysaccharide inflammation model in broiler chickens.
Beyaert, R; Croubels, S; de Backer, P; de Baere, S; de Boever, S; Meyer, E; Neirinckx, EA, 2010
)
0.85
" Suitability of the new assay was assessed in comparison with 36 reported bioanalytical assays and the pharmacokinetic results obtained by the new method were compared to 11 reported studies in humans."( An LC-MS/MS procedure for the quantification of naproxen in human plasma: development, validation, comparison with other methods, and application to a pharmacokinetic study.
Elsinghorst, PW; Holzgrabe, U; Kinzig, M; Rodamer, M; Sörgel, F, 2011
)
0.37
" However, pharmaceutical equivalence and pharmacokinetic bioequivalence between brand-name and generic products are not required."( [Prediction of systemic exposure of ketoprofen tapes by in vitro release test and pharmacokinetic model analysis: comparison between brand-name and generic formulations].
Awa, K; Hori, S; Satoh, H; Sawada, Y, 2012
)
0.65
"We evaluated the modulatory role of the groundwater contaminant arsenic on the pharmacodynamic responses of the nonsteroidal analgesic-antipyretic drug ketoprofen and the major pro-inflammatory mediators linked to the mechanism of ketoprofen's therapeutic effects."( Subacute arsenic exposure through drinking water reduces the pharmacodynamic effects of ketoprofen in male rats.
Ahmad, W; Chanderashekara, HH; Prawez, S; Sankar, P; Sarkar, SN; Tandan, SK, 2012
)
0.8
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38
"  Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h."( Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.
Boelsterli, UA; Fujimoto, K; Lee, KK; Redinbo, MR; Saitta, KS; Zhang, C, 2014
)
0.62
" Individual animal pharmacokinetic and pharmacodynamic parameters for COX-1 and COX-2 inhibition were generated by PK/PD modelling."( Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation.
Elliott, J; Hormazabal, V; King, JN; Lees, P; Pelligand, L; Toutain, PL, 2014
)
0.62
"The pharmacokinetic of the individual S-(+)-enantiomer of ketoprofen, S-(+)-ketoprofen, after intravenous (IV) and oral (PO) administration was determined in six dogs at 1 and 3 mg/kg."( Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels.
Gómez-Villamandos, RJ; Machuca, MM; Navarrete-Calvo, R; Rodríguez, JM; Serrano, JM; Serrano-Rodríguez, JM, 2014
)
0.9
" The purpose of the current study was to use physiologically based pharmacokinetic modeling (PBPK) quantitatively to predict the PK of the XR formulation in children and adolescents."( Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
Bui, KH; Johnson, TN; Zhou, D, 2014
)
0.4
"The pharmacokinetic properties of ketoprofen were determined in 4-week-old calves after intramuscular (i."( Enantioselective pharmacokinetics of ketoprofen in calves after intramuscular administration of a racemic mixture.
Croubels, S; De Backer, P; De Baere, S; Pardon, B; Plessers, E; Watteyn, A; Wyns, H, 2015
)
0.97
"Volume of distribution is one of the most important pharmacokinetic properties of a drug candidate."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
" KTP enantiomer concentrations were determined using LC–MS/MS, and pharmacokinetic analyses were performed."( Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses.
Arthur, RM; Knych, HK; McKemie, DS; Steinmetz, S, 2016
)
0.76
" Optimized proniosomal gel was evaluated for surface morphology, rheological behavior, texture studies, and pharmacodynamic activity in EPD."( Systematically Optimized Ketoprofen-Loaded Novel Proniosomal Formulation for Periodontitis: In Vitro Characterization and In Vivo Pharmacodynamic Evaluation.
Katare, OP; Nanda, S; Sharma, G; Yadav, NK, 2017
)
0.76
"In the present study the pharmacokinetic and bioequivalence parameter of Ketoprofen 100 mg fast dispersible tablets (test) were measured with marketed (reference) product."( Pharmacokinetic and bioequivalence studies of fast dispersible ketoprofen tablets in healthy volunteers.
Ali, H; Bushra, R; Shoaib, MH; Yousuf, RI; Zafar, F, 2017
)
0.93
" Cmax of tramadol for most CP patients was within the therapeutic range associated with its analgesic activity."( Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis.
Adrych, K; Grabowski, T; Grześkowiak, E; Karbownik, A; Mziray, M; Porażka, J; Siepsiak-Połom, M; Szałek, E, 2019
)
1.96
" Values for total clearance of compounds from plasma should be one of the most important pharmacokinetic parameters for predictions."( Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N, 2020
)
0.56
" The pharmacokinetic properties of ketoprofen SR tablets were described by a population pharmacokinetics (POP-PK) model which incorporated the pH-dependent dissolution of ketoprofen by a time-dependent Hill-type equation."( Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
Kim, DH; Kim, TH; Lim, JY; Shin, BS; Shin, S; Song, CH, 2022
)
1

Compound-Compound Interactions

Twice daily ketoprofen administration combined with interferon-alpha 2b produced an increase in complete and sustained responses.

ExcerptReferenceRelevance
" Subjects were studied after an initial dose given without gastric protection, after ingestion of a single dose given with aluminum phosphate and, lastly, after four days of continuous treatment with this product."( [The bioavailability of ketoprofen (Profenid) administered orally in combination with a gastric protector (aluminum phosphate, Phosphalugel)].
Ambert, D; Bannier, A; Brazier, JL; Tamisier, JN, 1983
)
0.57
"Twice daily ketoprofen administration combined with interferon-alpha 2b produced an increase in complete and sustained responses."( Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial.
Bartellini, MA; Cabanne, A; Flichman, D; González, J; Gorín, JM; Levi, D; Munne, MS; Muñoz, AE; Podestá, A; Terg, R, 2000
)
0.95
" Our aim was to evaluate feasibility, safety, and efficacy of ketoprofen combined with opioids in long-term continuous subcutaneous infusion (CSI) for cancer pain in a prospective observational open-label pilot study."( Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain.
Cruto, M; Debernardi, F; Massucco, P; Moselli, NM; Savojardo, M, 2010
)
0.86
"Ketoprofen CSI in combination with opioids is a feasible, safe, and effective approach to cancer pain."( Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain.
Cruto, M; Debernardi, F; Massucco, P; Moselli, NM; Savojardo, M, 2010
)
2.06
" This may be particularly the case when triptan therapy is combined with a nonsteroidal anti-inflammatory drug (NSAID)."( Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Cortelli, P; Curone, M; D'Onofrio, F; Frediani, F; Omboni, S; Pezzola, D; Reggiardo, G; Sette, G; Tullo, V; Valguarnera, F; Zava, D, 2014
)
0.64
"A fast and low-cost sample preparation method of graphene based dispersive solid-phase extraction combined with gas chromatography-mass spectrometric (GC-MS) analysis, was developed."( Graphene oxide-based dispersive solid-phase extraction combined with in situ derivatization and gas chromatography-mass spectrometry for the determination of acidic pharmaceuticals in water.
Lee, HK; Li, SF; Naing, NN, 2015
)
0.42
"The objective of this study was to develop a novel extended in vitro in vivo correlation (IVIVC) model combined with design of experiment (DoE) that integrates the DoE into IVIVC, which can predict the pharmacokinetics of sustained-release (SR) tablets from their formulation compositions, and vice versa."( Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
Kim, DH; Kim, TH; Lim, JY; Shin, BS; Shin, S; Song, CH, 2022
)
0.72

Bioavailability

The relative bioavailability of ketoprofen was low and highly variable when the drug was administered as a single dose in a PLO-based ketofen 20% gel. The absorption rate per hour for pure ketop rofen and proliposomal formulation (KPL3) was assessed in the stomach by conducting in situ gastric absorption studies in Wistar rats.

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" This method has been applied successfully to various biological studies: pharmacokinetic profiles, bioavailability and transfer of the drug through physiological barriers."( A quantitative selected ion monitoring assay for ketoprofen determination in human biological fluids.
De Graeve, J; Frankinet, C; Gielen, JE, 1979
)
0.51
"The bioavailability of ketoprofen after oral administration of aqueous solutions of various ketoprofen-dextran ester prodrugs in pigs was assessed."( Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig.
Jensen, BH; Larsen, C; Olesen, HP, 1991
)
0.92
" The extent of bioavailability of the two dosage forms in the patient groups and control subjects (n = 10) were essentially equal."( The clinical pharmacokinetics of two different preparations of intrarectal ketoprofen following spinal or local anesthesia for anal surgery.
Arai, H; Fujimaki, M; Hirokawa, S; Kasagi, T; Katsuki, S; Katsuyama, S; Takemori, S; Tazawa, K; Yamamoto, K, 1991
)
0.51
" The extent of bioavailability of ibuprofen was not increased by magnesium hydroxide."( The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac.
Neuvonen, PJ, 1991
)
0.51
" Although with these preparations the peak plasma drug concentration is reduced and time to peak is prolonged, the bioavailability is the same as that with regular release counterparts."( Clinical pharmacokinetics of ketoprofen and its enantiomers.
Brocks, DR; Jamali, F, 1990
)
0.57
" Results in group 1 showed that neither ketoprofen bioavailability nor maximal plasma concentration and time to reach maximal concentration were affected by the administration of sucralfate."( Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans.
Besner, JG; Caillé, G; du Souich, P; Gervais, P; Vézina, M, 1989
)
0.78
" The rank order of the dissolution rate of ketoprofen from Eudragit RS, RS-RL and RL microcapsules containing 30 and 40 per cent (w/w) ketoprofen was sufficiently clear as to enable prediction of the relative bioavailability of ketoprofen from these microcapsules."( Evaluation of the sustained release properties of Eudragit RS, RL and S (acrylic resins) microcapsules containing ketoprofen in beagle dogs.
Aoyama, T; Fujinaga, K; Goto, S; Kawata, M; Nagatsuma, Y; Nakamura, M,
)
0.6
" Sucralfate decreased significantly the rate of absorption (ka) of naproxen and indomethacin, but not that of ketoprofen; it had no significant effect on the elimination half-life and area under the plasma concentration as a function of time curves (AUC0----infinity) of the three drugs."( Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate.
Besner, JG; Caillé, G; Du Souich, P; Gervais, P,
)
0.63
" Changing the type of meal had no statistically significant effect on the maximum plasma level, apparent plasma elimination half-life (t 1/2 h), area under the plasma level versus time curve, total plasma clearance, and urinary recovery of total ketoprofen, indicating that the bioavailability (and the systemic level) of ketoprofen was not affected by meal composition."( Effect of meal size and composition on the bioavailability of ketoprofen (Oruvail).
Gudgeon, A; Havard, CW; Kaye, CM; Mitchell, P; Nievel, JG, 1987
)
0.69
" The absorption rate constant after treatment at 01."( Circadian changes in the pharmacokinetics of oral ketoprofen.
Cherrah, Y; Decousus, H; Levi, F; Mechkouri, M; Ollagnier, M; Queneau, P; Reinberg, A, 1987
)
0.53
" Bioavailability of the slow-release preparation is similar to that of capsules : surfaces under the serum concentration curves and urinary elimination were found to be identical."( [Pharmacokinetic profile of a slow-release ketoprofen preparation].
Flouvat, B; Massias, P; Stheneur, A, 1983
)
0.53
" Results of plasma peak level and its time of occurrence, area under the curve, half-life and elimination constant establish that bioavailability of ketoprofen is not changed by association with aluminum phosphate."( [The bioavailability of ketoprofen (Profenid) administered orally in combination with a gastric protector (aluminum phosphate, Phosphalugel)].
Ambert, D; Bannier, A; Brazier, JL; Tamisier, JN, 1983
)
0.77
" Bioavailability and pharmacokinetics of total serum ketoprofen studied in eight patients did not appear to be significantly modified by addition of aspirin."( [Ketoprofen-aspirin interaction].
Chales, G; Flouvat, B; Louboutin, JY; Pawlotsky, Y; Roux, A, 1983
)
1.43
" The patients' preference appears to be a result of the bioavailability of Bi-Profenid."( [Open clinical trial of a new oral galenic form of ketoprofen].
Asch, L; Huck, F; Kuntz, JL; Lecocq, J; Meyer, R, 1983
)
0.52
" The slow-release preparation had a bioavailability greater than 90% as compared with the conventional capsule and produced lower and longer lasting ketoprofen serum levels."( Pharmacokinetics of a slow-release preparation of ketoprofen lysine in man.
Borsa, M; Canali, S; Ronchi, C; Tonon, GC; Zanolo, G, 1983
)
0.72
"Four healthy subjects volunteered for a crossover bioavailability study to compare the rate and extent of absorption of plain capsules and new slow-release capsules of ketoprofen."( Bioavailability study on a new slow-release formulation of ketoprofen.
Caruso, I; Frigerio, E; Fumagalli, M; Liverta, C; Moro, L; Tamassia, V, 1982
)
0.7
" The bioavailability from the commercial capsule relative to that from the solution was 99."( Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay.
Buskin, JN; Guentert, TW; Riegelman, S; Upton, RA; Williams, RL, 1981
)
1.71
"The purpose of this study was to determine whether a concomitant single dose of antacid (aluminium phosphate), or multiple doses of this antacid, administered prior to and with ketoprofen would alter the bioavailability of this non steroidal anti-inflammatory agent."( Bioavailability of ketoprofen in man with and without concomitant administration of aluminium phosphate.
Ambert, D; Bannier, A; Brazier, JL; Tamisier, JN, 1981
)
0.78
"The relative bioavailability of ketoprofen from a liquid formulation as compared to a tablet formulation as reference after single oral dose administration was investigated in 16 healthy male subjects."( Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets.
Birkel, M; Jost, V; Lange, R; Lücker, PW; Stiegler, S; Wetzelsberger, N, 1995
)
0.8
" This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action."( Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease.
Franchimont, P; Reginster, JY, 1993
)
0.29
" The absolute bioavailability of the 50 mg oral dose was 84."( Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate.
Brune, K; Geisslinger, G; Menzel, S; Wissel, K, 1995
)
0.61
"The bioavailability of S(+) and R(-) ketoprofen (KTP) in six horses was investigated after oral administration of the racemic (rac) mixture."( Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses.
Landoni, MF; Lees, P, 1995
)
0.79
"Six healthy mares ranging in age from 6 to 12 years and weighing from 415 to 540 kg were used to determine the rectal bioavailability of ketoprofen."( Bioavailability of ketoprofen in horses after rectal administration.
Baeyens, W; Corveleyn, S; Deprez, P; Remon, JP; Van der Weken, G, 1996
)
0.83
" In humans, the relative bioavailability of oral dexketoprofen trometamol (12."( Preclinical and clinical development of dexketoprofen.
Artigas, R; Carganico, G; García, ML; Mauleón, D, 1996
)
0.81
" In this study the intramuscular bioavailability of ketoprofen administered as the lysine salt was evaluated in horses (n = 5) treated intravenously and intramuscularly (2."( Intramuscular bioavailability of ketoprofen lysine salt in horses.
Anfossi, P; Carli, S; Montesissa, C; Villa, R, 1997
)
0.83
"It is concluded that buffering of two ketoprofen formulations with magnesium hydroxide/citrate enhanced the concentration maximum by increasing the rate of absorption and leaving AUC unaffected."( Effect of buffering on pharmacokinetics of ketoprofen enantiomers in man.
Fuder, H; Lange, R; Lücker, PW; Stiegler, S; Wetzelsberger, N; Wieckhorst, G, 1997
)
0.83
" However, this treatment had no significant effect on the bioavailability and the elimination of R and S enantiomers, as shown by AUC, t1/2 and MRT values."( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen.
Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998
)
0.53
" Dimethicone did not significantly alter the bioavailability of ketoprofen, chosen as an example of an NSAID, especially that of the pharmacologically active S enantiomer."( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen.
Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998
)
0.76
" The relative systemic bioavailability of the gels compared with peroral administration ranged from 54% to 69%."( Pharmacokinetic and safety evaluations of ketoprofen gels in subjects with adult periodontitis.
Annett, M; Binder, T; Friedman, M; Lawrence, HP; Mann, GL; Maynor, G; Offenbacher, S; Paquette, DW; Smith, PC; Troullos, E; Wilder, R, 1998
)
0.56
"To enhance the dissolution rate and bioavailability of poorly water-soluble ketoprofen, a novel oral dosage form of ketoprofen, termed ketoprofen dry elixir, was developed by the spray-drying technique."( Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form.
Ahn, HJ; Kim, CK; Kim, KM, 1998
)
0.81
"Recent reports have disagreed on whether the bioavailability of S(+)-ketoprofen is affected by the presence of R(-)-ketoprofen."( Bioavailability of S(+)-ketoprofen after oral administration of different mixtures of ketoprofen enantiomers to dogs.
Carganico, G; García, ML; López, S; Mauleón, D; Tost, D; Vilageliu, J, 1998
)
0.84
" In the first study, the relative bioavailability of a single oral capsule of dexketoprofen free acid 25 mg or dexketoprofen trometamol 25 mg (given as 37 mg of the trometamol salt) was compared to ketoprofen 50 mg in 18 healthy volunteers."( Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.
Antonijoan, RM; Artigas, R; Barbanoj, MJ; García, ML; Gich, I; Mauleón, D; Moros, C; Tost, D, 1998
)
0.84
"This randomized three-way, crossover pharmacokinetic study was performed to determine whether food or an antacid alters the bioavailability of dexketoprofen trometamol."( The effect of food and an antacid on the bioavailability of dexketoprofen trometamol.
Artigas, R; Barbanoj, MJ; Casini, A; De Luca, M; Gich, I; Mauleón, D; McEwen, J; Tost, D, 1998
)
0.74
" The relative bioavailability of the oleo-hydrogel following transdermal administration in reference to oral administration was about 37%, and the Cmax value (4."( Topical oleo-hydrogel preparation of ketoprofen with enhanced skin permeability.
Hwang, SJ; Lee, CH; Lee, YW; Rhee, GJ; Woo, JS, 1999
)
0.58
" The present study was designed to examine the bioavailability of ketoprofen enantiomers after rectal administration of the racemate to healthy horses."( Bioavailability of racemic ketoprofen in healthy horses following rectal administration.
Aboul-Enein, HY; Baeyens, W; Corveleyn, S; Deprez, P; Haustraete, J; Henrist, D; Remon, JP; Sustronck, B; Van Der Weken, G, 1999
)
0.84
" Essential features of the method include the novel precolumn packing, the absence of sample pretreatment, a quantitave recovery, good precision and accuracy, as well as a considerable reduction of analysis time compared to conventional manual methods applied in bioavailability studies."( Direct HPLC analysis of ketoprofen in horse plasma applying an ADS-restricted access-phase.
Aboul-Enein, HY; Baeyens, WR; Corveleyn, S; Deprez, P; García-Campaña, AM; Haustraete, J; Remon, JP; Van der Weken, G, 1999
)
0.61
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Relative bioavailability of oral dexketoprofen (12."( Clinical pharmacokinetics of dexketoprofen.
Antonijoan, RM; Barbanoj, MJ; Gich, I, 2001
)
0.87
" A solubilized 200 mg liquigel formulation of ibuprofen has been shown to have a more rapid rate of absorption compared with ibuprofen 200 mg tablets."( Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain.
Cooper, S; Doyle, G; Jayawardena, S; Marrero, I; Olson, NZ; Otero, AM; Sunshine, A; Tirado, S, 2001
)
0.54
" The relative bioavailability of oral ketoprofen was about 100% of the intramuscular administration."( Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children.
Karvinen, M; Kokki, H; Tuomilehto, H, 2001
)
0.91
" In conclusion, sustained release Ibifen can ensure therapeutic ketoprofen plasma levels for the entire 24 h period, avoiding plasma concentration spikes, with bioavailability similar to other ketoprofen preparations."( Bioavailability of a new ketoprofen formulation for once-daily oral administration.
Baraldini, M; Mirasoli, M; Roda, A; Roda, E; Sabatini, L, 2002
)
0.86
" Occlusive dressing techniques had a greater enhancing effect on the bioavailability of ibuprofen when released from Pluronic gels."( Percutaneous absorption of non-steroidal anti-inflammatory drugs from in situ gelling xyloglucan formulations in rats.
Attwood, D; Bachynsky, J; Kawasaki, N; Kubo, W; Loebenberg, R; Miyazaki, S; Suzuki, S; Takahashi, A, 2002
)
0.31
"To assess oral bioavailability (F) and pharmacokinetic characteristics of the R- and S-enantiomers of ketoprofen administered IV and orally to captive Asian elephants (Elephas maximus)."( Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE, 2003
)
0.78
" Bioavailability after oral dosing was virtually complete."( Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics.
Arifah, AK; Landoni, FM; Lees, P; Taylor, PM; Waters, C, 2003
)
1.76
" The bioavailability of ketoprofen from the suppository was about 73%."( Pharmacokinetics of intravenous and rectal ketoprofen in young children.
Karvinen, M; Kokki, H; Suhonen, P, 2003
)
0.89
" Because the bioavailability of rectal ketoprofen is also relatively high, a suppository may be used in children in whom the drug cannot be given intravenously or by mouth."( Pharmacokinetics of intravenous and rectal ketoprofen in young children.
Karvinen, M; Kokki, H; Suhonen, P, 2003
)
0.85
" The validated method was successfully applied to pharmacokinetic and bioavailability studies on KTP enantiomers in humans after administration of standard and sustained release tablets of rac-KTP."( High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets.
Główka, FK; Karaźniewicz, M, 2004
)
0.52
" The aim of the present study was to compare the bioavailability of ketoprofen in a photo-stabilised formulation with a gel without photoprotection using a new dermatopharmacokinetic tape-stripping model and an established ex vivo penetration method using human skin."( Bioequivalence determination of topical ketoprofen using a dermatopharmacokinetic approach and excised skin penetration.
Akerström, U; Berne, B; Lindahl, K; Lodén, M, 2004
)
0.83
"The bioavailability of a single, topically applied, 200-mg dose of ketoprofen (delivered in a ketoprofen 20% gel) relative to a single 50-mg oral dose in healthy volunteers was studied."( Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel.
Allen, LV; Arjomand, M; Dowling, TC; Lin, ET; McPherson, ML, 2004
)
0.85
" Noncompartmental pharmacokinetic values were obtained after each dose, and relative bioavailability was calculated."( Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel.
Allen, LV; Arjomand, M; Dowling, TC; Lin, ET; McPherson, ML, 2004
)
0.62
"The relative bioavailability of ketoprofen was low and highly variable when the drug was administered as a single dose in a PLO-based ketoprofen 20% gel."( Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel.
Allen, LV; Arjomand, M; Dowling, TC; Lin, ET; McPherson, ML, 2004
)
0.9
" Firocoxib had moderate to high oral bioavailability (54% to 70%), low plasma clearance (4."( In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia.
Black, WC; Brideau, C; Cunningham, PK; Hickey, GJ; Hora, DF; McCann, ME; Rickes, EL; Zhang, D, 2005
)
0.33
"We examined the design of the versatile novel self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds."( The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs.
Araya, H; Hayashi, M; Nagao, S; Tomita, M, 2005
)
0.33
" Pharmacokinetic data indicate that although plasma levels of ketoprofen are higher when the drug is administered as a patch versus a gel, the total systemic bioavailability of ketoprofen 100 mg administered via a patch is no more than 10% of that reported for ketoprofen 100 mg administered orally."( Topical ketoprofen patch.
Mazières, B, 2005
)
1
" In this study, the in vivo results clearly show that the absorption rate of ketoprofen is not dissolution limited; therefore ketoprofen would be essentially equivalent to Class I drugs and could be considered for waiver of bioavailability and bioequivalence testing."( Rapid in vivo dissolution of ketoprofen: implications on the biopharmaceutics classification system.
Amidon, GL; Granero, GE; Ramachandran, C, 2006
)
0.85
" When delivered by the intramuscular route, bioavailability was 78%."( Pharmacokinetics of ketoprofen in the green iguana (Iguana iguana) following single intravenous and intramuscular injections.
Christian, S; Gunkel, C; Harms, CA; Lewbart, GA; Papich, M; Tuttle, AD, 2006
)
0.66
" The rate of absorption of ketoprofen from LT was significantly faster than that of IR tablet and had significantly higher Cmax (by about 50%) and earlier tmax (by 15 min), whereas the extent of absorption expressed by AUC was about 68% higher as compared to the IR tablet."( Pilot study of relative bioavailability of two oral formulations of ketoprofen 25 mg in healthy subjects. A fast-dissolving lyophilized tablet as compared to immediate release tablet.
Ahmed, IS; Fatahalla, FA, 2007
)
0.87
"The purposes of this study were to assess the mucoadhesion and bioavailability and their correlation for ketoprofen tablet dosage forms (F1-F6) containing polycarbophil (PC), sodium carboxymethylcellulose (Na CMC) as bioadhesives, Avicel pH 101 as direct compressible tablet vehicle or mixtures of these, and non compressible vehicles such as lactose and starch."( Ex vivo mucoadhesion and in vivo bioavailability assessment and correlation of ketoprofen tablet dosage forms containing bioadhesives.
Afouna, M; Khattab, I; Nazzal, S; Taha, E; Zaghloul, A, 2007
)
0.78
" By comparing the AUC0-infinity following oral and intravenous administrations, ketoprofen bioavailability was approximately 100%."( Possibility of enterohepatic recycling of ketoprofen in dogs.
Amidon, GL; Granero, GE, 2008
)
0.84
"To assess bioequivalence after oral, IM, and IV administration of racemic ketoprofen in pigs and to investigate the bioavailability after oral and IM administration."( Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs.
Heinonen, ML; Honkavaara, JM; Mustonen, KM; Peltoniemi, OA; Peltoniemi, SM; Raekallio, MR; Säkkinen, MS; Vainio, OM, 2008
)
0.79
" The bioavailability of ketoprofen was almost complete after each oral or IM administration."( Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs.
Heinonen, ML; Honkavaara, JM; Mustonen, KM; Peltoniemi, OA; Peltoniemi, SM; Raekallio, MR; Säkkinen, MS; Vainio, OM, 2008
)
0.87
" The drug from Gabrilen diffuses into body with low bioavailability (<10%) and limited regio-selectivity (AUC(deep muscle/plasma) approximately 45/0."( Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels.
Cevc, G; Mazgareanu, S; Rother, M, 2008
)
0.35
"The purpose was to investigate dermal microdialysis (DMD) for the assessment of the bioavailability of a ketoprofen topical gel formulation and to evaluate this technique as a tool for the determination of bioequivalence."( Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel.
Benfeldt, E; Kanfer, I; Skinner, MF; Tettey-Amlalo, RN; Verbeeck, RK, 2009
)
0.8
" The method was successfully applied to determine the bioavailability of KET following application of topical KET gel, Fastum gel, to the skin of human volunteers."( Rapid UPLC-MS/MS method for the determination of ketoprofen in human dermal microdialysis samples.
Kanfer, I; Tettey-Amlalo, RN, 2009
)
0.61
" The present method was successfully applied to the routine analysis of human plasma samples collected from healthy volunteers after dermal application of two topical formulations containing ketoprofen in order to assess the relative bioavailability and to demonstrate that the systemic bioavailability of ketoprofen administered topically is low enough to ensure a low incidence of gastrointestinal adverse events."( Fast HPLC method for the determination of ketoprofen in human plasma using a monolithic column and its application to a comparative bioavailability study in man.
Allegrini, A; Comuzio, S; Di Grigoli, M; Felaco, S; Giangreco, D; Martinotti, S; Mezzetti, A; Nuzzo, L; Pavone, D; Scaringi, AT; Toniato, E; Zucchelli, M, 2009
)
0.81
" Microspheres were then sterilized and bioavailability studies were carried out in New Zealand white rabbits."( Formulation and in vitro-in vivo evaluation of ketoprofen-loaded albumin microspheres for intramuscular administration.
Devi, SG; Mathew, ST; Prasanth, VV; Vinod, B, 2009
)
0.61
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
" The absolute bioavailability of R(-) and S(+) ketoprofen in chickens, turkeys, dogs and pigs was 31."( Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen.
Bosmans, T; Croubels, S; Daminet, S; De Backer, P; De Boever, S; Neirinckx, E; Remon, JP; Vervaet, C, 2011
)
0.85
"Systemic bioavailability is usually determined from plasma data."( Skin microdialysis-based estimation of systemic bioavailability fraction.
Juluru, R; Shukla, C; Stagni, G; Yin, H, 2012
)
0.38
" The extent of ketoprofen absorption seems not to depend on formulation or excipients, so the risk of bioinequivalence in terms of area under the curve is very low, but the rate of absorption (i."( Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen.
Abrahamsson, B; Barends, DM; Dressman, JB; Groot, DW; Kopp, S; Kulinich, JI; Langguth, P; Polli, JE; Ramenskaya, GV; Shah, VP; Shohin, IE, 2012
)
0.97
" Orally administered racemic ketoprofen has been reported to be absorbed well in pigs, and bioavailability was almost complete."( Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs.
Heinonen, M; Mustonen, K; Niemi, A; Palviainen, M; Peltoniemi, M; Peltoniemi, OA; Raekallio, M; Siven, M; Vainio, O, 2012
)
1.02
" Pharmacokinetic parameters were calculated and relative bioavailability (Frel) was determined for S and R -ketoprofen."( Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs.
Heinonen, M; Mustonen, K; Niemi, A; Palviainen, M; Peltoniemi, M; Peltoniemi, OA; Raekallio, M; Siven, M; Vainio, O, 2012
)
0.94
" The mean (± SD) relative bioavailability (PO compared to IM) was 83 ± 20% and 63 ± 23% for S-ketoprofen and R-ketoprofen, respectively."( Enantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigs.
Heinonen, M; Mustonen, K; Niemi, A; Palviainen, M; Peltoniemi, M; Peltoniemi, OA; Raekallio, M; Siven, M; Vainio, O, 2012
)
0.94
"The aim of the current study was to investigate the effect of poloxamer 188 (P-188) on the bioavailability of the BCS class 2 drug ketoprofen in vivo."( Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188.
Brandl, M; Buckley, ST; Fischer, SM; Fricker, G; Parmentier, J; Reimold, I, 2012
)
0.89
"The in-vivo performance of these solutions, a pure buffer solution and a P-188-containing buffer solution showed no significant difference, suggesting that the increase in bioavailability for Susp P-188 was primarily a consequence of the dissolution rate-enhancing effect."( Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188.
Brandl, M; Buckley, ST; Fischer, SM; Fricker, G; Parmentier, J; Reimold, I, 2012
)
0.69
"  Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h."( Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.
Boelsterli, UA; Fujimoto, K; Lee, KK; Redinbo, MR; Saitta, KS; Zhang, C, 2014
)
0.62
" The coupling of ketoprofen with β-CD resulted in increased solubility (100% in 60 min) of the newly-formed product, which further resulted in a higher bioavailability compared with ketoprofen (<40% in 120 min)."( Comparative assessment of effectiveness of ketoprofen and ketoprofen/beta-cyclodextrin complex in two experimental models of inflammation in rats.
Grecu, M; Ilie, C; Mareş, M; Miron, L; Năstasă, V, 2014
)
1
"In the last years a large variety of drug delivery systems have been developed to improve bioavailability of therapeutics in oral administration."( Polymer-filled microcontainers for oral delivery loaded using supercritical impregnation.
Boisen, A; Keller, SS; Marizza, P; Müllertz, A, 2014
)
0.4
" Its rapid absorption rate with higher maximum plasma concentrations and shorter time to maximum values suggest that this drug is a good option for acute migraine treatment."( Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study.
Maggioni, F; Mainardi, F; Pezzola, D; Zanchin, G; Zava, D, 2014
)
1.02
" The absolute bioavailability after PO route was 88."( Pharmacokinetics of the individual enantiomer S-(+)-ketoprofen after intravenous and oral administration in dogs at two dose levels.
Gómez-Villamandos, RJ; Machuca, MM; Navarrete-Calvo, R; Rodríguez, JM; Serrano, JM; Serrano-Rodríguez, JM, 2014
)
0.65
" The absorption rate per hour for pure ketoprofen and proliposomal formulation (KPL3) was assessed in the stomach by conducting in situ gastric absorption studies in Wistar rats and was found to be 27 ± 1."( Development of ketoprofen loaded proliposomal powders for improved gastric absorption and gastric tolerance: in vitro and in situ evaluation.
Bandari, S; Eedara, BB; Gangishetty, H, 2015
)
1.04
"To determine the efficacy and bioavailability of non-steroidal anti-inflammatory drugs (NSAIDs) when administered orally to sheep."( Randomised trial of the bioavailability and efficacy of orally administered flunixin, carprofen and ketoprofen in a pain model in sheep.
Colditz, IG; Hinch, G; Lee, C; Marini, D; Petherick, JC; Pippia, J, 2015
)
0.63
" The lower intestinal pH reported for men would lead to a higher oral bioavailability of the Test formulation and a higher reabsorption of both ketoprofen isomers in this sex."( Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.
Fagiolino, P; Guevara, N; Ibarra, M; Lorier, M; Magallanes, L; Vázquez, M, 2016
)
0.91
" On the other hand, in the in vivo percutaneous absorption experiment, the apparent absorption rate constant (ka) and the areas under the KET concentration-time curve values in the skin of rats receiving the KETnano gel ointment were significantly higher than those of rats receiving the KETmicro gel ointment, and the amounts of KET in the skin tissues of rats receiving the KETnano gel ointment were also significantly higher than those of rats receiving the KETmicro gel ointment."( Pharmacokinetics and Antiinflammatory Effect of a Novel Gel System Containing Ketoprofen Solid Nanoparticles.
Ito, Y; Iwamae, A; Nagai, N; Tanimoto, S; Yoshioka, C, 2015
)
0.65
" It is estimated that about 40% of drugs in the development pipeline and approximately 60% of the drugs coming directly from discovery suffer from poor aqueous solubility and slow dissolution, thereby reducing their bioavailability and efficacy and thus preventing their commercialization."( High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs.
Chen, X; Kalantar, TH; Kuo, TC; Ladika, M; Stoneburner, K, 2015
)
0.42
" The experimental findings elicited higher AUC and plasma concentration at 1 and 2 h indicating improved oral bioavailability as compared to parent drug ketoprofen."( Preparation and Pharmacological Evaluation of Novel Orally Active Ester Prodrugs of Ketoprofen with Non-Ulcerogenic Property.
Bandgar, BP; Bhale, PS; Chavan, HV; Dhakane, VD; Dongare, SB; Mule, YB; Thakare, VN, 2016
)
0.86
" These activities, associated to a good predictive bioavailability and a lack of cytotoxicity, design it as a promising hit for further in vivo investigation."( Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.
Corvaisier, S; Cresteil, T; Dallemagne, P; El Kihel, L; Jourdan, JP; Lecoutey, C; Legay, R; Malzert-Fréon, A; Rochais, C; Since, M; Sopkova-de Oliveira Santos, J, 2016
)
0.43
" The primary goal of the study reported here was to characterize the pharmacokinetics of KTP, including determination of bioavailability following oral administration of the currently available injectable formulation as well as a paste formulation."( Pharmacokinetics of ketoprofen enantiomers following intravenous and oral administration to exercised Thoroughbred horses.
Arthur, RM; Knych, HK; McKemie, DS; Steinmetz, S, 2016
)
0.76
" In conclusion, men showed a faster intestinal absorption rate with earlier time-to-peak plasma concentration of ketoprofen."( Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation.
Fagiolino, P; Guevara, N; Ibarra, M; Lorier, M; Magallanes, L; Vázquez, M, 2016
)
0.9
"SBA-15 is used to enhance the bioavailability of poorly soluble ketoprofen (KP) through stabilization of its amorphous state."( Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.
Abd-Elrahman, AA; El Nabarawi, MA; Hassan, DH; Taha, AA, 2016
)
2.12
"The development of oral modified-release (MR) dosage forms requires an active pharmaceutical ingredient (API) with a sufficiently high absorption rate in both the small and large intestine."( Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms.
Abrahamsson, B; Dahlgren, D; Johansson, P; Lennernäs, H; Lundqvist, A; Roos, C; Sjögren, E; Tannergren, C, 2016
)
0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
" However, most NSAIDs are insoluble in water leading them to have poor bioavailability and erratic absorption."( Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
Garg, N; Kumar, R; Singh, A; Siril, PF, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The low bioavailability of Ketoprofen is associated with its hydrophobic nature that can be solved by nanonization."( Enhanced dissolution rate of Ketoprofen by fabricating into smart nanocrystals.
Ahmad, S; Ali, FL; Bashir, S; Ghaffar, R; Isreb, M; Khan, J; Khan, MA; Khan, W; Naz, A; Ullah, A, 2019
)
1.1
"We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses."( Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD).
Fan, G; Liu, J; Ma, C; Ren, C; Shang, Y; Wang, Z; Yang, C; Yang, L; Zhang, J, 2020
)
1.05
" Correlation analysis further revealed the strong associations of PPCP concentrations in mollusks with those in water and sediment, suggesting the importance of controlling dissolved and sedimentary bioavailability of PPCPs for ecological risk management in this freshwater lake ecosystems."( Pharmaceuticals and personal care products (PPCPs) in water, sediment and freshwater mollusks of the Dongting Lake downstream the Three Gorges Dam.
Ni, J; Pan, B; Xu, N; Xu, X; Xu, Y, 2022
)
0.72

Dosage Studied

The application of 50 mg of the 1% ketoprofen gel on the rat hind paw at various time intervals from 0 to 24 h prior to the carrageenan injection significantly inhibited edema formation in all groups of dosed rats. In a multi-centre, double-blind, cross-over trial comprising 38 patients with rheumatoid arthritis, ketop rofen was given at a dosage of 150 mg daily and phenylbutazone at a dose of 300 mg daily. We conclude that ketopROfen in this dosage has no significance effect on the anticoagulant effect of warfarin.

ExcerptRelevanceReference
" Side-effects, notably nausea, epigastric discomfort and abdominal pain, were more frequent and severe with ketoprofen, leading to the withdrawal of 2 patients in the early stage of the trial, and were probably related to the high dosage used."( A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease.
Saxena, RP; Saxena, U, 1978
)
0.78
" at the dosage of 100 mg/day for 12 days."( Parenteral administration of ketoprofen in osteoarthritis: a double-blind trial versus the N-methyl-d-glucamine salt of indomethacin.
Franchi, R; Liverta, C; Pollini, C; Pontiroli, AE, 1979
)
0.55
"In a general practice study using ketoprofen (Orudis) in a twice-daily dosage regimen for the treatment of patients with articular and non-articular rheumatic conditions, data were collected on 2,644 patients, over one-third of whom had been previously treated with other anti-rheumatic preparations."( Ketoprofen (Orudis) twice daily dosage in arthritis and tissue injuries: a general practice study.
Baker, PG; Goulton, J, 1979
)
1.98
" The pyrogram enables the identification of the drug to be achieved as the pure compound, in a formulated dosage form or excreted in urine."( The identification of ibuprofen and analogues in urine by pyrolysis gas chromatography mass spectrometry.
Irwin, WJ; Slack, JA, 1978
)
0.26
"In a multi-centre, double-blind, cross-over trial comprising 38 patients with rheumatoid arthritis, ketoprofen was given at a dosage of 150 mg daily and phenylbutazone at a dosage of 300 mg daily, each for 2 weeks."( Clinical evaluation of ketoprofen (Orudis) in rheumatoid arthritis. Results of a multi-centre, double-blind, cross-over trial against phenylbutazone.
Brath, HK; Haerum, LB; Straume, S; Sydnes, O, 1976
)
0.78
" The daily dosage of ketoprofen was 150 mg in 3 doses of 50 mg."( Double-blind study of ketoprofen against a placebo in osteoarthritis of the hip.
Caroit, M; Forette, B; Hubault, A; Pasquier, P, 1976
)
0.89
" The two drugs were each given in a dosage of 150 mg daily for a period of 14 days."( Clinical evaluation of ketoprofen (19.583 R.P.) in rheumatoid arthritis. Double-blind cross-over comparison with indomethacin.
Fossgreen, J; Kirchheiner, B; Petersen, FO; Tophoj, E; Zachariae, E, 1976
)
0.57
" Further studies are underway to assess the value of ketoprofen administered in high dosage for longer duration."( A comparative trial of large doses of ketoprofen and indomethacin in the treatment of rheumatoid arthritis.
El-Ghobarey, AF; Hadidi, T; Hamid, HA; Mavrikakis, M; Rennie, JA, 1976
)
0.78
" The study was instituted during the early evaluation of ketoprofen when the dosage of 100 mg/day was being tried; it is felt that a more significant result may possibly have emerged if the dosage had been the now recommended one of 150 mg/day."( Double-blind cross-over study of ketoprofen and phenylbutazone in patients with chronic osteoarthrosis of the hip.
Cardoe, N, 1976
)
0.78
" The daily dosage of ketoprofen was 150 mg in three divided doses of 50 mg."( Double-blind trial of ketoprofen compared with placebo in osteoarthrosis of the hip.
Caroit, M; Forette, B; Hubault, A; Pasquier, P, 1976
)
0.89
"Preliminary results are reported on 30 patients treated with suppositories of ketoprofen at a dosage of two daily (200 mg)."( Ketoprofen suppositories in rheumatological practice.
Blotman, F; Simon, L, 1976
)
1.93
"A double-blind therapeutic trial carried out by the sequential method has demonstrated clearly a significant difference in efficacy between ketoprofen (given rectally at a dosage of 200 mg daily) and a placebo in a group of patients suffering from osteoarthritis of the hip or knee."( A controlled trial of ketoprofen (administered rectally) in arthritis of the hip and knee.
Cayla, J; Menkes, CJ; Rondier, J, 1976
)
0.77
" For each pig the response following the multiple dosing was deconvolved with the reference response using an algebraic deconvolution procedure adopted from the literature."( Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution.
Jensen, BH; Larsen, C; Larsen, F; Olesen, HP, 1992
)
0.56
" The effects of different polymer ratios of Eudragit RS30D and Eudragit RL30D, different particle sizes, and different combination of various formulations of solid dispersions on the in vitro release kinetics of drugs from the dosage forms were investigated."( Development of extended-release solid dispersions of nonsteroidal antiinflammatory drugs with aqueous polymeric dispersions: optimization of drug release via a curve-fitting technique.
Ho, C; Hwang, GC, 1992
)
0.28
" The extent of bioavailability of the two dosage forms in the patient groups and control subjects (n = 10) were essentially equal."( The clinical pharmacokinetics of two different preparations of intrarectal ketoprofen following spinal or local anesthesia for anal surgery.
Arai, H; Fujimaki, M; Hirokawa, S; Kasagi, T; Katsuki, S; Katsuyama, S; Takemori, S; Tazawa, K; Yamamoto, K, 1991
)
0.51
"5 hours) no dosage adjustment appears to be necessary in elderly patients unless there is concomitant renal insufficiency."( 20 years' experience with ketoprofen.
Veys, EM, 1991
)
0.58
" Sustained release dosage forms are available, which may be beneficial due to the short terminal phase half-life of ketoprofen (1 to 3h)."( Clinical pharmacokinetics of ketoprofen and its enantiomers.
Brocks, DR; Jamali, F, 1990
)
0.78
" The application of 50 mg of the 1% ketoprofen gel on the rat hind paw at various time intervals from 0 to 24 h prior to the carrageenan injection significantly inhibited edema formation in all groups of dosed rats."( Anti-inflammatory activity of ketoprofen gel on carrageenan-induced paw edema in rats.
Chi, SC; Jun, HW, 1990
)
0.84
" No relationship was found between the incidence of side-effects and age or dosing time."( Safety of ketoprofen in the elderly: a prospective study on 20,000 patients.
Le Loet, X, 1989
)
0.68
" However, the baseline control collections after chronic dosing did not differ from the no-drug control periods."( Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics.
Anderson, SA; Brater, DC; Brown-Cartwright, D; Toto, RD, 1986
)
0.27
" Furthermore, several alternate dosage forms, including intramuscular injection for relief of acutely painful conditions, suppositories, two slow-release forms (a sustained-release tablet [IBP 200] and a controlled-release capsule [Oruvail] ), and a topical gel for local treatment of certain superficial conditions and minor rheumatologic disease are available."( Ketoprofen: the European experience.
Avouac, B; Teule, M, 1988
)
1.72
" In each patient the plasma concentrations of the R- and S-enantiomers were similar at all times over a 24 h dosing interval."( The disposition of ketoprofen enantiomers in man.
Ahern, MJ; Meffin, PJ; Purdie, YJ; Sallustio, BC; Whitehead, AG, 1988
)
0.6
"Two kinds of dosage forms of commercially available suppositories containing ketoprofen (KP), fatty suppositories (FS) and gelatin capsulated suppositories (GCS), were administered to patients immediately after anal surgery, and results obtained were compared."( Pharmacokinetics of two rectal dosage forms of ketoprofen in patients after anal surgery.
Fujimaki, M; Horikoshi, I; Kanamoto, I; Koizumi, T; Nakagawa, T; Tazawa, K, 1988
)
0.76
" During chronic dosing with both forms of ketoprofen, peak drug concentrations were lower and occurred later in the synovial fluid than in the plasma."( A comparison of plasma and synovial fluid profiles of standard and controlled-release formulations of ketoprofen in patients with rheumatoid arthritis.
Boyd, MW; Kaye, CM; McCrea, JD; Telford, AM, 1986
)
0.75
" According to clinical observations, administration of a ketoprofen bolus suppressed pain within 5 to 30 minutes; the administration of a loading dose and a 24-hour infusion is almost never followed by a recurrence of pain, and this regimen was proposed as the dosage schedule of ketoprofen to treat renal colic."( Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion.
Albessard, F; Debruyne, D; Hurault de Ligny, B; Moulin, M; Ryckelynck, JP, 1987
)
0.81
"5 micrograms/kg and a double-sigmoidal dose-response relationship was observed."( The pyrogenic actions of the interferon-inducer, polyinosinic:polycytidylic acid are antagonised by ketoprofen.
Abul, HT; Davidson, J; Milton, AS; Rotondo, D, 1987
)
0.49
"4 h) and accumulation upon repeated dosing (28%) were essentially the same as reported for young volunteers."( Pharmacokinetic profile of controlled release ketoprofen in elderly patients.
Babiker, M; Crome, P; Dennis, MJ; French, PC; Hopkins, R; Shillingford, J, 1985
)
0.53
" The authors conclude that Bi-Profenid is effective at a daily dosage of 150 mg, thus enabling to adjust prescriptions to actual needs when pain is not continuous throughout the 24 hours."( [Double-blind comparative study of slow-release ketoprofen and a placebo in chronic inflammatory rheumatism].
Amor, B; Harrewyn, JM, 1983
)
0.52
" Dosage convenience, effectiveness on pain during the second part of the night and resolution of morning stiffness were considered better with Bi-Profenid by 23 patients and with conventional forms by four, while five reported no preference."( [Open clinical trial of a new oral galenic form of ketoprofen].
Asch, L; Huck, F; Kuntz, JL; Lecocq, J; Meyer, R, 1983
)
0.52
" In 6 patients the "therapeutic follow-up test" allowed to decrease dosage to one tablet a day."( [Long-term study of 150 mg. Bi-Profenid in patients followed at the Department of Rheumatology of Cochin Hospital].
Amor, B; Dougados, M; Harrewyn, JM, 1983
)
0.27
" A disproportionately large degree of elimination of free ketoprofen was observed between 0-6 h after dosing with ketoprofen capsules."( Urinary pharmacokinetics of orally administered ketoprofen in man.
Dennis, MJ; Houghton, GW; Parsons, RL; Rigler, ED,
)
0.63
"Nine volunteers were dosed once daily for 15 days with a controlled release formulation of ketoprofen."( A pharmacokinetic study of repeated doses of a new controlled release form of ketoprofen.
Calvert, RM; Cresswell, DG; Dennis, MJ; Houghton, GW; Templeton, R, 1984
)
0.72
" Knowledge of population kinetics can help one to choose initial drug dosage, to modify dosage appropriately in response to observed drug levels, to make rational decisions regarding certain aspects of drug regulation, and to investigate and elucidate certain research questions in pharmacokinetics."( The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.
Sheiner, LB, 1984
)
0.27
" Initial dosage was 100 mg/m2/d, gradually increased up to 200 mg/m2/d, not to exceed 320 mg/d."( Ketoprofen (Orudis) in the treatment of juvenile rheumatoid arthritis. A segment I study.
Baum, J; Bernstein, B; Brewer, EJ; Fink, CW; Giannini, EH; Knee, CM; Schaller, JG,
)
1.57
" The dosage has to be established individually for each patient because the resorption is independent from body size and body weight."( [Distribution of non-steroidal anti-inflammatory agents in human tissues].
Köhler, G, 1982
)
0.26
" The results of this clearly indicate that ketoprofen in a dosage of 12."( Comparison ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache.
Lange, R; Lentz, R, 1995
)
0.94
"A double-blind randomized parallel-group trial was undertaken to evaluate the influence of the dosing time of sustained-release ketoprofen (SRK) on its acceptability and efficacy."( Dosing time optimizes sustained-release ketoprofen treatment of osteoarthritis.
Buchmuller, A; Decousus, H; Hocquart, J; Mismetti, P; Perpoint, B; Queneau, P; Rambaud, C; Simitsidis, S, 1994
)
0.76
" The half-life of the drug from this dosage form is not significantly affected by the increasing age of the patients."( Ketoprofen extended-release capsules: a new formulation for the treatment of osteoarthritis and rheumatoid arthritis.
Schumacher, HR,
)
1.57
" All the cows were treated with 20 g sulphadiazine and 4 g trimethoprim intramuscularly upon diagnosis, and half the dosage was given once daily thereafter."( Anti-inflammatory ketoprofen in the treatment of field cases of bovine mastitis.
Chen, R; Longo, F; Saran, A; Shpigel, NY; Winkler, M; Ziv, G, 1994
)
0.62
" There was a linear dose-response curve that was steeper in women than in men."( Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs.
Dobson, A; Henry, D; Turner, C, 1993
)
0.29
" We conclude that ketoprofen in this dosage has no significance effect on the anticoagulant effect of warfarin."( Lack of interaction of ketoprofen with warfarin.
Mieszczak, C; Winther, K, 1993
)
0.93
" Outcome variables included overall pain scores (AUC(0,360 min), maximum pain relief, pain relief at 1 h after dosage and the number of patients taking escape analgesics."( The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery.
Hawkesford, JE; Kelly, PJ; Seymour, RA, 1996
)
0.64
" After dosing with optically pure enantiomer, the concentration of the administered enantiomer predominated during the absorption phase."( Bi-directional chiral inversion of ketoprofen in CD-1 mice.
Aberg, G; Jamali, F; Lovlin, R, 1997
)
0.57
"5 mg/kg CyA/day and dosage was increased cautiously to 5 mg/kg/day or less if the serum creatinine rose by > or = 30% above baseline."( Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs.
Baker, P; Bensen, W; Gent, M; Grace, E; Ludwin, D; Roberts, R; Tugwell, P, 1997
)
0.3
" The calculated steady state plasma concentrations of ketoprofen during multiple dosage were much higher after intramuscular (0."( Intramuscular bioavailability of ketoprofen lysine salt in horses.
Anfossi, P; Carli, S; Montesissa, C; Villa, R, 1997
)
0.83
"3% (S)-ketoprofen demonstrated a reduction and other groups demonstrated elevations over the 60-day dosing period."( Enantiospecific inhibition of ligature-induced periodontitis in beagles with topical (S)-ketoprofen.
Fiorellini, JP; Howell, TH; Martuscelli, G; McCullough, JR; Oringer, RJ; Paquette, DW; Reasner, DS; Williams, RC, 1997
)
0.97
"5 days of dosing were used to detect newly occurring hemorrhages and erosions."( Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)- ketoprofen, (R)- flurbiprofen, racemic ketoprofen, and paracetamol: a randomized, single-blind, placebo-controlled trial.
Caubet, JF; Handley, DA; Jerussi, TP; McCray, JE, 1998
)
0.53
"To enhance the dissolution rate and bioavailability of poorly water-soluble ketoprofen, a novel oral dosage form of ketoprofen, termed ketoprofen dry elixir, was developed by the spray-drying technique."( Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form.
Ahn, HJ; Kim, CK; Kim, KM, 1998
)
0.81
" Three dosage forms were selected for this study: capsules, suppositories, and creams."( Effect of chemical structure on the release of certain propionic acid derivatives from their dosage forms.
el-Bary, AA; el-Nabarawi, MA; Mohamed, MI, 1998
)
0.3
" Groups of six rats received either vehicle or analgesic drug and antinociception was evaluated by evaluating the dose-response curves over time."( Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid.
Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998
)
0.58
" The COX selectivity of each drug was evaluated from dose-response curves by calculating a ratio (COX-1:COX-2) of inhibitory concentration values on the basis of concentrations that reduced PGE2 by 50% in each COX model."( In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs.
Benn, SJ; Conlon, P; Kay-Mugford, P; LaMarre, J, 2000
)
0.31
" The importance of KP in the therapeutic field, has stimulated the development of topical dosage forms to improve its percutaneous absorption through the application site."( In vitro release and antiinflammatory activity of topical formulations of ketoprofen.
Gavini, E; Moretti, MD; Peana, AT,
)
0.36
" In comparing topical versus systemic formulations, all topical formulations were as equipotent as systemic dosing in altering local prostaglandin levels despite lower KTP exposures with gel treatments."( Pharmacodynamic effects of ketoprofen on crevicular fluid prostanoids in adult periodontitis.
Annett, M; Binder, TA; Friedman, M; Lawrence, HP; McCombs, GB; Offenbacher, S; Paquette, DW; Smith, PC; Troullos, E; Wilder, R, 2000
)
0.6
" Validation data and study sample data from patients dosed with either orally or topically administered ketoprofen were generated using both pcSFC and LC as the chromatographic methods to compare and contrast these analytical approaches."( Comparison of packed-column supercritical fluid chromatography--tandem mass spectrometry with liquid chromatography--tandem mass spectrometry for bioanalytical determination of (R)- and (S)-ketoprofen in human plasma following automated 96-well solid-phas
Bailey, RE; Eichhold, TH; Hoke, SH; Pinkston, JD; Tanguay, SL, 2000
)
0.71
" The purpose of this study was to evaluate the effect of focal cerebral ischaemia in the rat through the dosage of the glutamate and morphological findings, and to evaluate a possible protective effect of the ketoprofen to ischemic neurons."( [Focal cerebral ischaemia induced by middle cerebral artery occlusion and the neuroprotective effect of ketoprofen in rats].
Colli, BO; Coutinho Netto, J; Dias, LA; Lachat, JJ, 2000
)
0.71
" The antinociceptive efficacies were evaluated using several dose-response curves and time courses."( Effect of caffeine on antinociceptive action of ketoprofen in rats.
Díaz-Reval, MI; Domínguez-Ramírez, AM; Hernández-Delgadillo, GP; López-Muñoz, FJ; Ventura-Martínez, R,
)
0.39
" A dose-response relationship was observed for ketoprofen, with the two higher doses providing significantly greater analgesia than the lower dose."( Onset and duration of analgesia for low-dose ketoprofen in the treatment of postoperative dental pain.
Marrero, I; Olson, NZ; Sunshine, A; Tirado, S, 1998
)
0.82
" In order to be able to process the aqueous NanoCrystal colloidal dispersion into a hydrophobic solid dosage form a spray drying procedure was used."( An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen.
De Smedt, S; Demeester, J; Hoste, S; Jain, RA; Remon, JP; Ruddy, S; Van Driessche, I; Vergote, GJ; Vervaet, C, 2001
)
0.54
" A dose-response relationship between 12."( Clinical pharmacokinetics of dexketoprofen.
Antonijoan, RM; Barbanoj, MJ; Gich, I, 2001
)
0.59
" The dose-response curve for NE (0."( Lead-cadmium interaction effect on the responsiveness of rat mesenteric vessels to norepinephrine and angiotensin II.
Andrzejak, R; Skoczyńska, A; Wróbel, J, 2001
)
0.31
"A prophylactic approach to the management of postoperative pain is described: ketoprofen, a nonsteroid antiinflammatory drug, was used, which possesses numerous advantages and a variety of dosage forms."( [Ketoprofen (ketonal): a drug for preventing and treating postoperative pain].
Beresnev, VA; Dolgopolova, TV; Osipova, NA; Vetsheva, MS,
)
1.27
" All the microparticulate dosage forms were prepared using ketoprofen in the form of calcium salt (KP-Ca)."( Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylethylcellulose.
Machida, Y; Onishi, H; Yamada, T, 2001
)
0.89
" Dose-response curves were obtained for systemic and intrathecal antinociceptive effects of ketoprofen, phenylephrine, clonidine, desipramine, and prazosin; and ED50 were calculated."( Interaction between the antinociceptive effect of ketoprofen and adrenergic modulatory systems.
Miranda, HF; Pinardi, G; Sierralta, F, 2001
)
0.78
" Blood samples were collected at standardized times after dosing and assayed for ketoprofen by high-performance reversed-phase liquid chromatography (HPLC)."( Chiral inversion of (R)-ketoprofen: influence of age and differing physiological status in dairy cattle.
Auza, N; Igarza, L; Soraci, A; Zeballos, H, 2002
)
0.85
" Based on the pharmacokinetic data, a dosage of ketoprofen of 1 mg/kg every 48 hours to 2 mg/kg every 24 hours, PO or IV, is recommended for use in Asian elephants, although the safety and efficacy of ketoprofen during long-term administration in elephants have not been determined."( Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE, 2003
)
0.82
" Absorption of both S(+) and R(-) enantiomers was rapid after oral dosing and enantioselective pharmacokinetics was demonstrated by the predominance of S(+) KTP, as indicated by plasma AUC of 20."( Ketoprofen in the cat: pharmacodynamics and chiral pharmacokinetics.
Arifah, AK; Landoni, FM; Lees, P; Taylor, PM; Waters, C, 2003
)
1.76
"An example of application of experimental design methodologies to the set up of dissolution test conditions for a new ketoprofen oral extended-release dosage form is presented."( Optimization of dissolution test precision for a ketoprofen oral extended-release product.
Furlanetto, S; Maestrelli, F; Mura, P; Orlandini, S; Pinzauti, S, 2003
)
0.78
"Beginning on the first postoperative day, the patients were allowed to use 50 mg ketoprofen capsules at a dosage of 5 mg/kg/24 hr."( Ketoprofen for postoperative pain after uvulopalatopharyngoplasty and tonsillectomy: two-week follow-up study.
Aho, M; Kokki, H; Nikanne, E; Virtaniemi, J, 2003
)
1.99
" Explanations for these results include: (a) the analgesics were effective in relieving pain but had pharmacological side effects that altered the measured parameters, making it difficult to determine recovery; (b) the level of pain experienced did not notably affect recovery; (c) the analgesics, at the doses and/or dosing schedules used, were not effective in the relief of pain, thereby causing both groups of animals to recover at the same rate; and (d) the analgesics interfered with recovery."( Recovery of male rats from major abdominal surgery after treatment with various analgesics.
Azar, T; Lawson, D; Sharp, J; Zammit, T, 2003
)
0.32
" Since the disk assembly in the USP for patch dosage forms was unsuited for use in a release test due to penetration of the dissolution medium into the cataplasm from the screw part of the device and the cataplasm swelled, new holders were designed."( Investigation of the release test method for the topical application of pharmaceutical preparations: release test of cataplasm including nonsteroidal anti-inflammatory drugs using artificial sweat.
Kobayashi, D; Kogo, T; Morimoto, Y; Numajiri, S; Shimamura, T; Tairabune, T; Ueda, H, 2004
)
0.32
"The purpose of this study was to formulate a gelled self-emulsifying drug delivery system (SEDDS) containing ketoprofen as an intermediate in the development of sustained release solid dosage form."( Effect of formulation variables on preparation and evaluation of gelled self-emulsifying drug delivery system (SEDDS) of ketoprofen.
Joshi, P; Paradkar, A; Patil, P, 2004
)
0.74
"Fast drug release from solid dosage forms requires a very fast contact of the vast majority of the drug particles with the solvent; this, however, is particularly delayed in tablets and granulations."( Immediate drug release from solid oral dosage forms.
Loth, H; Schaefer, UF; Schreiner, T, 2005
)
0.33
" KP or PT-KP was given to rats by oral administration at a dosage of 10mg/kg."( Study on the characteristics of pectin-ketoprofen for colon targeting in rats.
Fang, KQ; Gu, Y; Wang, XY; Xi, MM; Zhang, SQ, 2005
)
0.6
" All patients began treatment with celecoxib, at a starting dosage of 100 mg twice daily; patients could increase this dosage to 200 mg twice daily or could switch to another NSAID while maintaining the same treatment strategy."( Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
Béhier, JM; Calin, A; Dougados, M; Heijde, Dv; Landewé, R; Olivieri, I; Wanders, A; Zeidler, H, 2005
)
0.33
", lidocaine and ketoprofen) from mucoadhesive buccal film dosage forms."( Effect of low-molecular-weight beta-cyclodextrin polymer on release of drugs from mucoadhesive buccal film dosage forms.
Arakawa, Y; Hashida, M; Kawakami, S; Yamashita, F, 2005
)
0.67
" Furthermore, to assess time profiles of KP concentration in the skin and plasma, guinea pigs received a repeated topical application of R-KP and S-KP at a dosage of 40 mg/kg over a period of 3 days."( Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig.
Chikamatsu, N; Igarashi, T; Nagata, O; Nakazawa, T; Shimo, T; Yamamoto, M, 2006
)
0.57
" The mixture was dosed into the pockets of blister packs and then was subjected to freezing and lyophilization."( Formulation of a fast-dissolving ketoprofen tablet using freeze-drying in blisters technique.
Ahmed, IS; Fatahalla, FA; Nafadi, MM, 2006
)
0.62
" Dexalgin was prescribed in dosage 75 mg daily during 5 days."( [Therapeutic effect of dexalgin on disturbances of vertebrogenic and nonvertebrogenic mechanisms in back pain].
Kryzhanovskiĭ, GN; Merkulov, IuA; Merkulova, DM, 2006
)
0.33
" PLO was adapted to contain fish oil, ketoprofen, or both, and 1,8-cineole as penetration enhancer, and used to determine the in-vitro permeation from infinite and finite dosing protocols across full thickness porcine skin."( In-vitro transcutaneous delivery of ketoprofen and polyunsaturated fatty acids from a pluronic lecithin organogel vehicle containing fish oil.
Bowen, JL; Heard, CM; Richards, H; Thomas, CP, 2006
)
0.88
" In the writhing test, the intraperitoneal administration of dexketoprofen or ketoprofen resulted in parallel dose-response curves with equal efficacy, but higher relative potency for dexketoprofen."( Dexketoprofen-induced antinociception in animal models of acute pain: synergy with morphine and paracetamol.
Dursteler, C; Miranda, HF; Pinardi, G; Prieto, JC; Puig, MM, 2007
)
1.2
" The effective dose that produced 50% antinociception (ED(50,mix)) was calculated from the log dose-response curve of fixed-ratio combinations of paracetamol with ketoprofen."( Isobolographic analysis of the antinociceptive interactions between ketoprofen and paracetamol.
Kong, H; Liu, J; Liu, Y; Mei, XG; Qiu, HX, 2007
)
0.77
" Freshly excised full-thickness porcine skin in Franz diffusion cells was dosed (both infinite and finite) with simple formulations based on fish oil as source of EPA."( Probing the skin permeation of eicosapentaenoic acid and ketoprofen 2. Comparative depth profiling and metabolism of eicosapentaenoic acid.
Heard, CM; Thomas, CP, 2007
)
0.58
" These data indicate the daily dosing that is generally recommended for reptile patients, as an extrapolation from mammalian data, may be more frequent than necessary."( Pharmacokinetics of ketoprofen in the green iguana (Iguana iguana) following single intravenous and intramuscular injections.
Christian, S; Gunkel, C; Harms, CA; Lewbart, GA; Papich, M; Tuttle, AD, 2006
)
0.66
" Formulation of SMES in solid dosage forms can be difficult and, to date, most SMES are applied in liquid dosage form or soft gelatin capsules."( Preparation of microcapsules with self-microemulsifying core by a vibrating nozzle method.
Gasperlin, M; Homar, M; Suligoj, D, 2007
)
0.34
"5 mg/kg) (MP group); and a group given a reduced dosage of ketoprofen (0."( The interaction between orally administered non-steroidal anti-inflammatory drugs and prednisolone in healthy dogs.
Hara, S; Motoishi, K; Naito, Y; Narita, T; Sato, R; Tani, K, 2007
)
0.58
"The purposes of this study were to assess the mucoadhesion and bioavailability and their correlation for ketoprofen tablet dosage forms (F1-F6) containing polycarbophil (PC), sodium carboxymethylcellulose (Na CMC) as bioadhesives, Avicel pH 101 as direct compressible tablet vehicle or mixtures of these, and non compressible vehicles such as lactose and starch."( Ex vivo mucoadhesion and in vivo bioavailability assessment and correlation of ketoprofen tablet dosage forms containing bioadhesives.
Afouna, M; Khattab, I; Nazzal, S; Taha, E; Zaghloul, A, 2007
)
0.78
" Maintained in Hanks buffer immediately post excision, full thickness membranes were mounted in Franz diffusion cells and dosed with 1 ml of individual formulations containing ketoprofen, fish oil or both."( Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX.
Davison, Z; Heard, CM; Thomas, CP, 2007
)
0.79
" A possibility of enterohepatic cycling of ketoprofen in dogs was proposed because of multiple peak phenomenon in the concentration-time profiles after intravenous and oral dosing was observed."( Possibility of enterohepatic recycling of ketoprofen in dogs.
Amidon, GL; Granero, GE, 2008
)
0.87
" This enabled the commencement of technological work on the design and manufacture of a model dosage form administered to the skin and containing the products of lanolin oxyethylation."( Equilibrium solubilization of lipophilic therapeutic agents by aqueous solutions of products of catalytic oxyethylation of Croda-type lanolin as model excipients of the class of non-ionic surface active agents.
Lukosek, M; Nachajski, MJ; Zgoda, MM, 2007
)
0.34
" Since ketoprofen was chosen as a model drug for the formulation of controlled-release dosage forms, it was encapsulated into these two types of synthetic zeolites by a soaking procedure."( Synthetic zeolites as a new tool for drug delivery.
Abignente, E; Curcio, A; Melisi, D; Mirabelli, R; Mondello, S; Rabaioli, MR; Rimoli, MG, 2008
)
0.8
"The aim of this study was to investigate the effect of physico-chemical properties of the polymers on the release profile of ketoprofen from the pellets dosage form."( The effect of the ratio of two acrylic polymers on the in vitro release kinetics of ketoprofen from pellets prepared by extrusion and spheronisation technique.
Kibria, G; Ul-Jalil, R, 2008
)
0.78
" Patients receiving the brand-name KP tape (product A) and/or a generic KP tape (product B) in our pharmacy were interviewed concerning 20 items including 1) dosage regimen, 2) outer package, 3) liner, 4) the tape itself, and 5) condition of application sites."( [Questionnaire survey of patients comparing the usability of brand-name and generic ketoprofen tapes].
Hori, S; Inoue, A; Ishibashi, H; Miki, A; Ohtani, H; Ono, N; Saita, A; Sawada, Y; Tominaga, K, 2008
)
0.57
"Though ketoprofen is commonly used in rodent surgical procedures, an optimal dosing regimen has not yet been established."( Refinement of the dosage and dosing schedule of ketoprofen for postoperative analgesia in Sprague-Dawley rats.
Cooper, DM; Hoffman, W; Lee, HY; Tomlinson, K, 2008
)
1.06
" However, SEP monitoring can be done with sevoflurane inhalation, but the dosage should be adjusted due to interindividual variability."( Somatosensory evoked potentials by median nerve stimulation in children during thiopental/sevoflurane anesthesia and the additive effects of ketoprofen and fentanyl.
Hyvärinen, A; Kokki, H; Nieminen, K; Partanen, J; Westerén-Punnonen, S; Yppärilä-Wolters, H, 2008
)
0.55
"The Biopharmaceutics Classification System (BCS) is based on the mechanistic assumptions that the rate and extent of oral drug absorption are governed by drug solubility, intestinal permeability, and dissolution rate from the dosage form administered."( An investigation into the importance of "very rapid dissolution" criteria for drug bioequivalence demonstration using gastrointestinal simulation technology.
Kovacevi, I; Langguth, P; Parojci, J; Tubi-Grozdanis, M, 2009
)
0.35
" Doses were administered by oral gavage or through feeding tissues from cattle dosed with ketoprofen at 6 mg kg(-1) cattle body weight, before slaughter."( Toxicity of non-steroidal anti-inflammatory drugs to Gyps vultures: a new threat from ketoprofen.
Cromarty, D; Cuthbert, R; Diekmann, M; Duncan, N; Meharg, AA; Naidoo, V; Taggart, MA; Venter, L; Wolter, K, 2010
)
0.81
" After 1 h, the pre-treatment was removed and the skin dosed with a saturated solution of ketoprofen in polyethylene glycol 400; the appearance of drug in the receptor phase was then monitored by HPLC."( Pre-treatment with Aloe vera juice does not enhance the in vitro permeation of ketoprofen across skin.
Ballam, L; Heard, CM, 2010
)
0.81
"In a safety study, Cape Griffon vultures (Gyps coprotheres) were dosed with ketoprofen at single doses of ~1 mg/kg (n = 5) and 5 mg/kg (n = 11)."( The toxicokinetics of ketoprofen in Gyps coprotheres: toxicity due to zero-order metabolism.
Cuthbert, R; Naidoo, V; Taggart, M; Venter, L; Wolter, K, 2010
)
0.9
") Moreover, the percentage of patients needing to increase the morphine dosage (40."( Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain.
Cruto, M; Debernardi, F; Massucco, P; Moselli, NM; Savojardo, M, 2010
)
0.62
" Pharmacokinetic studies show that drug exposure after a single intravenous dose is similar in children and adults (after dose normalization), and thus similar mg/kg bodyweight dosing may be used in children and adults."( Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients.
Kokki, H, 2010
)
1.8
"The aim of this study was to develop a pH-responsive dual pulse multiparticulate dosage form containing a model drug ketoprofen, a nonsteroidal anti-inflammatory drug used for rheumatoid arthritis."( pH-responsive dual pulse multiparticulate dosage form for treatment of rheumatoid arthritis.
Kadam, V; Kedar, U; Lotlikar, V; Shidhaye, S, 2010
)
0.57
"The study concluded that the formulated multiparticulate dosage form of ketoprofen was able to relieve circadian symptoms of rheumatoid arthritis during midnight and early morning."( pH-responsive dual pulse multiparticulate dosage form for treatment of rheumatoid arthritis.
Kadam, V; Kedar, U; Lotlikar, V; Shidhaye, S, 2010
)
0.59
"Powder layering technique was evaluated using laboratory scale centrifugal granulator instrument to prepare extended release pellet dosage form of ketoprofen."( Development and in vitro evaluation of ketoprofen extended release pellets using powder layering technique in a rotary centrifugal granulator.
Kohli, K; Pai, A; Pai, R; Srivastava, B, 2011
)
0.84
" Palatability and accuracy of dosing were also assessed."( Clinical evaluation of meloxicam versus ketoprofen in cats suffering from painful acute locomotor disorders.
Grant, D; Johnston, L; Letellier, IM; Morton, CM; Narbe, R, 2011
)
0.64
"In this work, a multiparticulate-sustained release dosage form containing ketoprofen in a carnauba wax matrix was developed."( Design and characterization of sustained release ketoprofen entrapped carnauba wax microparticles.
Lima, EM; Nascimento, TL; Oliveira, RB, 2012
)
0.86
" In fact, MW treatments under different time and irradiating regimes are able to modulate drug release from alginate beads; high levels of irradiation led to beads suitable for immediate release oral dosage forms whereas the lowest regime of irradiation led to beads that achieved a prolonged/sustained release of the drug till 8h in simulated intestinal medium."( A combined technique based on prilling and microwave assisted treatments for the production of ketoprofen controlled release dosage forms.
Aquino, RP; Auriemma, G; Barba, AA; d'Amore, M; Del Gaudio, P, 2011
)
0.59
"In the present study, an extended release pellet dosage form of ketoprofen was prepared using powder layering technique."( In vitro and in vivo evaluations of ketoprofen extended release pellets prepared using powder layering technique in a rotary centrifugal granulator.
Jain, G; Kohli, K; Pai, R; Srivastava, B, 2011
)
0.88
" Standard solutions of ibuprofen, ketoprofen and naproxen were dosed into the synthetic feed of the MBR."( Enantiospecific fate of ibuprofen, ketoprofen and naproxen in a laboratory-scale membrane bioreactor.
Hashim, NH; Khan, SJ; Nghiem, LD; Stuetz, RM, 2011
)
0.93
" Dose-response curves for DEX and TRM, individually and combined in a 1 : 1 proportion based on their potency were obtained, and the doses that produced a 50% inhibition calculated."( Antinociceptive and anti-exudative synergism between dexketoprofen and tramadol in a model of inflammatory pain in mice.
Miranda, HF; Puig, MM; Romero, MA, 2012
)
0.63
" In addition, we compiled dose-response data for 4 commonly used analgesics: buprenorphine, carprofen, ketoprofen, and acetaminophen."( Using the Mouse Grimace Scale to reevaluate the efficacy of postoperative analgesics in laboratory mice.
King, OD; Matsumiya, LC; Mogil, JS; Sorge, RE; Sotocinal, SG; Tabaka, JM; Wieskopf, JS; Zaloum, A, 2012
)
0.59
"Polymeric porous foams have been evaluated as possible new pharmaceutical dosage forms."( Drug delivery properties of macroporous polystyrene solid foams.
Aparicio, RM; Canal, C; Esquena, J; García-Celma, MJ; Vilchez, A, 2012
)
0.38
"We investigated the safety and efficacy of the bilateral periarticular multimodal drug injection (PMDI) at a reduced dosage in patients undergoing simultaneous bilateral total knee arthroplasty (SBTKA)."( Use of reduced-dose periarticular injection for pain management in simultaneous bilateral total knee arthroplasty.
Chang, CB; Jeon, YT; Kang, YG; Kim, TK; Koh, IJ; Song, J, 2012
)
0.38
"Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing ketoprofen are reviewed."( Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen.
Abrahamsson, B; Barends, DM; Dressman, JB; Groot, DW; Kopp, S; Kulinich, JI; Langguth, P; Polli, JE; Ramenskaya, GV; Shah, VP; Shohin, IE, 2012
)
0.8
" Dissolution/release rate could be tailored for rapid-release applications by selecting a suitable HPC polymer and altering the final dosage form."( Klucel™ EF and ELF polymers for immediate-release oral dosage forms prepared by melt extrusion technology.
Deng, W; Durig, T; Majumdar, S; Mohammed, NN; Murthy, NS; Pinto, E; Repka, MA; Singh, A; Tewari, D, 2012
)
0.38
" Different comonomer content formulations show limited drug release at low pH, a helpful properties to avoid gastric irritating effect of ketoprofen associated with conventional dosage forms."( Continuous-flow encapsulation of ketoprofen in copolymer microbeads via co-axial microfluidic device: influence of operating and material parameters on drug carrier properties.
Anton, N; Khan, IU; Serra, CA; Vandamme, T, 2013
)
0.87
" There are few works which optimize the drug loading step and often therapeutics are dosed in the microdevices through laborious and time consuming procedures."( Polymer-filled microcontainers for oral delivery loaded using supercritical impregnation.
Boisen, A; Keller, SS; Marizza, P; Müllertz, A, 2014
)
0.4
" With regard to the in vitro and in vivo experiments, liquid suppository formulation F5 might be a promising formulation for the development of an effective rectal dosage form."( In vitro-in vivo evaluation of in situ gelling and thermosensitive ketoprofen liquid suppositories.
Ertan, G; Kardhiqi, A; Ozgüney, I; Yıldız, G, 2014
)
0.64
" The results from the study can help inform dosing regimens in pediatrics using the quetiapine XR formulation."( Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
Bui, KH; Johnson, TN; Zhou, D, 2014
)
0.4
"Dexketoprofen has an antiepileptic feature and this effect increases as the dosage increases, however it is currently unknown through which mechanism this drug shows its anticonvulsant effect."( Inhibitor effect of dexketoprofen in rat model of pentylenetetrazol-induced seizures.
Aksoy, D; Erbaş, O; Solmaz, V, 2015
)
1.35
" It is a major determinant of half-life and dosing frequency of a drug."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
" SPF episodes at 24-h after early dosing were 25 % (Frova), 45 % (FroDex 25) and 41 % (FroDex 37."( Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group stu
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Colombo, B; Comi, G; Cortelli, P; Curone, M; D'Arrigo, G; d'Onofrio, F; Frediani, F; Omboni, S; Sette, G; Tullo, V; Valguarnera, F, 2015
)
0.65
"For the treatment of inflammatory-based diseases affected by circadian rhythms, the development of once-daily dosage forms is required to target early morning symptoms."( Design and In Vivo Anti-Inflammatory Effect of Ketoprofen Delayed Delivery Systems.
Aquino, RP; Auriemma, G; Cerciello, A; Del Gaudio, P; Morello, S; Pinto, A; Russo, P, 2015
)
0.67
"The present study was aimed to prepare, taste-masked mini-tablets, which are easily swallowed dosage forms, primarily to be used by pediatric and geriatric patients."( Preparation and Evaluation of Hot-Melt Extruded Patient-Centric Ketoprofen Mini-Tablets.
Almutairy, BK; Alshehri, SM; Alshetaili, AS; Alsulays, BB; Feng, X; Morott, JT; Park, JB; Repka, MA; Tiwari, RV; Zhang, F, 2016
)
0.67
"5 mg dosage strength."( Ketoprofen Dental Pain Study.
Betts, NJ; Cooper, SA; Hermann, DG; Hersh, EV; Lamp, C; Levin, LM; Secreto, SA; Wedell, D, 1997
)
1.74
"A novel, simple, sensitive, selective and reproducible stability-indicating high performance liquid chromatographic method was developed for the quantitative determination of degradation products and process-related impurities of ketoprofen (KET) and omeprazole (OMZ) in combined oral solid dosage form."( Development and Validation of a Novel Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Related Substances of Ketoprofen and Omeprazole in Combined Capsule Dosage Form.
Anireddy, JS; Koppala, S; Reddy, VR,
)
0.52
" Furthermore, time- and dose-response curves were obtained to determine the antinociceptive effect of the formulations."( Pomegranate seed oil nanoemulsions improve the photostability and in vivo antinociceptive effect of a non-steroidal anti-inflammatory drug.
Barbieri, AV; Beck, RCR; Cervi, VF; Cruz, L; Ferreira, LM; Gehrcke, M; Nogueira, CW; Sari, MHM; Zborowski, VA, 2016
)
0.43
"Ginsenoside Rg3 has an analgesic effect with a curvilinear dose-response relationship."( Antinociceptive Effects of Ginsenoside Rg3 in a Rat Model of Incisional Pain.
Ahn, EJ; Baek, CW; Bang, SR; Choi, GJ; Jung, YH; Kang, H; Woo, YC, 2016
)
0.43
"The development of oral modified-release (MR) dosage forms requires an active pharmaceutical ingredient (API) with a sufficiently high absorption rate in both the small and large intestine."( Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms.
Abrahamsson, B; Dahlgren, D; Johansson, P; Lennernäs, H; Lundqvist, A; Roos, C; Sjögren, E; Tannergren, C, 2016
)
0.43
" This has hindered the validation of preclinical models with regard to absorption in the distal parts of the intestinal tract, which can be substantial for BCS class II-IV drugs, and drugs formulated into modified-release (MR) dosage forms."( Regional Intestinal Permeability of Three Model Drugs in Human.
Abrahamsson, B; Dahlgren, D; Hellström, PM; Lennernäs, H; Lundqvist, A; Roos, C; Sjögren, E; Tannergren, C, 2016
)
0.43
"In the present investigation, simplex lattice mixture design was applied for formulation development and optimization of a controlled release dosage form of ketoprofen microspheres consisting polymers like ethylcellulose and Eudragit(®)RL 100; when those were formed by oil-in-oil emulsion solvent evaporation method."( Optimization of preparation method for ketoprofen-loaded microspheres consisting polymeric blends using simplex lattice mixture design.
Das, SK; Khanam, J; Nanda, A, 2016
)
0.9
"One of the most important challenges of the modern technology of solid oral dosage forms is to increase the effectiveness of the drug, reduce side effects and improve the comfort of use."( [Application of synthetic and semisynthetic polymers (Kollidon K30 and hydroxypropylmethylcellulose) as carriers of ketoprofen in solid oral prolonged-release dosage forms].
Kot, M; Kołodziejczyk, M; Linka, W,
)
0.34
"The aim of the study was to investigate the suitability of polymers (synthetic - Kollidon K30 and semisynthetic - hydroxypropyl methylcellulose), and calcium hydrogen phosphate dihydrate - as an inorganic insoluble filler - in the construction of the matrices of the solid oral dosage forms containing non-steroidal anti-inflammatory drugs (NSAIDs)."( [Application of synthetic and semisynthetic polymers (Kollidon K30 and hydroxypropylmethylcellulose) as carriers of ketoprofen in solid oral prolonged-release dosage forms].
Kot, M; Kołodziejczyk, M; Linka, W,
)
0.34
"A time-adjustable pulsatile release system (TAPS) containing ketoprofen (KF) as an active pharmaceutical agent was developed having been designed for bedtime dosing and releasing drug in the early morning to control the symptoms of rheumatoid arthritis (RA)."( A time-adjustable pulsatile release system for ketoprofen: In vitro and in vivo investigation in a pharmacokinetic study and an IVIVC evaluation.
Cheng, L; Li, C; Li, Y; Pan, W; Wang, H; Wang, T; Wang, Y; Wen, H; Yang, X; Zhang, X, 2017
)
0.95
"The purpose of the study was to investigate the stability and biopharmaceutical characteristics of ketoprofen, loaded in polymeric carriers, which were included into a bigel in a semisolid dosage form."( Ketoprofen-loaded polymer carriers in bigel formulation: an approach to enhancing drug photostability in topical application forms.
Andonova, V; Apostolova, E; Dimitrova, S; Georgiev, GS; Kassarova, M; Katsarova, M; Peneva, P; Petrova, N; Peychev, Z; Toncheva, VT, 2017
)
2.11
"This study demonstrates continuous enantiomeric inversion and further biotransformation of chiral profens including ibuprofen, naproxen and ketoprofen by an enzymatic membrane bioreactor (EMBR) dosed with laccase."( Continuous transformation of chiral pharmaceuticals in enzymatic membrane bioreactors for advanced wastewater treatment.
Hai, FI; Khan, SJ; McDonald, JA; Nghiem, LD; Nguyen, LN; Price, WE, 2017
)
0.66
" Because DT has a short half-life, high and frequent dosing is used in treatment."( Treatment of oxidative stress-induced pain and inflammation with dexketoprofen trometamol loaded different molecular weight chitosan nanoparticles: Formulation, characterization and anti-inflammatory activity by using in vivo HET-CAM assay.
Kıyan, HT; Öztürk, AA, 2020
)
0.79
"Orodispersible Tablets (ODTs) are an option to facilitate the intake of pharmaceutical solid dosage forms, which dissolve in the mouth within 30 seconds releasing the drug immediately with no need for water intake or chewing."( Development and Evaluation of Orodispersible Tablets Containing Ketoprofen.
Andreazza, IF; Cunha, AC; da Graça T Toledo, M; Murakami, FS; Oliveira, LJ; Stofella, NCF; Veiga, A, 2020
)
0.8
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" Concentrations were adapted to comparable relations of the recommended dosage for systemic application."( Nonsteroidal anti-inflammatory drugs affect the mammary epithelial barrier during inflammation.
Bruckmaier, RM; Sintes, GF; Wellnitz, O, 2020
)
0.56
"Delayed-release dosage forms are mainly manufactured as batch processes and include coated tablets, pellets, or particles with gastric resistant polymers."( Continuous Manufacturing of Ketoprofen Delayed Release Pellets Using Melt Extrusion Technology: Application of QbD Design Space, Inline Near Infrared, and Inline Pellet Size Analysis.
Bandari, S; He, H; Kutz, G; Narala, S; Repka, MA; Vo, AQ, 2020
)
0.85
" Dose-response curves were carried out for dexketoprofen, tapentadol, and dexketoprofen-tapentadol combinations in the acetic acid-induced writhing test in mice."( Antinociception and less gastric injury with the dexketoprofen-tapentadol combination in mice.
Alonso-Castro, ÁJ; Franco de la-Torre, L; Granados-Soto, V; Isiordia-Espinoza, MA; Partida-Castellanos, EM; Rivas-Carrillo, JD; Vidaurrazaga-Lugo, J; Zapata-Morales, JR, 2021
)
1.13
"The flexibility of dose and dosage forms makes 3D printing a very interesting tool for personalized medicine, with fused deposition modeling being the most promising and intensively developed method."( How to Obtain the Maximum Properties Flexibility of 3D Printed Ketoprofen Tablets Using Only One Drug-Loaded Filament?
Jachowicz, R; Jamróz, W; Jurkiewicz, K; Knapik-Kowalczuk, J; Kramarczyk, D; Kurek, M; Paluch, M; Pyteraf, J; Szafraniec-Szczęsny, J; Tarasiuk, J; Wroński, S, 2021
)
0.86
" Therefore, due to its higher solubility, KTP-Na may be a viable alternative for use in solid dosage forms."( A New Crystalline Ketoprofen Sodium Salt: Solid-State Characterization, Solubility, and Stability.
Barbosa, TWL; Batista, A; Bonfilio, R; Borges, BA; Braga, MTL; de Araújo, MB; de Oliveira Junior, H, 2022
)
1.06
" The resultant values of analytical recovery demonstrate accuracy and precision of the method and was found specific in identification of the drugs from dosage form and marketed products."( HPLC Method Validation for the Estimation of Lignocaine HCl, Ketoprofen and Hydrocortisone: Greenness Analysis Using AGREE Score.
Alafnan, A; Alamri, MA; Ali, I; Azhar, F; Hanif, S; Hussain, T; Mehmood, T; Moin, A; Syed, MA, 2022
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzophenonesAny aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups.
oxo monocarboxylic acidAny monocarboxylic acid having at least one additional oxo functional group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Ketoprofen Action Pathway2967

Protein Targets (101)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency15.84890.00137.762544.6684AID914; AID915
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency11.22020.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.54810.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency48.50860.007215.758889.3584AID1224835; AID588342
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.20810.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency34.92330.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency21.85280.004110.890331.5287AID504466; AID504467
SMAD family member 3Homo sapiens (human)Potency34.92330.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency0.24310.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency3.98110.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency24.52320.000221.22318,912.5098AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency21.66790.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346784
regulator of G-protein signaling 4Homo sapiens (human)Potency11.91730.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency5.49500.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency16.02660.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.60670.003041.611522,387.1992AID1159552; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency43.23310.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.46030.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency19.49710.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency23.15140.001024.504861.6448AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency54.90070.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency24.31180.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency43.60920.143427.612159.8106AID1159516
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency23.934123.934123.934123.9341AID1967
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency25.11890.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency8.91250.039816.784239.8107AID1454
flap endonuclease 1Homo sapiens (human)Potency5.97280.133725.412989.1251AID588795
gemininHomo sapiens (human)Potency0.29090.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency0.05010.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency0.31620.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency19.49710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency35.48130.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency25.11891.995325.532750.1187AID624288
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interleukin-8Homo sapiens (human)IC50 (µMol)0.02000.00800.04360.0900AID426392
C-X-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)0.03400.00102.022710.0000AID248424
C-X-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)0.03400.00000.30296.0130AID248424
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)IC50 (µMol)0.50000.50000.50000.5000AID678787
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)10.00000.00000.536910.0000AID1264567
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)1,233.25000.00582.14107.9000AID1803034
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)1,233.25000.00021.10608.3000AID1803034
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)1.19420.00032.177410.0000AID1164201; AID1164203; AID1264568; AID1397088
Seed linoleate 13S-lipoxygenase-1Glycine max (soybean)IC50 (µMol)130.00000.07002.12673.5000AID1083328
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Fatty acid-binding protein, intestinalHomo sapiens (human)Ki82.40000.30005.48149.4000AID1801103
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)180.00000.00101.191310.0000AID34782
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)0.00800.00021.557410.0000AID54529; AID625243
Serum paraoxonase/arylesterase 1Homo sapiens (human)Ki13,010.00009.00009.00009.0000AID1799750
Caspase-1Homo sapiens (human)IC50 (µMol)29.20000.00201.70138.8000AID1802657
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)1.16800.00010.995010.0000AID1164203; AID1264569; AID54555; AID625244
Caspase-3Homo sapiens (human)IC50 (µMol)29.20000.00021.19798.8000AID1802657
Caspase-4Homo sapiens (human)IC50 (µMol)29.20000.30002.26418.8000AID1802657
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Caspase-5Homo sapiens (human)IC50 (µMol)29.20000.30002.23588.8000AID1802657
Caspase-9Homo sapiens (human)IC50 (µMol)29.20000.30002.26418.8000AID1802657
Solute carrier organic anion transporter family member 1A3Rattus norvegicus (Norway rat)Ki1,900.00000.50003.30008.2000AID679945
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)0.18000.00101.453910.0000AID1397089
Lactoylglutathione lyaseHomo sapiens (human)Ki700.03330.00122.59479.1400AID568008; AID568009; AID604299
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)1.35000.27004.53069.9000AID681160; AID681331
Solute carrier family 22 member 7Rattus norvegicus (Norway rat)Ki1.84001.84001.84001.8400AID682050
Solute carrier family 22 member 8Homo sapiens (human)Ki1,160.00000.04004.22979.0000AID681372
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GTP-binding protein (rab7)Canis lupus familiaris (dog)EC50 (µMol)30.00000.02201.21466.4190AID2036
ras protein, partialHomo sapiens (human)EC50 (µMol)15.18850.02000.22371.9660AID2038; AID2043
Rac1 proteinHomo sapiens (human)EC50 (µMol)30.00000.02025.986029.5100AID2039; AID2040
cell division cycle 42 (GTP binding protein, 25kDa), partialHomo sapiens (human)EC50 (µMol)30.00000.05633.055413.5100AID2021; AID2022
Ras-related protein Rab-2ACanis lupus familiaris (dog)EC50 (µMol)30.00000.15800.37770.7042AID2046
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)15.18850.10601.07651.7000AID2038; AID2043
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A3Homo sapiens (human)Km84.00007.34007.34007.3400AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (391)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionInterleukin-8Homo sapiens (human)
negative regulation of gene expressionInterleukin-8Homo sapiens (human)
positive regulation of cellular biosynthetic processInterleukin-8Homo sapiens (human)
negative regulation of cell adhesion molecule productionInterleukin-8Homo sapiens (human)
angiogenesisInterleukin-8Homo sapiens (human)
response to molecule of bacterial originInterleukin-8Homo sapiens (human)
chemotaxisInterleukin-8Homo sapiens (human)
inflammatory responseInterleukin-8Homo sapiens (human)
signal transductionInterleukin-8Homo sapiens (human)
G protein-coupled receptor signaling pathwayInterleukin-8Homo sapiens (human)
negative regulation of cell population proliferationInterleukin-8Homo sapiens (human)
calcium-mediated signalingInterleukin-8Homo sapiens (human)
regulation of cell adhesionInterleukin-8Homo sapiens (human)
neutrophil chemotaxisInterleukin-8Homo sapiens (human)
receptor internalizationInterleukin-8Homo sapiens (human)
response to endoplasmic reticulum stressInterleukin-8Homo sapiens (human)
intracellular signal transductionInterleukin-8Homo sapiens (human)
neutrophil activationInterleukin-8Homo sapiens (human)
cellular response to fibroblast growth factor stimulusInterleukin-8Homo sapiens (human)
regulation of single stranded viral RNA replication via double stranded DNA intermediateInterleukin-8Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayInterleukin-8Homo sapiens (human)
positive regulation of angiogenesisInterleukin-8Homo sapiens (human)
embryonic digestive tract developmentInterleukin-8Homo sapiens (human)
induction of positive chemotaxisInterleukin-8Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-8Homo sapiens (human)
cellular response to interleukin-1Interleukin-8Homo sapiens (human)
cellular response to tumor necrosis factorInterleukin-8Homo sapiens (human)
positive regulation of neutrophil chemotaxisInterleukin-8Homo sapiens (human)
regulation of entry of bacterium into host cellInterleukin-8Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideInterleukin-8Homo sapiens (human)
chemokine-mediated signaling pathwayInterleukin-8Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 1Homo sapiens (human)
immune responseC-X-C chemokine receptor type 1Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 1Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-X-C chemokine receptor type 2Homo sapiens (human)
signal transductionC-X-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cell population proliferationC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil activationC-X-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 2Homo sapiens (human)
immune responseC-X-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
fatty acid metabolic processFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
intestinal lipid absorptionFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
androgen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B7Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
negative regulation of plasma lipoprotein oxidationSerum paraoxonase/arylesterase 1Homo sapiens (human)
cholesterol metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
response to toxic substanceSerum paraoxonase/arylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxSerum paraoxonase/arylesterase 1Homo sapiens (human)
carboxylic acid catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
organophosphate catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
phosphatidylcholine metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
lactone catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
bile acid secretionUDP-glucuronosyltransferase 1A3Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayCaspase-3Homo sapiens (human)
luteolysisCaspase-3Homo sapiens (human)
response to hypoxiaCaspase-3Homo sapiens (human)
B cell homeostasisCaspase-3Homo sapiens (human)
negative regulation of cytokine productionCaspase-3Homo sapiens (human)
proteolysisCaspase-3Homo sapiens (human)
apoptotic processCaspase-3Homo sapiens (human)
DNA damage responseCaspase-3Homo sapiens (human)
axonal fasciculationCaspase-3Homo sapiens (human)
heart developmentCaspase-3Homo sapiens (human)
sensory perception of soundCaspase-3Homo sapiens (human)
learning or memoryCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressCaspase-3Homo sapiens (human)
response to xenobiotic stimulusCaspase-3Homo sapiens (human)
response to UVCaspase-3Homo sapiens (human)
response to woundingCaspase-3Homo sapiens (human)
response to glucoseCaspase-3Homo sapiens (human)
response to X-rayCaspase-3Homo sapiens (human)
regulation of macroautophagyCaspase-3Homo sapiens (human)
protein processingCaspase-3Homo sapiens (human)
hippocampus developmentCaspase-3Homo sapiens (human)
protein catabolic processCaspase-3Homo sapiens (human)
erythrocyte differentiationCaspase-3Homo sapiens (human)
platelet formationCaspase-3Homo sapiens (human)
negative regulation of B cell proliferationCaspase-3Homo sapiens (human)
regulation of protein stabilityCaspase-3Homo sapiens (human)
response to cobalt ionCaspase-3Homo sapiens (human)
response to estradiolCaspase-3Homo sapiens (human)
response to lipopolysaccharideCaspase-3Homo sapiens (human)
glial cell apoptotic processCaspase-3Homo sapiens (human)
response to tumor necrosis factorCaspase-3Homo sapiens (human)
response to nicotineCaspase-3Homo sapiens (human)
response to hydrogen peroxideCaspase-3Homo sapiens (human)
T cell homeostasisCaspase-3Homo sapiens (human)
response to amino acidCaspase-3Homo sapiens (human)
fibroblast apoptotic processCaspase-3Homo sapiens (human)
cell fate commitmentCaspase-3Homo sapiens (human)
negative regulation of cell cycleCaspase-3Homo sapiens (human)
negative regulation of activated T cell proliferationCaspase-3Homo sapiens (human)
striated muscle cell differentiationCaspase-3Homo sapiens (human)
response to glucocorticoidCaspase-3Homo sapiens (human)
neuron apoptotic processCaspase-3Homo sapiens (human)
protein maturationCaspase-3Homo sapiens (human)
anterior neural tube closureCaspase-3Homo sapiens (human)
pyroptosisCaspase-3Homo sapiens (human)
leukocyte apoptotic processCaspase-3Homo sapiens (human)
cellular response to staurosporineCaspase-3Homo sapiens (human)
apoptotic signaling pathwayCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-3Homo sapiens (human)
execution phase of apoptosisCaspase-3Homo sapiens (human)
positive regulation of pyroptosisCaspase-3Homo sapiens (human)
positive regulation of amyloid-beta formationCaspase-3Homo sapiens (human)
epithelial cell apoptotic processCaspase-3Homo sapiens (human)
keratinocyte differentiationCaspase-3Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-3Homo sapiens (human)
neuron differentiationCaspase-3Homo sapiens (human)
proteolysisCaspase-4Homo sapiens (human)
inflammatory responseCaspase-4Homo sapiens (human)
protein autoprocessingCaspase-4Homo sapiens (human)
defense response to bacteriumCaspase-4Homo sapiens (human)
innate immune responseCaspase-4Homo sapiens (human)
regulation of inflammatory responseCaspase-4Homo sapiens (human)
positive regulation of inflammatory responseCaspase-4Homo sapiens (human)
defense response to Gram-positive bacteriumCaspase-4Homo sapiens (human)
protein maturationCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCaspase-4Homo sapiens (human)
pyroptosisCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-4Homo sapiens (human)
non-canonical inflammasome complex assemblyCaspase-4Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-4Homo sapiens (human)
cellular response to amyloid-betaCaspase-4Homo sapiens (human)
positive regulation of interleukin-18-mediated signaling pathwayCaspase-4Homo sapiens (human)
apoptotic processCaspase-4Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-4Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
proteolysisCaspase-5Homo sapiens (human)
substantia nigra developmentCaspase-5Homo sapiens (human)
protein maturationCaspase-5Homo sapiens (human)
cellular response to mechanical stimulusCaspase-5Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-5Homo sapiens (human)
apoptotic processCaspase-5Homo sapiens (human)
positive regulation of inflammatory responseCaspase-5Homo sapiens (human)
response to hypoxiaCaspase-9Homo sapiens (human)
kidney developmentCaspase-9Homo sapiens (human)
response to ischemiaCaspase-9Homo sapiens (human)
apoptotic processCaspase-9Homo sapiens (human)
DNA damage responseCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome cCaspase-9Homo sapiens (human)
protein processingCaspase-9Homo sapiens (human)
platelet formationCaspase-9Homo sapiens (human)
response to cobalt ionCaspase-9Homo sapiens (human)
response to estradiolCaspase-9Homo sapiens (human)
response to lipopolysaccharideCaspase-9Homo sapiens (human)
glial cell apoptotic processCaspase-9Homo sapiens (human)
cellular response to UVCaspase-9Homo sapiens (human)
signal transduction in response to DNA damageCaspase-9Homo sapiens (human)
positive regulation of apoptotic processCaspase-9Homo sapiens (human)
fibroblast apoptotic processCaspase-9Homo sapiens (human)
neuron apoptotic processCaspase-9Homo sapiens (human)
protein maturationCaspase-9Homo sapiens (human)
cellular response to dexamethasone stimulusCaspase-9Homo sapiens (human)
leukocyte apoptotic processCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-9Homo sapiens (human)
epithelial cell apoptotic processCaspase-9Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
Golgi organizationRas-related protein Rab-2ACanis lupus familiaris (dog)
protein transportRas-related protein Rab-2ACanis lupus familiaris (dog)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
carbohydrate metabolic processLactoylglutathione lyaseHomo sapiens (human)
regulation of transcription by RNA polymerase IILactoylglutathione lyaseHomo sapiens (human)
glutathione metabolic processLactoylglutathione lyaseHomo sapiens (human)
methylglyoxal metabolic processLactoylglutathione lyaseHomo sapiens (human)
osteoclast differentiationLactoylglutathione lyaseHomo sapiens (human)
negative regulation of apoptotic processLactoylglutathione lyaseHomo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (143)

Processvia Protein(s)Taxonomy
interleukin-8 receptor bindingInterleukin-8Homo sapiens (human)
protein bindingInterleukin-8Homo sapiens (human)
chemokine activityInterleukin-8Homo sapiens (human)
heparin bindingInterleukin-8Homo sapiens (human)
CXCR chemokine receptor bindingInterleukin-8Homo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 2Homo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
protein bindingFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 2B7Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B7Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
aryldialkylphosphatase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
arylesterase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
calcium ion bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
phospholipid bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
protein homodimerization activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protease bindingCaspase-3Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activityCaspase-3Homo sapiens (human)
death receptor bindingCaspase-3Homo sapiens (human)
protein bindingCaspase-3Homo sapiens (human)
peptidase activityCaspase-3Homo sapiens (human)
phospholipase A2 activator activityCaspase-3Homo sapiens (human)
protein-containing complex bindingCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-3Homo sapiens (human)
enzyme activator activityCaspase-3Homo sapiens (human)
lipopolysaccharide bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-4Homo sapiens (human)
protein bindingCaspase-4Homo sapiens (human)
lipid bindingCaspase-4Homo sapiens (human)
CARD domain bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-4Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-5Homo sapiens (human)
protein bindingCaspase-5Homo sapiens (human)
cysteine-type peptidase activityCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-9Homo sapiens (human)
protein bindingCaspase-9Homo sapiens (human)
enzyme activator activityCaspase-9Homo sapiens (human)
peptidase activityCaspase-9Homo sapiens (human)
SH3 domain bindingCaspase-9Homo sapiens (human)
protein kinase bindingCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-9Homo sapiens (human)
GTPase activityRas-related protein Rab-2ACanis lupus familiaris (dog)
GTP bindingRas-related protein Rab-2ACanis lupus familiaris (dog)
GDP bindingRas-related protein Rab-2ACanis lupus familiaris (dog)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
lactoylglutathione lyase activityLactoylglutathione lyaseHomo sapiens (human)
protein bindingLactoylglutathione lyaseHomo sapiens (human)
zinc ion bindingLactoylglutathione lyaseHomo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (84)

Processvia Protein(s)Taxonomy
extracellular regionInterleukin-8Homo sapiens (human)
extracellular spaceInterleukin-8Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
nucleoplasmC-X-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 2Homo sapiens (human)
microtubule cytoskeletonC-X-C chemokine receptor type 2Homo sapiens (human)
membraneC-X-C chemokine receptor type 2Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 2Homo sapiens (human)
mast cell granuleC-X-C chemokine receptor type 2Homo sapiens (human)
mitotic spindleC-X-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
microvillusFatty acid-binding protein, intestinalHomo sapiens (human)
apical cortexFatty acid-binding protein, intestinalHomo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
nucleusFatty acid-binding protein, intestinalHomo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
extracellular regionSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
endoplasmic reticulum membraneSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular exosomeSerum paraoxonase/arylesterase 1Homo sapiens (human)
blood microparticleSerum paraoxonase/arylesterase 1Homo sapiens (human)
high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
spherical high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
cytoplasmCaspase-3Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
nucleoplasmCaspase-3Homo sapiens (human)
cytosolCaspase-3Homo sapiens (human)
neuronal cell bodyCaspase-3Homo sapiens (human)
death-inducing signaling complexCaspase-3Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
extracellular regionCaspase-4Homo sapiens (human)
mitochondrionCaspase-4Homo sapiens (human)
endoplasmic reticulumCaspase-4Homo sapiens (human)
endoplasmic reticulum membraneCaspase-4Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
plasma membraneCaspase-4Homo sapiens (human)
protein-containing complexCaspase-4Homo sapiens (human)
non-canonical inflammasome complexCaspase-4Homo sapiens (human)
cytoplasmCaspase-4Homo sapiens (human)
NLRP1 inflammasome complexCaspase-4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
cytosolCaspase-5Homo sapiens (human)
NLRP1 inflammasome complexCaspase-5Homo sapiens (human)
cytoplasmCaspase-5Homo sapiens (human)
mitochondrionCaspase-9Homo sapiens (human)
nucleusCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
caspase complexCaspase-9Homo sapiens (human)
apoptosomeCaspase-9Homo sapiens (human)
protein-containing complexCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
cytoplasmCaspase-9Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
autophagosome membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
acrosomal vesicleRas-related protein Rab-2ACanis lupus familiaris (dog)
endoplasmic reticulum membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
endoplasmic reticulum-Golgi intermediate compartment membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
melanosomeRas-related protein Rab-2ACanis lupus familiaris (dog)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleoplasmLactoylglutathione lyaseHomo sapiens (human)
cytoplasmLactoylglutathione lyaseHomo sapiens (human)
cytosolLactoylglutathione lyaseHomo sapiens (human)
plasma membraneLactoylglutathione lyaseHomo sapiens (human)
extracellular exosomeLactoylglutathione lyaseHomo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (524)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID251770Inhibition of lipopolysaccharide-induced PGE-2 production at 10e-5 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID606366Noncompetitive inhibition of human CXCR1 assessed as inhibition of CXCL8-induced neutrophile chemotaxis at 10 nM2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Progress in structure based drug design for G protein-coupled receptors.
AID426478Cytotoxicity against mouse L1.2 cells assessed as cell viability by trypan blue dye exclusion assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
AID297158Inhibition of CXCL1-induced cell migration in human PMN cells at 0.01 uM by chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID426392Inhibition of CXCL8-induced chemotaxis in human polymorphonuclear leukocyte pretreated for 15 mins measured after 4 hrs by cell migration assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
AID426393Cytotoxicity against of human polymorphonuclear leukocytes assessed as cell viability by trypan blue dye exclusion assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
AID248424Inhibition of CXCL8-induced chemotaxis in human polymorphonuclear cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID297157Inhibition of CXCL8-induced cell migration in human PMN cells at 0.01 uM by chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346932Human SMCT1 (Sodium iodide symporter, sodium-dependent multivitamin transporter and sodium-coupled monocarboxylate transporters)2006Pharmaceutical research, Jun, Volume: 23, Issue:6
Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8).
AID1345206Human COX-2 (Cyclooxygenase)2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID1345284Human COX-1 (Cyclooxygenase)2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1499072Effective permeability of the compound at pH 7.4 by PAMPA2017European journal of medicinal chemistry, Sep-08, Volume: 137Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
AID1252801Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered prior to carrageenan challenge measured after 3 hrs by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID1261691Protein binding to human serum albumin at 0.5 to 1.5 mg/ml by HPLC method2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
AID681401TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, Ketoprofen: 1000 uM) in Xenopus laevis oocytes2002Journal of neurochemistry, Oct, Volume: 83, Issue:1
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain.
AID169240Incidence of melena defecation was recorded 24 hrs of last treatment given once daily for 4 days; Positive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity.
AID1156968Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID1175392Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 50 uM after 30 mins by Fluo-4 AM fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.
AID239780Percentage plasma protein binding towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID54529In vitro inhibition of cyclooxygenase-1 via inhibition of TXB2 generation in the presence of 1 uM arachidonic acid in human platelet2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-based design of cyclooxygenase-2 selectivity into ketoprofen.
AID1439788Antinociceptive activity in Swiss mouse assessed as inhibition of capsaicin-induced nociception at 100 mg/kg, po administered 1 hr followed by capsaicin challenge measured for 5 mins relative to vehicle-treated control2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis of novel trifluoromethyl-substituted spiro-[chromeno[4,3-d]pyrimidine-5,1'-cycloalkanes], and evaluation of their analgesic effects in a mouse pain model.
AID1164204Inhibition of human recombinant COX2 at saturation drug level pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
AID1083347Antioxidant activity assessed as inhibition of AAPH-induced lipid peroxidation at 1 X 10'-4 M2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1256760Permeability of the compound at 10 mM after 4 hrs by PAMPA2015European journal of medicinal chemistry, Nov-13, Volume: 105Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline.
AID619373Permeability across methotrexate treated human HT-29 cells assessed as compound recovery2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
AID1272494Anti-inflammatory activity in rat assessed as reduction of carrageenan-induced paw edema at 150 umol/kg, ip after 3.5 hrs relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Amides of non-steroidal anti-inflammatory drugs with thiomorpholine can yield hypolipidemic agents with improved anti-inflammatory activity.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1769838Permeability of the compound at pH 7.4 incubated for 4 hrs by PAMPA-based UV spectrophotometry2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1156963Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip administered prior to carrageenan challenge measured at 1 hr by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID192170Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.002 mM/kg (0.51 mg)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID192179Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.009 mM/kg (2.29 mg)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID28928Intrinsic permeability of the compound2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1221776Cytotoxicity against mock transfected HEK293 cells assessed as decrease in cell viability at 1 mM by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID118143Antiinflammatory activity, administered ip at 150 uM/kg dose was determined against carrageenan-induced mice paw edema model2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity.
AID1150274Toxicity in po dosed rat assessed as induction of gastric lesion1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID266769Membrane retention in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1220785Fraction unbound in rat plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1319400Toxicity in Swiss mouse assessed as effect on forced locomotory activity at 100 mg/kg administered via oral gavage for 1 hr measured up to 4 mins post dose by rotarod test2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and antinociceptive activity of new 2-substituted 4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolines.
AID1604513Antihyperalgesic activity in Sprague-Dawley rat model of Complete freund's adjuvant-induced arthritis assessed as reduction in difference between weight burdened on contralateral and ipsilateral paw at 30 mg/kg, po starting from day 14 after CFA injection2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID29845Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1083337Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID184534Mortality caused by the compound in rats after administration at 200 uM/kg for 4 days2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity.
AID266762Effective permeability coefficient in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1221794Cellular uptake in human hepatocytes at 1 mM measured at 6 hrs by LC-MS/MS analysis in presence of acyl glucuronidation inhibitor (-)-borneol2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1212341Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1220798Half life in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1232311Unbound volume of distribution at steady state in human2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID1083328Inhibition of Glycine max (soybean) lipoxygenase using sodium linoleate as substrate2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1918194Lipophilicity, log D of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1164212Analgesic activity in Sprague-Dawley rat assessed as protection against acetic acid-induced abdominal constriction dosed 1 hr before acetic acid challenge measured for 20 mins post acetic acid challenge2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
AID1221778Cytotoxicity against mock transfected HEK293 cells assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM by CellTiter-Glo luminescent assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1833698Antinociceptive activity in formalin-induced Sprague-Dawley rat model of acute inflammatory pain assessed as reduction in time spent on paw licking and guarding of injected hindpaw during second phase at 30 mg/kg, ip administered 30 mins prior to formalin2021Bioorganic & medicinal chemistry, 12-01, Volume: 51Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.
AID1083334Antiviral activity against Human coxsackievirus B4 infected VERO cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1743645Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1604490Inhibition of COX2 in mouse RAW264.7 cells assessed as reduction in LPS-induced inflammation by measuring PGE2 level at 100 uM treated 1 hr after LPS stimulation and measured after 18 hrs by ELISA (Rvb = (2437 +/- 93.17 pg/mL)2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID1220797Volume of distribution at steady state in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1421708Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, ip measured at 3 hrs post dose relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1150259Antiinflammatory activity in rat with prolonged phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1333576Permeability of the compound at pH 7.4 after 2 hrs by PAMPA2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation.
AID1333575Permeability of the compound at pH 6.2 after 2 hrs by PAMPA2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation.
AID1207023Permeability of the compound at pH 6.2 by PAMPA2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID1150264Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 2 mg/kg, po administered for 14 days prior to adjuvant challenge relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID362051Inhibition of COX2 in human whole blood2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID1156966Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered prior to carrageenan challenge measured at 1 hr by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID681372TP_TRANSPORTER: inhibition of MTX uptake in OAT3-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID1175391Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 250 uM after 30 mins by Fluo-4 AM fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.
AID1743648Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1252799Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered prior to carrageenan challenge measured after 1 hr by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID185305The percent inhibition was calculated from the average differences in hind paw volume between the adjuvant injected controls and the adjuvant-injected medicated rats at 0.08 mmol/kg; 0.009-821984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1220796Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1264567Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID680175TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Ketoprofen: 1000 uM) in OAT4-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID257050Inhibition of recombinant human AKR1C3 at 50 uM2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
AID1221789Cytotoxicity against human hepatocytes assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM measured at 6 hrs by CellTiter-Glo luminescent assay in presence of acyl glucuronidation inhibitor (-)-borneol2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID679361TP_TRANSPORTER: inhibition of Salicylate uptake (salicylate: 1 uM, Ketoprofen: 1000 uM) in Xenopus laevis oocytes1998FEBS letters, Jun-12, Volume: 429, Issue:2
Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.
AID389958Apparent permeability across human Caco-2 cells at 50 uM2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1221796Cellular uptake in human hepatocytes at 1 mM measured at 6 hrs by LC-MS/MS analysis in absence of acyl glucuronidation inhibitor (-)-borneol2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1743647Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID190506Ulcerogenic activity administered once daily at 200 uM/kg for 4 days was determined as no of animals showing perforating ulcers2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity.
AID568009Inhibition of glyoxalase 12011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
AID1833696Antinociceptive activity in formalin-induced Sprague-Dawley rat model of acute inflammatory pain assessed as reduction in time spent on paw licking and guarding of injected hindpaw during first phase at 30 mg/kg, ip administered 30 mins prior to formalin 2021Bioorganic & medicinal chemistry, 12-01, Volume: 51Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.
AID190534Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of animals tested at 0.06 mM/kg (15.2 mg) was reported; toxic1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1333574Permeability of the compound at pH 5 after 2 hrs by PAMPA2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation.
AID1083349Inhibition of Glycine max (soybean) lipoxygenase using sodium linoleate as substrate at 1 X 10'-42011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1397089Inhibition of ovine COX2 assessed as reduction in PGH2 production by enzyme immunoassay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthesis and biological properties of aryl methyl sulfones.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID192177Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.006 mM/kg (0.152 mg)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID1319397Antinociceptive activity in CFA-induced arthritic pain Swiss mouse model assessed as inhibition of mechanical hyperalgesia by measuring paw withdrawal threshold administered via oral gavage measured at 2 hrs post dose by Von Frey filament assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and antinociceptive activity of new 2-substituted 4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolines.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1164201Inhibition of purified ovine COX1 pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
AID1252796Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po administered prior to carrageenan challenge measured after 1 hr by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID1083348Antioxidant activity assessed as inhibition of AAPH-induced lipid peroxidation at 1 X 10'-5 M2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1198256Antiproliferative activity against human U373MG cells assessed as effect on cell number at 1 nM to 10 uM incubated for 1 to 6 days by trypan blue dye exclusion dye based inverted microscopy2015European journal of medicinal chemistry, Mar-26, Volume: 93Effect of new hybrids based on 5,16-pregnadiene scaffold linked to an anti-inflammatory drug on the growth of a human astrocytoma cell line (U373).
AID107291Analgesic activity in mice by mouse phenylquinone writhing assay relative to aspirin.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1421706Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, ip measured at 1 hr post dose relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID490949Antioxidant activity assessed as inhibition of lipid peroxidation at 100 uM2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1198262Antiproliferative activity against human U373MG cells assessed reduction in cell number at 10 uM incubated for 6 days by trypan blue dye exclusion dye based inverted microscopy2015European journal of medicinal chemistry, Mar-26, Volume: 93Effect of new hybrids based on 5,16-pregnadiene scaffold linked to an anti-inflammatory drug on the growth of a human astrocytoma cell line (U373).
AID1223483Unbound fraction in iv dosed human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1083341Antiviral activity against Sindbis virus infected Hela cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID681331TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1252800Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered prior to carrageenan challenge measured after 2 hrs by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1220783Drug metabolism in human assessed as glucuronide concentration in bile and urine2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220794Plasma clearance in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220788Fraction unbound in human plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID681926TP_TRANSPORTER: inhibition of E217betaG in the presence of Ketoprofen at a concentration of 50uM in membrane vesicles from MRP4-expressing Sf9 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1223486Intrinsic clearance in human hepatocytes from chimeric mouse with humanized liver assessed per 10'6 cells at 10 uM after 0.25 to 2 hrs by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1221817Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM by CellTiter-Glo luminescent assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221813Activity of human UGT1A4 expressed in HEK293 cells assessed as enzyme-mediated ketoprofen acyl-beta-D-glucuronide formation at 1 mM measured at 24 hrs by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1083339Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1743651Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1744121Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1743646Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID190676Ulcerogenicity was measured in stomach during the 3 week adjuvant arthritis test, no of animals with ulcers out of 31 animals tested at 0.03 mM/kg (7.62 mg) was reported1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID1221799Genotoxicity in HEK293 cells expressing UGT1A3 assessed as DNA strand breaks at 1 mM after 24 hrs by comet assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1150275Acute toxicity in po dosed rat after 7 days1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID681776TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Ketoprofen: 1000 uM) in Xenopus laevis oocytes1999Molecular pharmacology, May, Volume: 55, Issue:5
Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.
AID679830TP_TRANSPORTER: uptake in OAT1-expressing CHO cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID362052Antiproliferative activity against human PC3 cells at 100 uM after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID362050Inhibition of COX1 in human whole blood2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
AID1397090Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX22018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthesis and biological properties of aryl methyl sulfones.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID185298The mean increase in paw volume was compared between drug treated groups and placebo to calculate the percent inhibition in rats at 0.02 mmol/kg by carrageenan Edema Assay; 60-691984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID266767Membrane retention in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID432063Apparent permeability at pH 7.4 after 24 hrs by PAMPA method2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1083331Antiviral activity against Feline coronavirus infected feline kidney crandell cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1220792Ratio of drug level in blood to plasma in dog2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1221830Activity of human UGT1A3 expressed in HEK293 cells assessed as enzyme-mediated ketoprofen acyl-beta-D-glucuronide formation at 1 mM measured at 24 hrs by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID34786In vitro inhibition of rabbit lens aldose reductase at 10e-4 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1083332Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1252798Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po administered prior to carrageenan challenge measured after 3 hrs by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1499472Effective permeability of the compound at pH 7.4 by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1156960Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered prior to carrageenan challenge measured at 1 hr by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID288190Permeability coefficient through artificial membrane in presence of stirred water layer at 100 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1220786Fraction unbound in monkey plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1743649Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28921Partition coefficient (logP) (hexadecane)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID490946Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID260248Distribution coefficient at pH 5.0, log D2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
AID190674Ulcerogenicity was measured in stomach during the 3 week adjuvant arthritis test, no of animals with ulcers out of 24 animals tested at 0.009 mM/kg (2.29 mg) was reported1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID1221772Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability at 1 mM by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID54555In vitro inhibition of PGE-2 generation by LPS-stimulated monocytes isolated from human blood.2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-based design of cyclooxygenase-2 selectivity into ketoprofen.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1083329Antiviral activity against Unidentified Influenza A virus (H1N2) infected MDCK cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1083353Antioxidant activity assessed as DPPH radical scavenging activity at 5 X 10'-5 M after 20 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1220787Fraction unbound in dog plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID288186Permeability coefficient through artificial membrane in presence of stirred water layer at 200 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID1223481Elimination half life iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1604511Antihyperalgesic activity in Sprague-Dawley rat model of Complete freund's adjuvant-induced arthritis assessed as reduction in difference between weight burdened on contralateral and ipsilateral paw at 30 mg/kg, po starting from day 14 after CFA injection2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1743654Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID490943Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 20 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID678787TP_TRANSPORTER: inhibition of MTX uptake in Xenopus laevis oocytes2000European journal of pharmacology, Dec-01, Volume: 409, Issue:1
Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter.
AID1604510Antihyperalgesic activity in Sprague-Dawley rat model of Complete freund's adjuvant-induced arthritis assessed as reduction in difference between weight burdened on contralateral and ipsilateral paw at 30 mg/kg, po starting from day 14 after CFA injection2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1220795Plasma clearance in po dosed human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID490944Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 60 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID1319392Antinociceptive activity in Swiss mouse assessed as inhibition of capsaicin induced nociception by measuring paw licking time at 100 mg/kg administered via oral gavage for 1 hr followed by capsaicin challenge measured for 5 mins post dose relative to cont2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and antinociceptive activity of new 2-substituted 4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolines.
AID1207024Permeability of the compound at pH 7.4 by PAMPA2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID681850TP_TRANSPORTER: inhibition of Digoxin uptake (Digoxin: 0.05 uM, Ketoprofen: 1000 uM) in Oatp2-expressing LLC-PK1 cells2002Pharmaceutical research, Feb, Volume: 19, Issue:2
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
AID1220793Ratio of drug level in blood to plasma in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID260246Aqueous solubility at pH 5.02006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1221815Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID183672Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.002 mM/kg (0.51 mg)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID1150252Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID170138Inhibition of carrageenan-induced inflammation of rat paw relative to phenylbutazone.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1083342Antiviral activity against Punta Toro virus infected Hela cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1156961Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered prior to carrageenan challenge measured at 2 hrs by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID624640Drug glucuronidation reaction catalyzed by human recombinant UGT2B72005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1439790Antinociceptive activity in Swiss mouse assessed as inhibition of CFA-induced mechanical allodynia at 100 mg/kg, po measured over 4 hrs2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis of novel trifluoromethyl-substituted spiro-[chromeno[4,3-d]pyrimidine-5,1'-cycloalkanes], and evaluation of their analgesic effects in a mouse pain model.
AID1083343Antiviral activity against Vesicular stomatitis virus infected Hela cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1156964Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip administered prior to carrageenan challenge measured at 2 hrs by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID1220791Ratio of drug level in blood to plasma in monkey2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID703844Inhibition of 5-lipoxygenase in A23187-stimulated human neutrophils assessed as inhibition of enzyme product formation by RP-HPLC analysis2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX.
AID1221819Cytotoxicity against HEK293 cells expressing UGT assessed as LDH leakage at 1 mM after 6 to 24 hrs by spectrophotometric analysis relative to total cell LDH level2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID180479Percent inhibition of edema was measured by adjuvant arthritis paw edema (rat) assay1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID34782In vitro inhibition of rabbit lens aldose reductase.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1156962Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID1264569Inhibition of recombinant human COX-2 preincubated for 15 mins by fluorescence analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.
AID490945Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1223477Total clearance in iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1232307Lipophilicity, log P of the compound2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID490947Inhibition of soybean LOX at 100 uM2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1232306Dissociation constant of the compound2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID1220784Fraction unbound in mouse plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID266761Effective permeability coefficient in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1320616Permeability of the compound after 4 hrs by PAMPA2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1083338Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID767618Antinociceptive activity in po dosed Albino-Swiss mouse assessed as acetic acid-induced abdominal writhing compound administered 30 mins prior challenge measured over 30 mins post acetic acid challenge2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
High analgesic and anti-inflammatory in vivo activities of six new hybrids NSAIAs tetrahydropyran derivatives.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID413979Inhibition of ovine cyclooxygenase 1 assessed as prostaglandin F2alpha level at 10 uM by enzyme immunoassay relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1207022Permeability of the compound at pH 5 by PAMPA2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID156202Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID177075Compound was evaluated for highest non-ulcerogenic dose (less than 50% ulcer incidence)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1743650Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1604489Inhibition of COX2 in mouse RAW264.7 cells assessed as reduction in LPS-induced inflammation by measuring PGE2 level at 1 uM treated 1 hr after LPS stimulation and measured after 18 hrs by ELISA (Rvb = (2437 +/- 93.17 pg/mL)2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID1439789Antinociceptive activity in Swiss mouse assessed as inhibition of CFA-induced mechanical allodynia at 100 mg/kg, po after 2 hrs relative to vehicle-treated control2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis of novel trifluoromethyl-substituted spiro-[chromeno[4,3-d]pyrimidine-5,1'-cycloalkanes], and evaluation of their analgesic effects in a mouse pain model.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID604299Inhibition of human glyoxalase 12011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I.
AID1220790Ratio of drug level in blood to plasma in rat2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID190677Ulcerogenicity was measured in stomach during the 3 week adjuvant arthritis test, no of animals with ulcers out of 4 animals tested at 0.002 mM/kg (0.51 mg) was reported1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID243647In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive2004Journal of medicinal chemistry, Sep-23, Volume: 47, Issue:20
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID624632Drug glucuronidation reaction catalyzed by human recombinant UGT1A32005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID156204Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1150257Antiinflammatory activity in rat with acute phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1223482Ratio of drug level in blood to plasma in iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1743655Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1164202Inhibition of purified ovine COX1 at saturation drug level pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1156965Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip administered prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID1294650Permeability of the compound at 50 uM at pH 7.4 after 4 hrs by PAMPA-GIT assay2016European journal of medicinal chemistry, May-23, Volume: 114Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.
AID28926Effective permeability corrected for ionization2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID703840Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX.
AID1918193Dissociation constant, pKa of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID260247Aqueous solubility at pH 7.42006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
AID266770Membrane permeability, CA(t)/CD(0) in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID1319394Antinociceptive activity in CFA-induced arthritic pain Swiss mouse model assessed as inhibition of mechanical hyperalgesia by measuring paw withdrawal threshold at 100 mg/kg administered via oral gavage measured at 2 hrs post dose by Von Frey filament ass2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and antinociceptive activity of new 2-substituted 4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolines.
AID1212314Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1083330Antiviral activity against Unidentified Influenza A virus (H1N2) infected MDCK cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1164203Inhibition of human recombinant COX2 pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
AID1252797Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po administered prior to carrageenan challenge measured after 2 hrs by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID288193Flux ionization constant, pKa of the membrane permeability coefficient of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1918192Inhibition of human OAT2 tv.1 variant expressed in HEK293 cells assessed as inhibition of [3H]cGMP uptake by scintillation analysis2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID1223475Elimination half life in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1150269Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 1 mg/kg, po administered for 14 days followed by adjuvant challenge relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1221846Cytotoxicity against human hepatocytes assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM measured at 6 hrs by CellTiter-Glo luminescent assay in absence of acyl glucuronidation inhibitor (-)-borneol2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1439793Antinociceptive activity in Swiss mouse assessed as inhibition of CFA-induced mechanical allodynia at 300 mg/kg, po after 2 hrs relative to vehicle-treated control2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis of novel trifluoromethyl-substituted spiro-[chromeno[4,3-d]pyrimidine-5,1'-cycloalkanes], and evaluation of their analgesic effects in a mouse pain model.
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID1083340Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID619346Apparent permeability across methotrexate treated human HT-29 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
AID1319396Antinociceptive activity in CFA-induced arthritic pain Swiss mouse model assessed as inhibition of mechanical hyperalgesia by measuring paw withdrawal threshold at 100 mg/kg administered via oral gavage measured up to 4 hrs post dose by Von Frey filament 2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and antinociceptive activity of new 2-substituted 4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1743652Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1604488Inhibition of COX1 in human platelet rich plasma in assessed as inhibition of ADP-induced platelet aggregation at 10 uM incubated for 5 mins by turbidimetry based Born's method relative to control2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID1083350Antioxidant activity assessed as DPPH radical scavenging activity at 1 X 10'-4 M after 60 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1743653Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1220801Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1430075Permeability of the compound at pH 7.42017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol.
AID1319399Toxicity in Swiss mouse assessed as effect on spontaneous locomotory activity by measuring number of areas crossed at 100 mg/kg administered via oral gavage for 1 hr measured up to 5 mins post dose by open field test (Rvb = 27 +/- 6 No_unit )2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and antinociceptive activity of new 2-substituted 4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolines.
AID1221782Cytotoxicity against HEK293 cells expressing UGT assessed as decrease in cell viability at 1 mM measured up to 72 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID34788In vitro inhibition of rabbit lens aldose reductase at 10e-5 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1264568Inhibition of Ovine COX-1 preincubated for 15 mins by fluorescence analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.
AID260249Distribution coefficient at pH 7.4, log D2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
AID413981Inhibition of human recombinant cyclooxygenase 2 assessed as prostaglandin F2alpha level at 10 uM by enzyme immunoassay relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.
AID1083352Antioxidant activity assessed as DPPH radical scavenging activity at 5 X 10'-5 M after 60 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID24265Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of methyl ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID1150270Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1397088Inhibition of ovine COX1 assessed as reduction in PGH2 production by enzyme immunoassay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthesis and biological properties of aryl methyl sulfones.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1232309Unbound fraction in human plasma2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID1083351Antioxidant activity assessed as DPPH radical scavenging activity at 1 X 10'-4 M after 20 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID679945TP_TRANSPORTER: inhibition of MTX uptake in OAT-K1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Dec, Volume: 283, Issue:3
Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1.
AID679544TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Ketoprofen: 1000 uM) in OAT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID1083336Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID288187Permeability coefficient through artificial membrane in presence of stirred water layer at 250 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1223478Total clearance in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1083333Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1833703Antinociceptive activity in formalin-induced Sprague-Dawley rat model of acute inflammatory pain assessed as reduction in time spent on guarding of injected hindpaw during second phase at 30 mg/kg, ip administered 30 mins prior to formalin stimulation mea2021Bioorganic & medicinal chemistry, 12-01, Volume: 51Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.
AID680472TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.1 uM, Ketoprofen: 1000 uM) in Oatp1-expressing LLC-PK1 cells2002Pharmaceutical research, Feb, Volume: 19, Issue:2
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID490948Antioxidant activity assessed as inhibition of lipid peroxidation at 10 uM2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID408486Inhibition of recombinant Curvularia lunata trihydroxynaphthalene reductase2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.
AID1232308Distribution coefficient, log D of the compound2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID1252791Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered prior to carrageenan challenge measured after 2 hrs by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID1319398Antinociceptive activity in CFA-induced arthritic pain Swiss mouse model assessed as inhibition of mechanical hyperalgesia by measuring paw withdrawal threshold at 300 mg/kg administered via oral gavage measured at 2 hrs post dose by Von Frey filament ass2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and antinociceptive activity of new 2-substituted 4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolines.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID190515Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of 31 animals tested at 0.03 mM/kg (7.62 mg) was reported1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID1164213Anti-inflammatory activity in Swiss mouse model of carrageenan-induced paw edema assessed as reduction in paw swelling at 50 mg/kg, sc dosed 30 mins before carrageenan challenge measured at 1 to 4 hrs post carrageenan challenge by mercury plethysmometry2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1220799Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1230989Permeability of the compound at pH 7.4 by PAMPA2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study.
AID1256770Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw oedema at 0.15 mmol/kg, ip administered 5 mins before carrageenan challenge measured after 3.5 hrs2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Esters of some non-steroidal anti-inflammatory drugs with cinnamyl alcohol are potent lipoxygenase inhibitors with enhanced anti-inflammatory activity.
AID1833701Antinociceptive activity in formalin-induced Sprague-Dawley rat model of acute inflammatory pain assessed as reduction in time spent on guarding of injected hindpaw during first phase at 30 mg/kg, ip administered 30 mins prior to formalin stimulation meas2021Bioorganic & medicinal chemistry, 12-01, Volume: 51Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.
AID1220789Ratio of drug level in blood to plasma in mouse2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID681160TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
AID1604509Antihyperalgesic activity in Sprague-Dawley rat model of Complete freund's adjuvant-induced arthritis assessed as reduction in difference between weight burdened on contralateral and ipsilateral paw at 30 mg/kg, po starting from day 14 after CFA injection2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID171175Body weight change after once daily administration at 200 uM/kg for 4 days in rats was determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID266768Membrane permeability, CA(t)/CD(0) in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1252790Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered prior to carrageenan challenge measured after 1 hr by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID1156967Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered prior to carrageenan challenge measured at 2 hrs by plethysmometric analysis relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1375707Antiarthritic activity in CFA-induced Sprague-Dawley rat rheumatoid arthritis model assessed as decrease in difference between weight burden on contralateral and ipsilateral paw at 5.8 mg/kg, po measured up to 75 mins by incapacitance test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis.
AID1439792Antinociceptive activity in po dosed Swiss mouse assessed as inhibition of CFA-induced mechanical allodynia after 2 hrs2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis of novel trifluoromethyl-substituted spiro-[chromeno[4,3-d]pyrimidine-5,1'-cycloalkanes], and evaluation of their analgesic effects in a mouse pain model.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1744122Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1221774Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM by CellTiter-Glo luminescent assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID190516Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of 4 animals tested at 0.002 mM/kg (0.51 mg) was reported1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID187307Potency relative to phenylbutazone at 0.006 mM/kg1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID24263Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of N,N-diethylglycolamide ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID183803Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.006 mM/kg (0.152 mg)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID1604504Antihyperalgesic activity in Sprague-Dawley rat model of Complete freund's adjuvant-induced arthritis assessed as increase in pain threshold of ipsilateral paw at 30 mg/kg, po starting from day 14 after CFA injection and measured at 15 to 30 mins by paw p2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
AID34789In vitro inhibition of rabbit lens aldose reductase at 10e-6 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID288194Intrinsic artificial membrane permeability coefficient, log P0 of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1769837Permeability of the compound at pH 5.5 incubated for 4 hrs by PAMPA-based UV spectrophotometry2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
AID262717Permeability in Caco-2 cell2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID183804Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.009 mM/kg (2.29 mg)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID568008Inhibition of human recombinant His-tagged glyoxalase 1 expressed in Escherichia coli BL21 (DE3) preincubated for 20 mins by Dixon plot analysis2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150271Analgesic activity in carrageenan-treated po dosed rat assessed as concentration required to double pain index of control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1252792Antiinflammatory activity in albino Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered prior to carrageenan challenge measured after 3 hrs by plethysmometry relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 103(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands.
AID1083335Antiviral activity against Mammalian orthoreovirus 1 infected VERO cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID112732Antiinflammatory activity, administered ip at 150 uM/kg dose was determined against carrageenan-induced mice paw edema model2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity.
AID1375677Antiarthritic activity in CFA-induced Sprague-Dawley rat rheumatoid arthritis model assessed as increase in tolerated weight on ipsilateral paw at 5.8 mg/kg, po measured at 15 mins by paw pressure test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID190512Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of 24 animals tested at 0.009 mM/kg (2.29 mg) was reported1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Bulky amine analogues of ketoprofen: potent antiinflammatory agents.
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID384956Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID1743656Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1232310Volume of distribution at steady state in human2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1220800Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1287899Antiinflammatory activity against albino rat assessed as inhibition of carrageenin induced paw edema at 100 mg/kg, po administered for 1 hr followed by carrageenin challenge measured after 4 hrs2016European journal of medicinal chemistry, May-04, Volume: 113Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline-thiazolidine-based hybrids.
AID1421707Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, ip measured at 2 hrs post dose relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1801103Fluorophore Displacement Assay from Article 10.1021/cb5005178: \\Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.\\2014ACS chemical biology, Nov-21, Volume: 9, Issue:11
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.
AID1799750Paraoxonase Activity Assay from Article 10.1080/14756360802608351: \\Effect of some analgesics on paraoxonase-1 purified from human serum.\\2009Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 24, Issue:4
Effect of some analgesics on paraoxonase-1 purified from human serum.
AID1802657Caspase Catalytic Activity Assay from Article 10.1016/j.chembiol.2017.02.003: \\Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.\\2017Cell chemical biology, Mar-16, Volume: 24, Issue:3
Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.
AID1803034CA Enzyme Assay from Article 10.3109/14756366.2011.574130: \\Evaluation of in vitro effects of some analgesic drugs on erythrocyte and recombinant carbonic anhydrase I and II.\\2012Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 27, Issue:1
Evaluation of in vitro effects of some analgesic drugs on erythrocyte and recombinant carbonic anhydrase I and II.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,868)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990434 (15.13)18.7374
1990's489 (17.05)18.2507
2000's834 (29.08)29.6817
2010's895 (31.21)24.3611
2020's216 (7.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 104.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index104.20 (24.57)
Research Supply Index8.23 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index195.68 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (104.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials677 (21.92%)5.53%
Reviews1 (16.67%)6.00%
Reviews107 (3.46%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies181 (5.86%)4.05%
Observational0 (0.00%)0.25%
Observational2 (0.06%)0.25%
Other5 (83.33%)84.16%
Other2,122 (68.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (83)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Ketoprofen Gel vs Placebo in Children Presented With Ankle Sprain to the Emergency Department: A Randomised Controlled Trial [NCT02491736]Phase 4100 participants (Anticipated)Interventional2015-06-30Recruiting
The Effect of Intraoperative Nefopam, Ketoprofen and Paracetamol Combination vs Ketoprofen and Paracetamol Combination on Postoperative Morphine Requirements After Laparoscopic Cholecystectomy: A Randomized, Controlled Trial [NCT04622813]Phase 390 participants (Actual)Interventional2021-04-08Completed
Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery [NCT02238340]Phase 440 participants (Actual)Interventional2012-03-31Completed
Efficacy of Regional Analgesia Techniques (Quadratus Lumborum Block and Transversus Abdominis Plane Block) in Acute and Chronic Pain Treatment in Patients After Cesarean Delivery [NCT03244540]Phase 4105 participants (Actual)Interventional2017-09-04Completed
Paracetamol With or Without Ketoprofen in the Management of Pain During Hospitalisation and at Home for Patients Receiving Brachytherapy: Phase-2 Randomized Study [NCT02439034]Phase 2120 participants (Anticipated)Interventional2015-02-28Recruiting
Clinical Multicenter, Phase III, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ibuprofen 50mg/g Gel in the Treatment of Patients With Muscle Pain, Joint, or Pain Caused by Sprains, Contusions, Tendinitis, or Myofascial Compared to [NCT01373697]Phase 3144 participants (Anticipated)Interventional2011-06-30Not yet recruiting
Effectiveness of Transversus Abdominis Plane Block Versus Quadratus Lumborum Technique in Patients After Cesarean Section [NCT02804126]Phase 4232 participants (Actual)Interventional2017-06-01Completed
Comparison of Topical Dexketoprofen Versus Placebo in Patients Presented With Ankle Sprain to the Emergency Department: A Randomised Placebo Controlled Trial [NCT02393846]Phase 4100 participants (Actual)Interventional2015-02-28Completed
Randomized, Double-Blind, Parallel, Placebo Controlled 4 Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of Transdermal Ketoprofen When Administered With Controlled Heat in Patients With Mild to Moderate OA Pain of the Knee [NCT00108810]Phase 2118 participants (Actual)Interventional2005-04-30Completed
Protocol HKT-500-US10: A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Grade I or Grade II Ankle Sprain [NCT00680784]Phase 3260 participants (Actual)Interventional2008-04-30Completed
Protocol HKT-500-US08: A Randomized, Multicenter, Double-blind, Placebo-controlled, Two-week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Acute Shoulder Pain [NCT00680472]Phase 3368 participants (Actual)Interventional2008-04-30Completed
An Open-Label, Long-Term Safety Study to Evaluate the Safety of ThermoProfen™ for the Treatment of Mild to Moderate Pain Associated With Osteoarthritis of the Knee [NCT00532038]Phase 3179 participants (Actual)Interventional2007-09-30Terminated(stopped due to Corporate decision)
A Randomized Double Blind, Placebo Controlled Phase III Trial to Determine the Efficacy and Safety of Topical Intra-oral Ketoprofen for the Treatment of Acute Migraine [NCT01228552]Phase 3100 participants (Anticipated)Interventional2011-12-31Not yet recruiting
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel™ (Ketoprofen Topical Cream 10%) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury [NCT00765700]Phase 3364 participants (Actual)Interventional2008-09-30Completed
Relieving Outpatient Hysteroscopy-associated Pain: What is the Most Effective Method? [NCT05801172]201 participants (Actual)Interventional2022-07-01Completed
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Confirmatory Phase 3 Study to Assess the Efficacy and Safety of TDLP-110 (Ketotransdel®, Ketoprofen 10% Cream) in the Treatment of Pain Associated With Mild to Moderate Acute Sof [NCT01223053]Phase 30 participants (Actual)InterventionalWithdrawn(stopped due to Revised Development Program)
Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder [NCT03514810]Phase 128 participants (Actual)Interventional2017-01-10Completed
Comparison of a Patient Controlled Oral Administration (PCOA) of Analgesic Protocol With an IV Administration After Planned Caesarian Section : Monocentric, Randomised and Controlled Study [NCT01566253]Phase 480 participants (Actual)Interventional2012-03-31Completed
Ketoprofen With or Without Vaginal Isonicotinic Acid Hydrazide (INH) Prior to Hysterosalpingography in Primarily Infertile Patients: a Randomized Controlled Trial [NCT04500470]200 participants (Actual)Interventional2020-09-01Completed
Phase III Double Blind Randomized Placebo Controlled Trial Using 20% Intra-Oral Ketoprofen Gel for Migraine Prevention. [NCT01211795]Phase 367 participants (Actual)Interventional2009-10-31Completed
Phase III, National, Multicenter, Randomized, Double-blind, Double-masked, Compare the Efficacy of Ketoprofen, Cyclobenzaprine and Caffeine Association Versus Cyclobenzaprine and Caffeine (Miosan Caf®) in the Treatment of Osteomuscular Pain in Adults [NCT02862977]Phase 3414 participants (Actual)Interventional2017-11-10Completed
Non-inferiority Study of Bi-Profenid® 200 mg Versus Bi-Profenid® 300 mg in Patients Presenting With Pain Related to Closed, Benign, Acute Post-traumatic Conditions of the Motor System or Acute, Non-infectious Rheumatologic Conditions [NCT00810121]Phase 3409 participants (Actual)Interventional2008-11-30Completed
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee [NCT00792727]Phase 3380 participants (Actual)Interventional2007-09-30Completed
"MISTRAL (Mouthwash In Sore Throat Relief: Antiinflammatory vs. Local Anesthetic Therapy) Efficacy and Tolerability of Ketoprofen Lysine Salt as a Mouthwash in Acute Phlogosis of the Pharyngeal Cavity; Multicentre, Randomized, Single-blind, Parallel-group [NCT02178293]Phase 4214 participants (Actual)Interventional1998-09-30Completed
Reduce Nonsteroidal Antiinflammatory Drugs Doses for Analgesia After Sternotomy [NCT02180087]Phase 2100 participants (Anticipated)Interventional2014-02-28Recruiting
The Effect of Intravenous Paracetamol in Combination With NSAIDs for Postoperative Pain in Children [NCT02248493]Phase 454 participants (Actual)Interventional2012-11-30Completed
Multi Center Lymphedema Treatment Registry (LET) Study [NCT04272372]60 participants (Anticipated)Observational [Patient Registry]2023-10-31Not yet recruiting
Randomized, Double Blind, Placebo Controlled Clinical Trial of Compare With Doxycycline Plus Ketoprofen Gel in Chronic Periodontitis [NCT02538224]Phase 2/Phase 320 participants (Actual)Interventional2013-07-31Completed
Multiple-dose, Randomized, Subject and Observer Blinded, Placebo-controlled, Double-dummy Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Ex [NCT01020279]Phase 182 participants (Actual)Interventional2009-10-31Completed
Evaluation of the Efficacy of Different Drugs in the Treatment of the Pain in Patients With Temporomandibular Disorder [NCT05529290]Phase 4200 participants (Actual)Interventional2019-07-16Completed
Comparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole, in the Control of Pain, Swelling and Trismus in Lower Third Molar Removal [NCT02730026]Phase 450 participants (Actual)Interventional2015-06-30Completed
Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions [NCT00971581]Phase 352 participants (Actual)Interventional2009-08-31Completed
Efficacy and Safety of a Fixed Combination (Thiocolchicoside 8 mg + Ketoprofen 100 mg ) Compared to Thiocolchicoside 8 mg Administered Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain [NCT00679146]Phase 3334 participants (Actual)Interventional2008-04-30Completed
Intravenous Treatment With Non Steroidal Anti Inflammatory Drugs (NSAID) Versus Nebulized Morphine (NM) Analgesia for First-line Renal Colic: Randomized Controlled Double-blind Single-center Study. [NCT02156596]Phase 1100 participants (Actual)Interventional2013-02-28Completed
A Double-Blind, Placebo-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 (Ketoprofen in Transfersome) in Comparison to Oral Celecoxib for the Treatment of Pain Associated With Osteoarthritis of the Knee [NCT00317733]Phase 2360 participants InterventionalCompleted
Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Study of Safety and Efficacy of Two Dosages of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee [NCT00716547]Phase 31,399 participants (Actual)Interventional2008-05-31Completed
Multicentre, Randomized, Double-blind, Placebo-controlled Study of Safety and Efficacy of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee [NCT00722852]Phase 3555 participants (Actual)Interventional2008-06-30Completed
An Open-Label, Phase II, Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee [NCT00903994]Phase 217 participants (Actual)Interventional2007-06-30Completed
Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial [NCT04252521]150 participants (Actual)Interventional2019-07-03Completed
Comparison of iv Paracetamol, iv Dexketoprofen and Topical Lidocaine in Scorpion Sting: a Placebo Randomized Controlled Trial [NCT05125796]106 participants (Actual)Interventional2020-09-01Completed
A Randomized, Double-Blind, Cross-Over, Placebo-Controlled Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine [NCT02057315]Phase 1/Phase 248 participants (Actual)Interventional2014-03-31Completed
A Bioequivalence Study of a Test Formulation of Ketoprofen Oral Gel 25 mg Versus a Marketed Reference of Ketoprofen Lysine Salt as Granules for Oral Solution (80 mg Bipartite Sachet, Half Sachet) After Single Dose Administration Under Fed Conditions to He [NCT04678076]Phase 136 participants (Actual)Interventional2018-07-23Completed
A Randomised Double Blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of 2 Doses of Ketoprofen Lysinate Lozenges (6.25 mg & 12.5 mg) in Patients With Sore Throat [NCT00929877]Phase 3801 participants (Actual)Interventional2009-06-30Completed
A Double-Blind, Double-Dummy, Randomized, Multicenter Study Comparing The Analgesic Efficacy And Safety Of Parecoxib 40mg I.V. To Ketoprofen 100mg I.V. In Renal Colic [NCT00553605]Phase 4340 participants (Actual)Interventional2007-06-30Completed
Local, Phase IV, Multicenter, Double-blind, Randomized, Parallel, With Two Treatment Arms, Placebo-controlled Study to Evaluate the Reduction of Inflammatory Symptoms in the Treatment of Bacterial Pharyngitis With Ketoprofen and Amoxicillin in Pediatric P [NCT00799838]Phase 4106 participants (Actual)Interventional2008-11-30Terminated(stopped due to Recruitment challenges despite several attenpts to increase enrollment)
Effects of Genotype on CYP2C9 Drug Interactions [NCT01061112]23 participants (Actual)Observational2009-12-31Completed
Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room [NCT04726592]Phase 3420 participants (Anticipated)Interventional2021-07-08Recruiting
Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia. [NCT01882530]Phase 4223 participants (Actual)Interventional2013-07-23Terminated(stopped due to Practice on postoperative pain management changed)
Comparing the Efficacy of Intravenous Paracetamol and Ketoprofen When Treating Renal Colic in Emergency Situations: a Randomized, Bi-centric, Double-blind Controlled Trial [NCT01685658]Phase 40 participants (Actual)Interventional2016-09-30Withdrawn(stopped due to same study already published)
Postoperative Analgesia With Transversus Abdominis Plane Block or Quadratus Lumborum Block in Patients After Cesarian Delivery [NCT03404908]Phase 4105 participants (Actual)Interventional2018-02-07Completed
Open Label Randomized Study for Evaluating Efficacy and Safety of Ketorolac Tromethamine and Ketoprofen in Gel in Patients With Gonarthrosis and Low Back Pain [NCT02638831]Phase 4240 participants (Actual)Interventional2013-03-31Completed
Randomized Controlled Trial on the Effectiveness of Metoclopramide Alone or in Combination With Ketoprofen in Acute Migraine of Child [NCT00557544]Phase 30 participants (Actual)Interventional2009-06-30Withdrawn
Effect of Oral Ketoprofen on Intra Uterine Device Insertion Pain: A Randomized Controlled Trial [NCT02905058]Phase 3100 participants (Actual)Interventional2016-10-31Completed
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients [NCT01893879]14 participants (Actual)Interventional2014-04-30Terminated(stopped due to insufficient enrollment)
A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe. [NCT00530387]1,000 participants (Actual)Interventional2008-07-31Completed
Harnessing Chronomodulation to Enhance Osteogenesis - A Pilot Randomized Controlled Trial - [NCT03911336]Phase 40 participants (Actual)Interventional2023-01-01Withdrawn(stopped due to Decided not to proceed)
A Double-Blind, Long-Term Evaluation of the Safety of IDEA-033 in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of Osteoarthritis of the Knee [NCT00265304]Phase 2550 participants Interventional2005-07-31Completed
A Phase III Study of the Efficacy, Tolerability and Safety of the Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee, Including a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase [NCT00365586]Phase 3300 participants (Anticipated)Interventional2006-08-31Completed
Safety and Efficacy of Nonsteroidal Antiinflammatory Drug and Glucocorticoids in Acute Sciatica [NCT01816334]Phase 450 participants (Actual)Interventional2013-01-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee [NCT00426985]Phase 3330 participants (Anticipated)Interventional2007-01-31Terminated(stopped due to Sufficient number of subjects accrued to conduct analysis)
Effect of Oral Ketoprofen on Hysterosalpingography Pain: A Randomized Controlled Trial [NCT02905045]Phase 3100 participants (Actual)Interventional2016-10-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Grade 1 or Grade 2 Ankle Sprain or Strain [NCT00351104]Phase 3200 participants (Actual)Interventional2006-06-30Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee [NCT00352625]Phase 3330 participants Interventional2006-06-30Completed
Double-blind, Randomised, Placebo and Active Controlled, Parallel Group Study to Evaluate the Analgesic Effect of a Single Oral Administration of Four Different Combination Doses of DKP.TRIS With TRAM.HCL in Comparison With the Single Agents, on Moderate [NCT01307020]Phase 2745 participants (Actual)Interventional2011-02-28Completed
Effect of a Transversus Abdominis Plane Block on Operative Wound Healing, Stress, and Immune Response After a Cesarean Delivery [NCT05840406]120 participants (Anticipated)Interventional2024-04-01Not yet recruiting
Intraoperative Use of Dexketoprofen Trometamol, Tramadol Hcl, Pethidine Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication [NCT01558622]Phase 472 participants (Anticipated)Interventional2012-03-31Active, not recruiting
Placebo-controlled, Case-controlled, Open Label Therapeutic Trial for Unilateral or Bilateral Lymphedema of Arm or Leg. [NCT02257970]Phase 4117 participants (Actual)Interventional2009-03-31Completed
Postoperative Pain After Medical Abortion Under Local Anesthesia : a Prospective and Randomized Trial Comparing Several Analgesic Regimen [NCT00188071]240 participants Interventional2002-09-30Completed
Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP [NCT02400047]Phase 3580 participants (Actual)Interventional2015-06-03Completed
COMPARATION BETWEEN SPHENOPALATINE BLOCK AND MULTIMODAL CLINICAL TREATMENT IN TREATMENT OF HEADACHE AFTER DURAL PUNCTION IN PREGNANT WOMEN. [NCT04148846]45 participants (Anticipated)Interventional2019-09-20Recruiting
Efficacy and Safety of Methoxyflurane Vaporized (PENTHROX®) in the Treatment of Acute Trauma Pain in Pre-hospital Setting and in the Emergency Department in Italy: a Multicentre, Randomized, Controlled, Open-label Study [NCT03585374]Phase 3272 participants (Actual)Interventional2018-02-08Completed
Novel Topical Therapies for the Treatment of Genital Pain [NCT02099006]Phase 2/Phase 39 participants (Actual)Interventional2013-11-30Completed
A Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy of ThermoProfen™ in the Treatment of Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee (ZMK-301) [NCT00488267]Phase 3679 participants (Actual)Interventional2007-06-30Completed
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Mild to Moderate Ankle Sprain [NCT00927641]Phase 3240 participants (Actual)Interventional2009-07-31Completed
A Multicenter, Double Blind, Randomised, Parallel Study to Assess Efficacy and Tolerability After Single Administration of Ketoprofen Lysine Salt 40 mg Granules vs Placebo in Subjects With Acute Pain Syndrome After Removal of Molar Teeth [NCT03836807]Phase 370 participants (Actual)Interventional2018-04-04Completed
A Randomized, Multicenter, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee [NCT01890902]Phase 30 participants (Actual)Interventional2013-08-31Withdrawn
A Study to Comparing the Efficacy and Safety of the Ketoprofen and Diclofenac in Patients With Osteoarthritis [NCT04421911]Phase 3236 participants (Actual)Interventional2020-03-20Completed
Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) Addition to Ketoprofen for the Acute Treatment of Migraine Attacks [NCT02568644]60 participants (Actual)Interventional2014-07-31Completed
A Phase I, Double-Blind, PK, Safety, Tolerability Study of KSL + KLS-GABA vs KLS Alone in Healthy Males (Part A) Followed by a Study to Investigate the PD of KLS and KLS + GABA in Healthy Males (Part B) [NCT04802967]Phase 1140 participants (Actual)Interventional2021-02-08Completed
Phase III, National, Multicenter, Randomized, Double-blind, Double-Masked, Compare the Efficacy of Ketoprofen + Cyclobenzaprine Association Versus Cyclobenzaprine (Miosan®) in the Treatment of Osteomuscular Pain in Adults [NCT03025113]Phase 3416 participants (Actual)Interventional2018-03-08Completed
Protocol HKT-500-US12: A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee [NCT00647231]Phase 2300 participants (Actual)Interventional2008-03-31Completed
Ketoprofen Gel vs Placebo in Patients Presented With Low-back Pain to Emergency Department: A Ranodmized Controlled Trial [NCT02491879]Phase 4100 participants (Anticipated)Interventional2015-06-30Recruiting
Characterization of Treatment Responses in Lymphedema [NCT03783715]2 participants (Actual)Observational2019-06-21Terminated(stopped due to Study was halted due to Covid-19 pandemic and unavailability of ketoprofen.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00553605 (10) [back to overview]Mean Pain Intensity Difference at 120 Min (mPID120min)
NCT00553605 (10) [back to overview]Mean Pain Intensity Difference at 30 Minutes (mPID30min)
NCT00553605 (10) [back to overview]Number of Participants With Response in Pain Intensity
NCT00553605 (10) [back to overview]Number of Participants With Use of Rescue Medication (RM)
NCT00553605 (10) [back to overview]Time-weighted Sum of Pain Relief Score Over 120 Min (TOTPAR120min)
NCT00553605 (10) [back to overview]Number of Participants With Pain Relief (PR)
NCT00553605 (10) [back to overview]Patient's Global Evaluation of Study Medication
NCT00553605 (10) [back to overview]Physician's Global Evaluation of Study Medication
NCT00553605 (10) [back to overview]Time-specific Pain Intensity (PI) VAS Score
NCT00553605 (10) [back to overview]Time-specific Pain Intensity Difference (PID) at Minute 15, 30, 45, 60, 90 and 120
NCT01307020 (3) [back to overview]Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.
NCT01307020 (3) [back to overview]Percentage of Patients Using Rescue Medication at 6 Hours
NCT01307020 (3) [back to overview]Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.
NCT01893879 (1) [back to overview]Number of Participants With Incidence of Lymphedema
NCT02099006 (2) [back to overview]Reduction in Daily Genital Pain.
NCT02099006 (2) [back to overview]Reduction in Tampon Test Pain
NCT02257970 (8) [back to overview]Part 1: Count of Participants Able to Complete Ketoprofen Treatment
NCT02257970 (8) [back to overview]Part 2: Change From Baseline in Cutaneous Histological Architecture
NCT02257970 (8) [back to overview]Part 2: Measurement of Skin Thickness
NCT02257970 (8) [back to overview]Part 2/Part 3: Change From Baseline in Bioimpedance Spectroscopy
NCT02257970 (8) [back to overview]Part 2/Part 3: Change in Limb Volume
NCT02257970 (8) [back to overview]Part 3: Change From Baseline in Cutaneous Histological Architecture
NCT02257970 (8) [back to overview]Part 3: Change in Systemic Inflammatory Mediator Granulocyte Colony Stimulating Factor (G-CSF)
NCT02257970 (8) [back to overview]Part 3: Measurement of Skin Thickness
NCT02568644 (4) [back to overview]Change in Headache Severity.
NCT02568644 (4) [back to overview]Change in Headache Severity.
NCT02568644 (4) [back to overview]Change in Headache Severity.
NCT02568644 (4) [back to overview]Change in Serum Levels of Biomarkers.

Mean Pain Intensity Difference at 120 Min (mPID120min)

"mPID score was obtained by summation of product of length of the interval and difference in pain intensity (PI) divided by summation of length of the interval. Summation was done from zero to 120 minutes. Difference in pain intensity was obtained by subtracting the Pain Intensity Visual Analogue Scale (PI-VAS) at Minute 120 from baseline PI-VAS score. PI-VAS assessed with response to the question How much pain are you having right now? on a 100 millimeter (mm) line, with 0 mm=no pain, 100 mm= worst possible pain. mPID score ranged from -100 to 100. Positive score= improved response in pain." (NCT00553605)
Timeframe: Minute 120

Interventionmm (Least Squares Mean)
Parecoxib51.608
Ketoprofen51.697

[back to top]

Mean Pain Intensity Difference at 30 Minutes (mPID30min)

"mPID score was obtained by summation of product of length of the interval and difference in pain intensity (PI) divided by summation of length of the interval. Summation was done from zero to 30 minutes. Difference in pain intensity was obtained by subtracting the Pain Intensity Visual Analogue Scale (PI-VAS) at Minute 30 from baseline PI-VAS score. PI-VAS assessed with response to the question How much pain are you having right now? on a 100 millimeter (mm) line, with 0 mm=no pain, 100 mm= worst possible pain. mPID score ranged from -100 to 100. Positive score= improved response in pain." (NCT00553605)
Timeframe: Minute 30

Interventionmm (Least Squares Mean)
Parecoxib34.147
Ketoprofen35.266

[back to top]

Number of Participants With Response in Pain Intensity

"PI-VAS assessed with response to the question How much pain are you having right now? on a 100 mm line, with 0 mm=no pain, 100 mm= worst possible pain. Responders were those who had a decreased in VAS of at least 20 mm." (NCT00553605)
Timeframe: Minute 30

Interventionparticipants (Number)
Parecoxib132
Ketoprofen124

[back to top]

Number of Participants With Use of Rescue Medication (RM)

Rescue medications included intravenous 0.1 to 0.2 mg/kilogram (kg) of morphine or 1 mg/kg of pethidine or muscle relaxants. (NCT00553605)
Timeframe: Up to Minute 120

Interventionparticipants (Number)
Parecoxib26
Ketoprofen25

[back to top]

Time-weighted Sum of Pain Relief Score Over 120 Min (TOTPAR120min)

TOTPAR: time-weighted sum of Pain Relief (PR) over 120 min. TOTPAR score range was 0 (worst) to 480 (best). PR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT00553605)
Timeframe: Baseline through Minute 120

Interventionunits on a scale (Least Squares Mean)
Parecoxib362.42
Ketoprofen352.29

[back to top]

Number of Participants With Pain Relief (PR)

PR was assessed on a 5-point categorical pain relief rating scale wherein 0= None, 1= a little, 2= Some, 3= a lot and 4= Complete relief. (NCT00553605)
Timeframe: Minute 30, 120

,
Interventionparticipants (Number)
Minute 30: none (n= 171, 162)Minute 30: a little (n= 171, 162)Minute 30: some (n= 171, 162)Minute 30: a lot (n= 171, 162)Minute 30: complete (n= 171, 162)Minute 120: none (n= 146, 139)Minute 120: a little (n= 146, 139)Minute 120: some (n= 146, 139)Minute 120: a lot (n= 146, 139)Minute 120: complete (n= 146, 139)
Ketoprofen9194465251484680
Parecoxib102135743110164089

[back to top]

Patient's Global Evaluation of Study Medication

"Participants' response to the question How would you rate the study medication you received for pain? on a 4-point categorical scale, 1=Poor, 2= Fair, 3=Good, 4=Excellent was evaluated." (NCT00553605)
Timeframe: Minute 30, 120

,
Interventionparticipants (Number)
Minute 30: poorMinute 30: fairMinute 30: goodMinute 30: excellentMinute 120: poorMinute 120: fairMinute 120: goodMinute 120: excellent
Ketoprofen101766705164696
Parecoxib122176638164998

[back to top]

Physician's Global Evaluation of Study Medication

"Physicians' response to the question How would you rate the study medication the patient received for pain? on a 4-point categorical scale, 1=Poor, 2= Fair, 3=Good, 4=Excellent was evaluated." (NCT00553605)
Timeframe: Minute 30, 120

,
Interventionparticipants (Number)
Minute 30: poorMinute 30: fairMinute 30: goodMinute 30: excellentMinute 120: poorMinute 120: fairMinute 120: goodMinute 120: excellent
Ketoprofen112363668154595
Parecoxib1122697081445104

[back to top]

Time-specific Pain Intensity (PI) VAS Score

"PI-VAS assessed with response to the question How much pain are you having right now? on a 100 mm line, with 0 mm=no pain, 100 mm= worst possible pain." (NCT00553605)
Timeframe: Baseline, Minute 15, 30, 45, 60, 90, 120

,
Interventionmm (Mean)
Baseline (n= 173, 164)Minute 15 (n= 173, 164)Minute 30 (n= 172, 162)Minute 45 (n= 163, 156)Minute 60 (n= 156, 152)Minute 90 (n= 151, 144)Minute 120 (n= 147, 139)
Ketoprofen76.9950.9533.6523.1517.5312.278.02
Parecoxib77.1450.4234.1321.7514.629.807.68

[back to top]

Time-specific Pain Intensity Difference (PID) at Minute 15, 30, 45, 60, 90 and 120

"PID score was obtained by subtracting the PI-VAS at each time point from baseline PI score. PI-VAS assessed with response to the question How much pain are you having right now? on a 100 mm line, with 0 mm=no pain, 100 mm= worst possible pain. PID score ranged from -100 to 100. Positive score= improved response in pain." (NCT00553605)
Timeframe: Baseline, Minute 15, 30, 45, 60, 90, 120

,
Interventionmm (Mean)
Minute 15 (n= 173, 164)Minute 30 (n= 172, 162)Minute 45 (n= 163, 156)Minute 60 (n= 156, 152)Minute 90 ( n= 151, 144)Minute 120 (n= 147, 139)
Ketoprofen26.0443.2253.5559.3464.3368.51
Parecoxib26.7242.8954.3761.3565.9968.07

[back to top]

Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.

Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is % (NCT01307020)
Timeframe: 6 hours

Interventionpercentage of patients (Number)
DKP-TRIS 12.5mg - TRAM.HCl 37.5mg36.7
DKP-TRIS 12.5mg - TRAM.HCl 75mg59.7
DKP-TRIS 25mg - TRAM.HCl 37.5mg55.6
DKP-TRIS 25mg - TRAM.HCl 75mg72.1
DKP-TRIS 12.5mg26.7
DKP-TRIS 25mg55.0
TRAM.HCl 37.5mg10.2
TRAM.HCl 75mg25.4
Ibuprofen 400mg45.0
Placebo9.7

[back to top]

Percentage of Patients Using Rescue Medication at 6 Hours

Percentage of patients using rescue medication at 6 hours post-dosing. (NCT01307020)
Timeframe: Baseline to 6 hours

Interventionpercentage of patients (Number)
DKP-TRIS 12.5mg - TRAM.HCl 37.5mg66.7
DKP-TRIS 12.5mg - TRAM.HCl 75mg46.8
DKP-TRIS 25mg - TRAM.HCl 37.5mg39.7
DKP-TRIS 25mg - TRAM.HCl 75mg37.7
DKP-TRIS 12.5mg65.0
DKP-TRIS 25mg53.3
TRAM.HCl 37.5mg69.5
TRAM.HCl 75mg64.4
Ibuprofen 400mg48.3
Placebo72.6

[back to top]

Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.

Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is % (NCT01307020)
Timeframe: 4, 8 and 12 hours

,,,,,,,,,
Interventionpercentage of patient (Number)
at 4 hours post-doseat 8 hours post-doseat 12 hours post-dose
DKP-TRIS 12.5mg40.016.710.0
DKP-TRIS 12.5mg - TRAM.HCl 37.5mg63.321.711.7
DKP-TRIS 12.5mg - TRAM.HCl 75mg72.648.435.5
DKP-TRIS 25mg65.031.713.3
DKP-TRIS 25mg - TRAM.HCl 37.5mg65.144.428.6
DKP-TRIS 25mg - TRAM.HCl 75mg78.754.137.7
Ibuprofen 400mg56.733.325.0
Placebo6.56.56.5
TRAM.HCl 37.5mg11.96.85.1
TRAM.HCl 75mg23.720.315.3

[back to top]

Number of Participants With Incidence of Lymphedema

Participants were evaluated every 3 months up to one year post lymph node dissection (NCT01893879)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
(RS)2-(3-benzoylphenyl)-Propionic Acid2
Placebo for Study Drug1

[back to top]

Reduction in Daily Genital Pain.

"Each subject was asked to keep a symptom diary recording her daily genital pain, measured on a 10 point Likert scale. A score of 0 was defined as no pain and a score of 10 was defined as worst imaginable pain. These daily values were collected and a mean pain score for the period of treatment was calculated." (NCT02099006)
Timeframe: 13 weeks

,
Interventionunits on a scale (Mean)
LoperamideKetamineGabapentinamtriptyline/baclofenketoprofen
Medications2.43.423.703.875.05
Placebo2.922.773.413.615.05

[back to top]

Reduction in Tampon Test Pain

"Reduction in the pain, as measured on a 10 point Likert scale, associated with the insertion and removal of a tampon. This is a validated surrogate for pain associated with intercourse. Subjects were asked to insert and remove a tampon each week and report the degree of pain associated with this. A score of 0 was defined as no pain, and a score of 10 was defined as worst imaginable pain." (NCT02099006)
Timeframe: 13 weeks

,
Interventionunits on a scale (Mean)
loperamideketaminegabapentinketoprofenamitriptyline/baclofen
Medications4.715.925.1256.175.43
Placebo5.295.924.8756.05.36

[back to top]

Part 1: Count of Participants Able to Complete Ketoprofen Treatment

Participants who were able to complete ketoprofen treatment and experienced no treatment-related serious adverse events. (NCT02257970)
Timeframe: Baseline to month 6

InterventionParticipants (Count of Participants)
Part 1: Exploratory Group50

[back to top]

Part 2: Change From Baseline in Cutaneous Histological Architecture

Quantitative assessment of paired histological specimens of lymphedema skin pre- and post-treatment with ketoprofen. The impact of treatment on cutaneous histopathology was evaluated through the use of an empirically-derived scoring system (comprised of dermal thickness, intercellular mucin content, deep dermal collagen content, and perivascular infiltrate); this quantitative assessment was developed and performed by a dermatopathologist. Each characteristic was weighted equally and each specimen was assigned a cumulative subscale score of 0-5. The scores were summed for a total score (range: 0-20) which is presented here. Higher scores indicate a higher degree of pathology. A quantitatively higher negative change indicates a more favorable therapeutic response in the histology. (NCT02257970)
Timeframe: Baseline; Month 4

,
Interventionscore on a scale (Mean)
BaselineMonth 4
Part 2: Open-label Group6.1252.688
Part 2: Unaffected Tissue Samples0.80.6

[back to top]

Part 2: Measurement of Skin Thickness

Caliper measured skin thickness (mm) of lymphedema-affected limb was serially assessed and pre-to-post paired analysis was performed. (NCT02257970)
Timeframe: Baseline and 4 months

Interventionmm (Mean)
BaselineMonth 4
Part 2: Open-label Group6227

[back to top]

Part 2/Part 3: Change From Baseline in Bioimpedance Spectroscopy

A four-electrode configuration was used to non-invasively assess the extracellular and intracellular fluid contents of the limb. Data were analyzed according to Cole theory, using the manufacturer's software (Impedimed Ltd.), to provide values for a bioimpedance ratio (Ro), the resistance of the extracellular fluid including lymph, R∞ the resistance of total tissue fluid and Ri, the resistance of the intracellular fluid. For the purposes of these investigations, in patients with unilateral lymphedema, the ratio of Ro in the affected:unaffected limbs was analyzed in each patient, as a measure of the bioimpedance attributable to the extracellular fluid content. An Ro level of 1.034 was considered normal; values ≥1.034 were considered abnormal. (NCT02257970)
Timeframe: Baseline; 4 months

,,
Interventionratio of Ro values (Mean)
BaselineMonth 4
Part 2: Open-label Group1.51.6
Part 3: Ketoprofen Group1.41.4
Part 3: Placebo Group1.51.5

[back to top]

Part 2/Part 3: Change in Limb Volume

Quantitative assessment of limb volume (ml) of the affected limb at study end compared to pre-treatment values. (NCT02257970)
Timeframe: Baseline; 4 months

,,
Interventionml (Mean)
BaselineMonth 4
Part 2: Open-label Group98669465
Part 3: Ketoprofen Group85988675
Part 3: Placebo Group71967256

[back to top]

Part 3: Change From Baseline in Cutaneous Histological Architecture

Quantitative assessment of paired histological specimens of lymphedema skin pre- and post-treatment with ketoprofen or placebo, respectively. The impact of treatment on cutaneous histopathology was evaluated through the use of an empirically-derived scoring system (comprised of dermal thickness, intercellular mucin content, deep dermal collagen content, and perivascular infiltrate); this quantitative assessment was developed and performed by a dermatopathologist. Each characteristic was weighted equally and each specimen was assigned a cumulative subscale score of 0-5. The scores were summed for a total score (range: 0-20) which is presented here. Higher scores indicate a higher degree of pathology. For the analysis, the 4-month post-minus-pre change in this score for ketoprofen- and placebo-recipients, respectively, was compared. A quantitatively higher negative change indicates a more favorable therapeutic response in the histology. (NCT02257970)
Timeframe: Baseline; 4 months

,,
Interventionscore on a scale (Mean)
BaselineMonth 4
Part 3 Placebo2.71.0
Part 3: Ketoprofen Group4.11.18
Part 3: Unaffected Tissue Samples0.80.6

[back to top]

Part 3: Change in Systemic Inflammatory Mediator Granulocyte Colony Stimulating Factor (G-CSF)

The systemic inflammatory response of G-CSF, in the two treatment groups, Ketoprofen and Placebo, will be assessed with Luminex-bead inflammasome analysis of pre- and post-treatment plasma samples. G-CSF, a glycoprotein, is an inflammatory cytokine produced by endothelium and immune cells. Ketoprofen is a unique NSAID possessing dual pathways of inflammatory inhibition, blocking cyclooxygenase (COX) and 5-LO. Measurement using median fluorescence intensity (MFI) was employed. (NCT02257970)
Timeframe: Baseline; 4 months

,
InterventionMFI (log10) (Mean)
BaselineMonth 4
Part 3: Ketoprofen Group131126
Part 3: Placebo121209

[back to top]

Part 3: Measurement of Skin Thickness

Caliper-measured skin thickness (mm) was serially assessed and pre-to-post paired analysis was performed for both arms (Placebo and Ketoprofen) of the study. (NCT02257970)
Timeframe: Baseline and 4 months

,
Interventionmm (Mean)
BaselineMonth 4
Part 3: Ketoprofen Group4941
Part 3: Placebo Group4745

[back to top]

Change in Headache Severity.

"The severity of headache was assessed with faces pain scale. It is a self-reported pain scale consisting of face drawings which have a score ranging from zero (absence of pain) to five (maximal intensity of pain).~Higher scores mean a worse outcome." (NCT02568644)
Timeframe: 2 hours

Interventionunits on a scale (Mean)
Extract of Ginger0.43
Cellulose0.90

[back to top]

Change in Headache Severity.

The severity of headache was assessed with four-point scale. Scale ranges: 0 - Absence of pain, 1 - Mild Pain, 2 - Moderate Pain and 3 - Severe pain Higher scores mean a worse outcome (NCT02568644)
Timeframe: 2 hours

Interventionunits on a scale (Mean)
Extract of Ginger0.81
Cellulose0.97

[back to top]

Change in Headache Severity.

The severity of headache was assessed with visual numeric scale. Scale ranges: from zero (absence of pain) to 10 (maximum intensity of pain). Higher scores mean a worse outcome. (NCT02568644)
Timeframe: 2 hours

Interventionunits on a scale (Mean)
Extract of Ginger1.03
Cellulose2.30

[back to top]

Change in Serum Levels of Biomarkers.

Evaluated biomarkers: neurotrophic factors and inflammatory mediators. (NCT02568644)
Timeframe: 2 hours

InterventionBDNF (pg/mL) (Median)
Extract of Ginger6077
Cellulose6503

[back to top]